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ABC ATP-binding cassette 
BCRP/Bcrp* breast cancer resistance protein 
BIM bisindolylmaleimide 
8Br-cGMP 8-bromo-cGMP 
BSA bovine serum albumin 
calcein-AM calcein-acetoxymethylester 
CAR constitutive androstane receptor 
cAMP cyclic adenosine monophosphate 
CDNB chlorodinitrobenzene 
CEALP cumulative excretion of alkaline phosphatase 
cGMP cyclic guanosine monophosphate 
CMFDA 5-chloromethylfluorescein diacetate 
DAPI 4´,6-diamidino-2-phenylindole 
DAF-FM 4-amino-5-methylamino-2',7'-difluorofluorescein 
ET endothelin 
FL fluorescein 
FL-MTX fluorescein methotrexate 
fluo-3-AM fluo-3-acetoxymethylester 
GAPDH glyceraldehyde-3-phosphate dehydrogenase 
GFR glomerular filtration rate 
GSH glutathione 
GS-MF glutathione-methylfluorescein 
GSSG glutathione disulfide 
HBSS Hank’s Balanced Salt Solution 
HEPES 4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid 
HPLC High Performance Liquid Chromatography 
LDH lactate dehydrogenase 
L-NMMA NG-methyl-L-arginine 
LY lucifer yellow 
MAP mitogen-activated protein 
MDCKII Madin Darby Canine Kidney type II 
MDCKII+MRP2 MRP2-transfected Madin Darby Canine Kidney type II cells
MDR1/Mdr1 P-gp* multidrug resistance 1 P-glycoprotein 
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MRP/Mrp* multidrug resistance protein 
NFDM non-fat dried milk 
NO nitric oxide 
NOS nitric oxide synthase 
ODQ oxadiazole quinoxalin 
OK Opossum Kidney 
PAH para-aminohippuric acid 
Pax-2 paired box 2 
PK protein kinase 
PMA phorbol 12-myristate 13-acetate 
PXR pregnane X nuclear receptor 
RES-701-1 ETB receptor antagonist 
Rp-8Br-cGMP inactive isoform of 8-bromo-cGMP 
ROS reactive oxygen species 
RQ-PCR quantitative real-time polymerase chain reaction 
Sf9 Spodoptera frugiperda  
SLC solute carrier 
SNP sodium nitroprusside 
TR- rat mutant transport deficient rat, lacking Mrp2 
Tris tris(hydroxymethyl)-aminomethane 
TRITC-dextran tetramethylrhodamine isothiocyanate-dextran 
WH rat Wistar Hannover rat 
 
 
 
*: for non-human variants the first letter is capitalized  
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Mechanisms and therapeutic implications of 
tubular endothelin signaling in renal drug 
transport and toxicity 
 
Sylvia Notenboom, Frans G.M. Russel and Rosalinde Masereeuw 
 
 
 Summary 
 
Endothelin release and impaired activity of drug transporters have both been 
implicated in renal damage due to toxicity. Endothelin is released after exposure to 
different drugs, such as aminoglycoside antibiotics, chemotherapeutics and 
immunosuppressants, but also to compounds like radiocontrast agents and heavy 
metals. Endothelin has several actions promoting kidney damage, including 
vasoconstriction, the production of reactive oxygen species, the release of growth 
and inflammatory factors and the inhibition of the drug transporters, multidrug 
resistance 1 P-glycoprotein (Mdr1 P-gp) and multidrug resistance protein 2 (Mrp2). 
However, at prolonged exposure time, nephrotoxicants can also up-regulate these 
drug transporters in which endothelin is implicated as well, suggesting protection. 
This thesis focuses mainly on the regulation of two important drug efflux 
transporters, Mdr1/MDR1 P-gp and Mrp2/MRP2, by endothelin. In addition the 
usefulness of endothelin receptor antagonists in the prevention of nephrotoxicity 
will be discussed. 
 
1. Introduction 
2. Transport and toxicity 
1. Renal drug transport 
2. Short-term regulation after exposure to toxic compounds 
3. Long-term regulation after exposure to toxic compounds 
3. Endothelin and toxicity 
1. Endothelin 
2. Role of endothelin in the kidney 
3. Role of endothelin in pathological situations 
a. Vasoconstriction 
b. Reactive oxygen species 
c. Inflammatory and growth factors 
d. Transporters 
4. Aim and outline of this thesis 
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1. Introduction 
 
One of the most important functions of the kidney is the excretion of a variety of 
compounds, both endogenous and exogenous. To this end the kidney is equipped 
with a range of detoxifying enzyme systems and is able to excrete these compounds 
and their metabolic products. For the latter process, the kidney possesses disposal 
and uptake mechanisms in the nephron, its functional unit. These are glomerular 
filtration, tubular secretion and reabsorption. The renal proximal tubule is 
responsible for the excretory transport of xenobiotics, xenobiotic metabolites and 
waste products of metabolism from blood into urine. As a result of its transport 
function and role in urine concentration, the proximal tubule is also an important 
target for toxic effects.  
Among the transport proteins expressed in the proximal tubule are the efflux 
pumps, multidrug resistance protein 2 (MRP2) and the multidrug resistance 1 P-
glycoprotein (MDR1 P-gp). It was previously discovered in killifish that these 
proteins are under the influence of endothelin (ET), the release of which is 
triggered by exposure to several nephrotoxicants (67; 94). This vasoactive hormone 
is implicated in physiological renal functioning and in several pathological 
situations, including nephrotoxicity (39; 54; 72). ET release after nephrotoxicant 
exposure can occur directly or indirectly as a consequence of injury (5). The role of 
ET in (nephrotoxic) damage seems dual. On the one hand, ET is involved in 
vasoconstriction, inhibition of essential transporters, direct or indirect formation of 
reactive oxygen species and the release of growth and inflammatory mediators 
favoring kidney damage. On the other hand, the possible involvement of ET in 
stimulation of xenobiotic transporters like Mdr1 P-gp and Mrp2 seems to favor a 
renal protective system. This raises the question whether ET receptor antagonists 
may be useful in the prevention of nephrotoxicity.  
 
 
2. Transport and toxicity 
 
2.1. Renal drug transport 
 
Active drug secretion in proximal tubule is thought to involve a three step 
process: uptake from the blood across the basolateral membrane, intracellular 
trafficking and subsequent secretion across the apical membrane into the tubular 
lumen. The majority of drug transport in the proximal tubule is mediated by 
proteins located at the basolateral or apical membrane. These transporter proteins 
belong either to the solute carrier (SLC) or ATP-binding cassette (ABC) 
superfamily as reviewed by Masereeuw et al., Russel et al., Wright et al. and van 
de Water et al. (66; 77; 99; 104). In general, the SLC family consists of a variety of 
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 anion and cation transporting proteins. The processes supported by these proteins 
known until now are not primary active, but facilitated diffusion or secondary and 
tertiary transport mechanisms, e.g. gradient-driven. Most SLC transporters 
described so far are bidirectional, although unidirectional transporters have also 
been reported. (33; 36). Members of the ABC superfamily, on the other hand, are 
primary active unidirectional efflux transporters, driven by ATP-binding and 
subsequent hydrolysis (16; 77; 82). The ABC transporters, MDR1 P-gp and MRP2, 
are responsible for the tubular efflux of a variety of endogenous and exogenous 
substrates, as depicted in table 1.1 (2; 40; 66; 77; 82). Efflux processes are often the 
rate limiting step in the excretion of substrates into urine. The regulation of MDR1 
P-gp and MRP2 is an important tool for the cell to prevent damage, either caused 
by accumulation of xenobiotic and endogenous waste products or excessive efflux 
of essential nutrients. This chapter and thesis focuses on these efflux transporters, 
with special reference to their regulation and their role in renal toxicity and 
pathology. 
 
 
Table 1.1 Some relevant endogenous and exogenous substrates of MDR1/Mdr1 P-gp and 
MRP2/Mrp2 
 
MDR1 P-gp  
Endogenous substrates Compounds 
cytokines interleukine, γ-interferon 
steroids estradiol-17β-D-glucuronide 
others glucosylceramide, platelet-activating factor 
Exogenous substrates  
analgesics asimadoline, methadone, morphinea  
antibiotics 
amphotericin Bb, gramicidin D, erythromycinb, 
ketoconazoleb, mefloquineb, ofloxacin, primaquineb, 
quinacrine, quinine, rifampicin, tetracycline, valinomycin 
anticancer drugs 
anthracyclines (doxrubucinb, daunorubicin, epirubucinb), 
anthracenes (bisantreneb, mitoxantroneb), 
epipodophyllotoxins (etoposide, teniposide), taxanes 
(paclitaxelb, docetaxelb), vinca alkaloids (vinblastine, 
vincristineb), actinomycin D, mitomycin Cb, mitramycin, 
methotrexatea, topotecana
antidepressants citalopramb, thioperidone, trazodone, trimipramine 
antidiarrheal agents loperamideb
antiemetics domperidoneb, ondansetron, benzquinamide 
antiepileptics phenytoin 
antigout agents  colchicine 
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Ca2+ channel blockers bepridil, diltiazem
b, flunarizineb, lomerizine, secoverine, 
tamolarizine, verapamila
cardiac glycosides digoxin, digitoxin, α-methyldigoxin, β-acetyldigoxin 
corticosteroids dexamethasone, corticosterone, hydrocortisone, triamcinolone 
diagnostic dyes rhodamine 123, hoechst 33342 
HIV protease inhibitors amprenavir
b, indinavirb, lopinavirb, nelfinavirb, ritonavirb, 
saquinavirb
H2-receptor antagonists cimetidine 
immunosuppressive agents cylcosporin Ab, FK506b
neuroleptics fluphenazine, haloperidol, thioridazineb, trifluoperazine 
anthelmintics abamectin, ivermectinb
others heavy metals, forskolin, lamellarins 
  
MRP2  
Endogenous substrates Compounds 
bile constituents bilirubin, glucuronides, conjugated bile salts  
(local) hormones leukotriene C4, leukotrien D4, N-acetyl leukotriene E4, ET, PGA1-SG 
steroids estradiol-17β-D-glucuronide 
vitamins folates 
others GSH, GSSG 
Exogenous substrates  
ACE inhibitor temocaprilat 
analgesics acetaminophen(glucuronide), indomethacin(glucuronide) 
antibiotics ampicillin, cefodizime, cefpiramide
b, ceftriaxone, 
grepafloxacineb
anticancer drugs  
(GSH conjugated and 
glucuronidated) 
anthracyclines (doxorubicinb), epipodophyllotoxins 
(etoposide), vinca alkaloids (vinblastine, vincristineb), 
cisplatin, methotrexate, mitoxantroneb, irinotecanb
cholesterol synthase inhibitors pravastatineb
ET receptor blockers BQ 123b, BQ 485b, BQ 518b
HIV protease inhibitors adefovir, cidofovir, indinavirb, ritonavirb, saquinavirb
others GSH conjugated metals, ochratoxin A, PAH 
 
a poor substrate, b mainly excreted by liver, although renal excretion may occur as well. 
Based on following reviews (2; 40; 66; 77; 82). Abbreviations: ET: endothelin; GSH: glutathione; 
GSSG: glutathione disulfide; PAH: para-aminohippuric acid; PGA1-SG: S-(prostaglandin A1)-
glutathione  
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 MDR1 P-gp was initially found to be expressed in tumor cell lines resistant to 
chemotherapeutics and was first described by Juliano and Ling (49). Mrp2 was 
characterized and identified due to comparative studies in liver between normal and 
Mrp2 deficient rat strains, e.g. TR- rats and Eisai hyperbilirubinemic rats (44; 68). 
MDR1 P-gp and MRP2 are both apically expressed and consist of two nucleotide 
binding domains and two or three transmembrane domains, respectively. For more 
detailed structural information see Schinkel and Jonker (82). Both transporters were 
found to be part of important xenobiotic defense mechanisms in several barrier and 
excretory tissues. MDR1/Mdr1 P-gp and MRP2/Mrp2 limit xenobiotic absorption 
from the gut and entry into the central nervous system in several species including 
human (20; 22; 70; 92; 98). They are also present in liver and kidney, the two 
major organs involved in excretion of potentially toxic compounds (69; 77).  
MDR1 P-gp preferentially transports large hydrophobic organic cations and 
neutral compounds, including a wide variety of drugs, as described in table 1.1 (2; 
40; 66; 82). However, other physiological roles suggested for MDR1 P-gp are 
regulation of apoptosis, transport of cytokines and initiation of an immune response 
(40). It has also been speculated that the transporter plays a role in repair 
mechanisms by regulating the differentiation of stem cells (10; 111).  
MRP2 handles a wide range of compounds (see table 1.1), ranging from large, 
lipophillic, organic anions to polypeptides, including glutathione (GSH) conjugates 
as extensively reviewed by others (2; 40; 66; 77; 82). In addition, it has been 
suggested that MRP2 plays a role in cellular signaling by transporting the local 
mediator leukotriene C4 (13). Another role for MRP2 proposed in physiology is 
transport of GSH, thereby influencing detoxification of potentially harmful 
(reactive) compounds outside the cell, as well as whole body GSH turnover (3; 61). 
Both ABC transporters have been associated with pathological situations as well. 
Their overexpression in tumor cells confers multidrug resistance which is a major 
complication for successful cancer chemotherapy. MDR1 P-gp has been implicated 
in inflammatory bowel disease and HIV. On the other hand, it has been suggested 
that an increased MDR1 P-gp expression might prevent apoptotic processes leading 
to another mechanism of multidrug resistance (48; 78).  
A disturbance of MRP2 has also been reported in pathological situations. 
Examples are the Dubin Johnson syndrome, bile duct obstruction and ischemia in 
liver, which are characterized by cholestasis caused by absence of functional MRP2 
or decreased MRP2 levels, respectively (27). In contrast, after nephrectomy, the 
expression of rat Mrp2 in kidney and liver was increased (59). MRP2 has also been 
associated with oxidative stress. Under normal conditions most cellular GSH 
(>98%) is in its reduced state relative to its oxidized state, glutathione disulfide 
(GSSG), due to the acitivity of GSSG reductase. This GSH/GSSG ratio enables the 
cell to prevent damage through the radical scavenging ability of GSH (61; 102). 
MRP2 induces oxidative stress or at least favors it through the excretion of GSH, 
diminishing the GSH pool, thereby decreasing the GSH/GSSG ratio and, thus, 
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increasing the concentration of radicals (47). However, it should be noted, that the 
GSH/GSSG ratio in pathological situations is not solely determined by GSH efflux. 
In addition to GSH synthesis and degradation, GSH uptake and/or GSSG efflux 
may contribute. The latter process complicates the possible role of MRP2 in 
oxidative stress. MRP2 is able to transport GSSG (table 1.1), thereby shifting the 
GSH/GSSG in favor of protection against oxidative stress (61; 102).  
MRP2 and MDR1 P-gp seem to be regulated in a similar way. Both transporters 
are under the regulation of protein kinase C (PKC) through phosphorylation (40). 
Previous results suggest a regulatory mechanism for Mdr1 P-gp and Mrp2 in 
killifish renal proximal tubule, involving stimulation of PKC and subsequent 
inhibition of transport (67). Comparable results for PKC were found in human 
hepatocytes, viz. a decrease of MRP2 insertion in the canalicular membrane due to 
PKC, although this effect vanished after 24 h - 36 h of PKC stimulation (57). 
Insertion of Mrp2 into the canalicular membrane, however, was also stimulated by 
a PKC-dependent mechanism in cholestatic rat liver (6). Furthermore, Roelofsen et 
al. (76) observed a stimulation of Mrp2 sorting to the apical domain in rat 
hepatocyte couplets by cAMP. 
Disturbances of renal drug transport activity can have major consequences for 
cell function. It is, therefore, important to understand how these transporters are 
influenced either directly by potentially toxic substrates or indirectly. Insight in 
these regulation processes can be an important step towards the therapeutic 
intervention of nephrotoxicity.  
 
2.2. Short-term regulation after exposure to toxic compounds 
 
In addition to direct inhibition by binding to or competition with the transporters, 
nephrotoxicants are also known to influence the efflux pumps indirectly through 
regulation. Over the last few years, inhibition of killifish Mrp2 and Mdr1 P-gp 
mediated transport due to short-term exposure to heavy metals, aminoglycosides 
and radiocontrast fluids has been described. In this process the following sequence 
of events are triggered after exposure to these nephrotoxicants: influx of calcium, 
release of ET, binding of ET to the basolateral ETB receptor, and finally stimulation 
of PKC inhibition of Mdr1 P-gp and Mrp2 mediated transport. This process is 
depicted in figure 1.1A (35; 67; 93; 94). Inhibition of both transporters may result 
in the aggravation of cell injury due to accumulation of potentially toxic 
substances. On the other hand, inhibition of MDR1 P-gp and MRP2 saves ATP 
necessary for cell survival.  
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 Figure 1.1 Scheme illustrating the proposed sequence of events by which nephrotoxicants reduce 
Mrp2-mediated transport after short-term exposure and up-regulate Mrp2-mediated transport after 
prolonged exposure. (A) Nephrotoxicants cause a transient opening of calcium channels, which 
increases intracellular Ca2+ concentration and stimulates ET release. The hormone binds to a 
basolateral ETB receptor, which activates PKC. PKC activation rapidly reduces transport by 
Mrp2. (B) Long-term exposure to nephrotoxicants results in up-regulation of Mrp2-mediated 
transport due to increased insertion of Mrp2 in the membrane, decreased retrieval of Mrp2 from 
the apical membrane or de novo synthesis of Mrp2. PXR, CAR or MAP kinase are possible 
candidates to be involved in the latter process. 
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2.3 Long-term regulation after exposure to toxic compounds 
 
Long-term consequences of renal toxicant exposure appear to be different from 
the effects observed at short-term. Heavy metals and metal related compounds, e.g. 
cisplatin, up-regulate Mrp2 after prolonged exposure in rat and killifish (52; 93). 
Also ischemia, which may result from toxicant exposure, is known to increase 
Mrp2 expression in rat kidney, although simultaneously a down-regulation of Mdr1 
P-gp was found (59). This response can be hypothesized as a possible survival 
mechanism of the cell through increased efflux of potentially toxic conjugates by 
MRP2 and increased resistance against apoptosis by MDR1 P-gp. However, after 
prolonged cadmium exposure an impairment of NF-κB activation leading to Mdr1 
P-gp-mediated apoptosis in rat proximal tubule has been described as well (97). 
Up-regulation of transport activity observed in renal cells is, at least in part, due to 
an increased amount of transporter abundance in the apical membrane. Several 
mechanisms may lead to an increased membrane expression, including 1) increased 
insertion of transporters in the apical membrane; 2) inhibition of transport protein 
retrieval from the apical membrane; 3) de novo synthesis or 4) a combination of the 
above mentioned (figure 1.1B). Shuttling processes of MRP2/Mrp2 from 
intracellular stores towards the apical membrane are under the influence of PKC 
and cAMP, but is also known to result from pathological situations like cholestasis 
(6; 57; 76).  
An additional regulatory pathway involved in the de novo synthesis of MRP2, is 
activation of the nuclear receptors like the pregnane X nuclear receptor (PXR). This 
receptor is influenced by exposure to rifampicin, clotrimazol, hyperforin and 
phenobarbital, which results in an up-regulation of transport protein (11; 51; 53). 
The up-regulation of MRP2 is mostly accompanied by a simultaneous up-
regulation in MDR1 P-gp and an increased activity of drug metabolizing enzymes, 
indicating a coordinated regulation of drug detoxifying proteins (11; 25; 51; 73; 
90). However, until now this up-regulation was mostly observed in liver and not in 
kidney. 
The mitogen-activated protein (MAP) kinase pathways might be an alternative 
route for regulating transport protein expression. Recently, it was observed that 
aminoglycosides and chronically elevated ET-1 are associated with the regulation 
of the MAP kinases extracellular signal regulated kinase 1 and 2, similar to short-
term regulation of organic anion uptake (9; 81; 103). In addition, context-dependent 
signaling has been demonstrated for protein kinases (7; 42). In other words, the 
MAP kinase pathway is able to change its outcome in time due to negative and 
positive feedback loops, supporting the change from inhibition of transport directly 
after exposure to up-regulation at longer time. 
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 3. Endothelin and toxicity 
 
3.1. Endothelin 
 
The endothelium-derived polypeptide vasoconstrictor ET-1, first described by 
Hickey et al. (38) and isolated by Yanagisawa et al. (107), consists of 21 amino 
acids and is formed by cleavage of pre-pro-endothelin into pro-endothelin and is, 
subsequently, converted into ET-1 by an endothelin converting enzyme (38; 107). 
Screening a genomic DNA library revealed two other isoforms of ET, namely ET-2 
and ET-3 (43). The ET-1 gene has been localized to chromosome 6, while the ET-2 
gene and ET-3 genes were localized to chromosomes 1 and 20, respectively (43). 
ETs trigger several pathways through binding to the ET receptors, which belong to 
the family of G-protein coupled receptors. Until now two ET receptor subtypes 
have been cloned from mammalian tissues, ET receptor subtype A (ETA receptor) 
and B (ETB receptor) both with different affinities towards the different isoforms. 
The ETA receptor, mainly expressed in smooth muscle cells, has a high affinity for 
ET-1 and ET-2 (1). The ETB receptor has equal affinity for all three subtypes and is 
expressed in a variety of tissue, although predominantly in endothelial cells (79). 
Another receptor subtype, the ETC receptor, has been cloned from amphibian tissue 
and seems to have a greater affinity for ET-3 than for ET-1 and ET-2 (65). In the 
kidney, ET-1 and ET-2 are synthesized in the glomeruli (both endothelial and 
epithelial cells), while ET-1 and ET-3 are produced in the tubular epithelium. ETA 
receptors are present in the vascular system and glomeruli, ETB receptors are found 
in greatest abundance in inner medullary collecting ducts and glomeruli and to a 
lesser amount in tubular epithelial cells (17; 56; 108).  
 
3.2. Role of endothelin in the kidney 
 
Under physiological circumstances, circulating ET-1 concentrations have been 
reported to be in the picomolar range (88). Generally, it is accepted that circulating 
ET-1 binds preferentially to fenestrated endothelia of glomerular and peritubular 
capillaries and vasa recta (17). However, more autocrine and/or paracrine functions 
of locally synthesized ET-1 have been suggested since systemic ET-1 
concentrations seem to be low and ET receptors are located in tubular epithelial 
cells adjacent to endothelial and smooth muscle cells (64; 108).  
Until now, several major functions for ET in the kidney have been proposed 
(72). Most extensively described is the role of ET in the local control of blood flow 
in the renal microvasculature, in which ET, secreted by endothelial cells, 
counteracts vasodilatory signals relaseaed by endothelial cells and works in concert 
with other endothelium-derived vasoactive factors. An increase in the release of ET 
is presumably triggered by either a rise in blood flow, sensed by shear stress 
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receptors present in the endothelium. A second important function of ET in the 
kidney is its role in the regulation of glomerular haemodynamics. A rise in ET is 
known to increase efferent and afferent resistance, to decrease glomerular capillary 
flow rate and to reduce filtering surface area by triggering the contraction of 
mesangial cells. Together, all these actions result in a decrease in glomerular 
filtration rate (72; 87; 89). A third role of ET in the regulation of renal function is 
the maintenance of water and salt balance. In general, ET at low concentrations is 
natriuretic. As extensively reviewed by others, there is evidence to support that ET 
acting through ETB receptor binding is able to inhibit sodium and water 
reabsorption along various parts of the nephron, including the proximal tubule (24; 
31; 72). In addition, ET is involved in the regulation of Na+-phosphate cotransport 
and Na+/H+ exchange in the proximal tubule (32) and in the regulation of chloride 
flux in the thick ascending limb (46; 75).  
 
3.3. Role of endothelin in pathological situations 
 
ET has been associated with a variety of renal pathological situations as well. 
These include acute ischemic renal failure, renal parenchymal disease, fibrosis, 
acute transplant rejection and nephrotoxicity. In all these circumstances, ET was 
found to be increased locally (39; 54; 72). It is known that ET exerts its toxic 
actions through processes in which vasoconstriction, release of inflammatory and 
growth factors, the formation of reactive oxygen species (ROS) and drug 
transporters are involved. All these processes are discussed below. 
 
3.3.a. Vasoconstriction 
A possible event leading to nephrotoxicity is the ability of ET to reduce renal 
blood flow and glomerular filtration rate through vasoconstriction (60). In addition, 
reduced renal blood flow can result from oxidative stress. In particular, 
immunosuppresants, like cyclosporine A (15; 30) and FK-506 (tacrolimus) (34; 
71), cause this functional toxicity. Both immunosuppresants seem to induce an 
imbalance in vasoconstrictor and -dilator production (95). The vasoconstrictive 
action of ET triggered by cyclosporine A is mediated by ETA receptor activation 
(21; 41; 55), although lower doses of cyclosporin can activate the ETB receptor as 
well (91). Other groups of nephrotoxicants, e.g. heavy metals (100; 105; 106) and 
radiocontrast agents (8; 74), produce vasoconstrictive effects, however, this seems 
not to be the primary cause of renal injury.  
 
3.3.b. Reactive oxygen species 
The formation of reactive oxygen species (ROS) is another mechanism leading 
to kidney damage due to exposure to nephrotoxicants, like mercury (109), cadmium 
(96; 110), lead (12; 29), CSA (4; 101) and gentamicin (14; 86). ROS production 
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 results in lipid peroxidation and formation of adducts with essential proteins/DNA, 
eventually resulting in necrosis due to direct injury or oxidative stress. The relation 
between ROS and ET is direct through the ability of ROS to stimulate ET actions 
and vice versa (80; 83), and might involve NO formation (37). However, ROS can 
also be formed indirectly through oxidative stress caused by reduced renal blood 
flow due to (nephrotoxic) vasoconstriction. In addition, depletion of oxidant 
scavengers, e.g. GSH, resulting in diminished activity of important enzyme systems 
such as glutathione-S transferase, reductase and peroxidase, contribute to the 
formation of ROS as well (28; 101). Oxidant scavengers are known to be depleted 
through direct excessive binding of the heavy metals and cytotoxic drugs to thiol 
containing groups (58; 96; 109; 110).  
 
3.3.c. Inflammatory and growth factors 
Inflammatory factors and the release of growth factors in response to 
nephrotoxicants is generally an attempt of the cell to repair damage. However, it 
often results in scar tissue and diminished renal function, resulting in chronic renal 
failure. In general, an up-regulation of ET-1 synthesis and proinflammatory peptide 
synthesis is observed in damaged kidneys. (4; 45; 84; 85). ET seems to be one of 
the triggers for the excretion of these factors, which may result in chronic kidney 
inflammation (19; 23; 63). However, factors like TGFβ2 can also activate ET, 
resulting in fibrosis in the tubulointerstitium and the vasa recta through severe 
vasoconstriction (62). Furthermore, inflammatory and growth factors are released 
by ruptured lysosomes, as a result of an attempt of lysosomal degradation of the 
nephrotoxicants or excessive reabsorption of proteins (50).  
 
3.3.d. Transporters 
ET seems to be involved in the inhibition of the efflux transporters, Mdr1 P-gp 
and Mrp2, when looking at a short time period (see 2.2 and figure 1.1A), possibly 
supporting the hypothesis that this reaction of the cell promotes the aggravation of 
injury. However, when a longer time period is taken into account Mrp2 is up-
regulated suggesting a cell protective mechanism (see 2.3 and figure 1.1B). Other 
studies even suggest a role for transporters in repair mechanisms further supporting 
the protective mechanism (10; 111). It should be taken into account that 
transporters can be expressed differentially in the kidney in response to the same 
stimulus. In addition, the presence and possible opposite simultaneous regulation of 
other transporters with substrate overlap might lead to a small or even an 
undetectable physiological change. (18; 26).  
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4. Aim and outline of this thesis 
 
From the foregoing it seems that the role of ET in renal drug transport and renal 
toxicity is dual. ET is involved in vasoconstriction, inhibition of essential 
transporters, including Mrp2 and Mdr1 P-gp, and direct or indirect formation of 
ROS, growth and inflammatory mediators, favoring kidney damage. On the other 
hand, the apparent involvement of ET in stimulation of the xenobiotic transporters 
Mdr1 P-gp and Mrp2 seems to favor a renal protective system. This raises the 
question whether ET receptor antagonists can be used to prevent nephrotoxicity.  
In order to understand the role of ET receptor antagonists in nephrotoxicity, the 
mechanisms fired by ET leading to either nephrotoxicity or nephroprotection, need 
to be studied more extensively. Indeed, ET seems to be involved in a novel 
autocrine/paracrine mechanism in an early response to renal injury. The 
pathophysiological context concerning its role in regulation, however, is still 
unclear. One possible role of ET release during renal damage is to reduce certain 
ATP-consuming processes, like a reduction in fluid reabsorption, and MRP2 and 
MDR1 P-gp mediated transport. As a result, ATP could be conserved for duties 
more immediately relevant for cell survival. In addition, ET might prevent 
oxidative stress through decreased transport of GSH by inhibiting MRP2/Mrp2 (47; 
61). On the other hand, these effects of ET on the proximal tubule may be part of 
the normal progression of cellular events that occur during ET-mediated renal 
injury. Reduction of drug efflux may contribute to the progression of cellular 
damage as a result of higher intracellular concentrations of toxic compounds and 
metabolites. In particular accumulation of glutathione conjugates and GSSG, 
normally efficiently transported by MRP2, may occur (61; 102). 
The objective of this thesis is to gain insight in the ET-fired pathway responsible 
for the regulation of ATP-dependent transporters, in order to understand whether 
this leads to either nephroprotection or renal damage. An answer to this question 
will not only increase our understanding of the role of ET in renal tubular drug 
transport and toxicity, but may also have important therapeutical implications. 
When ET is harmful, ETB receptor antagonists could provide a novel way to protect 
the kidney against nephrotoxicity. However, when the role of ET is protective, 
caution should be taken with drugs antagonizing the ETB receptor. 
 
In this thesis we addressed this issue using isolated killifish proximal tubules, 
cultured mammalian renal cells and isolated perfused rat kidneys as renal 
experimental models. 
Chapter 2 and 3 describe the involvement of NO and cGMP in short-term 
regulation of Mrp2 as crucial steps in the ET-pathway triggered by aminoglycoside 
antibiotics, radiocontrast fluids and heavy metals. NO and cGMP followed ET 
binding to the ETB receptor and preceded PKC stimulation. In chapter 4, the long-
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 term effects caused by short-term exposure were studied. Here it is described that 
an up-regulation of Mrp2 occurs after the initial inhibition of Mrp2 followed by a 
recovery period. Interestingly, the up-regulation of Mrp2 occurs simultaneously 
with protection of the cells against a toxic insult. Chapter 5, a pilot study, describes 
the presence of several ABC transporters in progenitor cells present in damaged or 
developing kidneys of the skate, dogfish shark and zebrafish. The regulation of 
MRP2/Mrp2 in mammalian models is described in chapters 6 and 7. Chapter 6 
shows the validation of the isolated perfused rat kidney as a model to study Mrp2-
mediated transport. In chapter 7, an up-regulation of MRP2/Mrp2 is described after 
long-term exposure of renal cells to gentamicin or after a short-term exposure 
followed by a recovery period of 24 h, and in the rat in vivo. Again, involvement of 
ET in Mrp2 signaling was found. The thesis is concluded with a general discussion 
and summary in chapters 8 and 9, respectively.  
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 Summary 
 
We previously demonstrated in intact killifish renal proximal tubules that 
endothelin (ET), acting through an ETB receptor and protein kinase C (PKC) 
reduced transport mediated by multidrug resistance-associated protein 2 (Mrp2), 
i.e., luminal accumulation of fluorescein methotrexate (FL-MTX) (13). In the 
present study, we used confocal microscopy and quantitative image analysis to 
measure Mrp2-mediated transport of FL-MTX in killifish tubules as an indicator of 
the status of this ET-fired, intracellular signaling pathway. Exposing tubules to 
sodium nitroprusside (SNP), a nitric oxide (NO) donor, signaled a reduction in 
luminal accumulation of FL-MTX, suggesting pathway activation. NG-methyl-L-
arginine (L-NMMA), a NO synthase inhibitor, blocked the action of ET-1 on 
transport. Since SNP effects on transport were blocked by bisindolylmaleimide, a 
PKC selective inhibitor, but not by RES-701-1, an ETB receptor antagonist, 
generation of NO occurred after ETB receptor signaling but before PKC activation. 
NO generation was implicated in the actions of several nephrotoxicants, i.e., 
diatrizoate, gentamicin, amikacin, HgCl2 and CdCl2, each of which decreased 
Mrp2-mediated transport by activating ET signaling. For each nephrotoxicant, 
decreased FL-MTX transport was prevented when tubules were exposed to L-
NMMA. ET-1 and each of the nephrotoxicants stimulated NO production by the 
tubules as determined by a fluorescence–based assay. Together, the data show that 
NO generation follows ET binding to the basolateral ETB receptor and that, in 
activating the ET signaling pathway, nephrotoxicants produce NO, a molecule that 
could contribute to subsequent toxic effects. 
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Introduction 
 
Metabolism and excretion provide a first line of defense against the wide variety 
of potentially toxic chemicals to which we are continually exposed. In the kidney, 
the proximal tubule is responsible for the excretory transport from blood to urine of 
xenobiotics, xenobiotic metabolites and waste product of metabolism. As a result of 
its rich transport function, the proximal tubule is also an important target for toxic 
effects (2; 27).  
To accomplish this excretory function, epithelial cells in the proximal tubule 
possess multiple plasma membrane transporters that use ATP and transmembrane 
ion gradients to drive active drug secretion into urine. Among the proteins 
implicated in this process is a member of the ATP-binding cassette superfamily of 
membrane transporters: the multidrug resistance protein 2 (Mrp2). This transport 
protein is present at high levels in the luminal membrane of proximal tubule cells 
and handles a wide range of chemicals, from large, lipophillic organic anions to 
polypeptides (12; 22). 
Using intact killifish (Fundulus heteroclitus) renal proximal tubules, a 
fluorescent methotrexate derivative (FL-MTX) and confocal microscopy, we 
recently demonstrated that Mrp2 was regulated by ET, acting through a basolateral 
ETB receptor and protein kinase C (PKC) (13). By activating this signaling 
pathway, ET rapidly decreased cell to lumen transport of the fluorescent Mrp2 
substrate, FL-MTX. Interestingly, a similar decrease in transport was seen when 
tubules were exposed to several known nephrotoxic drugs (aminoglycoside 
antibiotics and radiocontrast agents) and that decrease was found to be due to 
activation of ET- ETB -PKC signaling (13; 25). The nephrotoxicants caused release 
of ET from the tubules and the hormone acted by an autocrine mechanism to signal 
a decrease in Mrp2-mediated transport. ET release appeared to be Ca2+-dependent 
in that elevated medium Ca2+ triggered the pathway and the effects of 
nephrotoxicants and elevated medium Ca2+ were abolished by nifedipine, a Ca2+ 
channel blocker (25). 
The precise sequence of events by which ET regulates Mrp2 transport is unclear. 
However, there is reason to believe that nitric oxide (NO) could be part of this ET-
signaling cascade in the kidney (18). NO is produced by NO synthase (NOS). Both 
NOS and ET were found to be localized to the same nephron segments including 
the proximal tubule (16; 18). In the vascular wall it is well documented that ET can 
trigger the endothelial release of NO via stimulation of the ETB receptors (4; 5; 26). 
Recent data suggest comparable cross talk between ET and NO in renal tubular 
cells (19; 20). In addition, NO has been implicated in cyclosporin A- and FK506-
induced nephrotoxicity in renal proximal tubules (6). 
In the present study, we used killifish renal proximal tubules to demonstrate that 
release of NO is an intermediate step in ET signaling. The data also show that ET-
Role of NO in endothelin regulated drug transport     33 
 activated NO production is also an early event in the action of nephrotoxicants, 
thus providing a possible mechanistic link between signaling and toxicity.  
 
 
Methods 
 
Chemicals 
The chemicals included fluorescein methotrexate (FL-MTX), 
bisindolylmaleimide (BIM), NG-methyl-L-arginine (L-NMMA) and 4-amino-5-
methylamino-2',7'-difluorofluorescein (DAF-FM) diacetate (Molecular Probes, 
Eugene, OR); RES-701-1, an ETB receptor antagonist (Peninsula Laboratories, 
Belmont, CA); sodium nitroprusside (SNP; Calbiochem, San Diego, Ca). HgCl2 
and CdCl2, gentamicin, amikacin, and diatrizoic acid (Sigma Chemicals, St. Louis, 
MO). All other chemicals used, were obtained at the highest purity available. 
 
Animals and tissue preparation 
Killifish were collected by local fishermen in the vicinity of Mount Desert 
Island, Maine and maintained at the Mount Desert Island Biological Laboratory in 
tanks with natural flowing seawater. Renal tubular masses were isolated in a marine 
teleost saline based on that of Forster and Taggart (3), containing (in mM) 140 
NaCl, 2.5 KCl, 1.5 CaCl2, 1.0 MgCl2 and 20 Tris at pH 8.0. All experiments were 
carried out at 18-20 °C. Under a dissecting microscope each mass was teased with 
fine forceps to remove adherent hematopoietic tissue. Individual killifish proximal 
tubules were dissected and transferred to a foil-covered Teflon chamber (Bionique) 
containing 1.5 ml of marine teleost saline with 1 µM FL-MTX and added effectors. 
The chamber floor was a 4 x 4 cm glass coverslip to which the tubules adhered 
lightly and through which the tissue could be viewed by means of an inverted 
microscope. Tubules were incubated at room temperature for 30 minutes until 
steady state was reached for FL-MTX. Analysis of tubule extracts by HPLC 
showed no metabolic degradation of FL-MTX when incubated with killifish 
proximal tubules for periods of at least 1 hour (12;23). 
 
Confocal microscopy 
The chamber containing renal tubules was mounted on the stage of an Olympus 
FluoView inverted confocal laser scanning microscope and viewed through a 40x 
water immersion objective (numerical aperature 1.15). Excitation was provided by 
the 488 nm line of an argon ion laser. A 510 nm dichroic filter and a 515 nm long-
pass emission filter were used. Neutral density filters and low laser intensity were 
used to avoid photobleaching. With the photomultiplier gain set to give an average 
luminal fluorescence intensity of 1500 to 3000 (on a scale of 0-4096), tissue auto-
fluorescence was undetectable. To obtain an image, dye-loaded tubules in the 
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chamber were viewed under reduced, transmitted light illumination, and a single 
proximal tubule with well-defined lumen and undamaged epithelium was selected. 
The plane of focus was adjusted to cut through the center of the tubular lumen and 
an image was acquired by averaging four scans. The confocal image was viewed on 
a high-resolution monitor and saved to an optical disk or Zip disk (omega). In 
previous studies, it has been shown that there is a linear relationship between 
fluorescence intensity and dye concentration (15). However, because of the many 
uncertainties in relating cellular fluorescence to actual compound concentration in 
cells and tissues with complex geometry, data are reported here as average 
measured pixel intensity rather than estimated dye concentration. Fluorescence 
intensities were measured from stored images using Scion image version 1.8 for 
Windows as described previously (12;14). Briefly, two or three adjacent cellular 
and luminal areas were selected from each tubule, and the average pixel intensity 
for each area was calculated. The values used for that tubule were the means of all 
selected areas. 
NO production by tubules was measured using an indicator, DAF-FM, that 
increases fluorescence intensity upon exposure to NO. For experiments tubules 
were loaded for 1 h in medium containing 10 µM DAF-FM diacetate. This non-
fluorescent derivative is membrane permeant and upon entering cells is hydrolyzed 
to DAF-FM. After loading, tubules were transferred to confocal chambers 
containing medium without (control) and with effectors. After 5 min, confocal 
images were collected (as for FL-MTX) and saved to a Zip disk. Average tubule 
fluorescence was measured from the stored images as described above. 
 
Data analysis 
Values are given as mean ± SE. Mean values were considered to be significantly 
different, when P<0.05 by use of the unpaired t-test, or by a one-way ANOVA 
followed by Bonferroni’s multiple comparison test. Software used for statistical 
analysis was GraphPad Prism (version 3.00 for Windows; GraphPad Software, San 
Diego CA). 
 
 
Results 
 
The present experiments were conducted using isolated renal proximal tubules 
from a marine teleost fish, the killifish. This has proven a powerful model for the 
study of secretory transport in an intact proximal tubule (21). As in mammalian 
proximal tubules, killifish express high levels of Mrp2 in the luminal membrane of 
renal proximal tubule cells. Moreover, intact killifish tubules exhibit Mrp2-
mediated transport of a number of fluorescent substrates, e.g., FL-MTX, that can be
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 Figure 2.1 Representative confocal images of killifish proximal tubules after incubation in marine 
teleost saline with 1 µM fluorescein methotrexate (FL-MTX) for 30 min in the absence (A) and 
presence (B) of the nitric oxide (NO) donor sodium nitroprusside (SNP). Treatment with 100 µM 
SNP reduced luminal fluorescence, indicating that FL-MTX secretion on multidrug resistance 
protein 2 (Mrp2) was inhibited. 
 
 
visualized and measured using confocal microscopy (12-14). Figure 2.1A shows a 
typical confocal image of a control killifish tubule after 30 min (steady state) 
incubation in medium with 1 µM FL-MTX. The fluorescence distribution pattern is 
the same as shown previously, i.e., fluorescence intensity in lumen>cells>medium 
(12;13). We have demonstrated that this pattern is indicative of a two-step process, 
involving uptake at the basolateral membrane mediated by an as yet 
uncharacterized transporter for large organic anions and secretion into the lumen 
mediated by a teleost form of Mrp2 (for data on substrate and inhibitor specificities 
as well as immunostaining with Mrp2 antibodies, see Refs. 13 and 25). 
Figure 2.1 also shows confocal images of FL-MTX transport in tubules exposed 
to the NO donor, SNP. In previous experiments using ET-1, a decrease in luminal 
accumulation of FL-MTX and no effect on cellular accumulation has been taken to 
indicate decreased transport on Mrp2 (13). Similar to the effects of ET-1, 100 µM 
SNP decreased luminal, but not cellular accumulation of FL-MTX (figure 2.1B). 
Quantitation of images showed that 50-100 µM SNP reduced steady state luminal 
accumulation of FL-MTX by about 50% (figure 2.2A). The action of SNP was 
rapid, causing a significant reduction of luminal fluorescence within 10 min of 
exposure and a sustained decrease over the 30 min time course of the experiment 
(figure 2.2B). SNP did not affect cellular fluorescence. 
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Figure 2.2 The NO-donor, SNP, 
reduces transport of FL-MTX on 
Mrp2. (A) shows the effects of 10-
100 µM SNP on steady state (30 
min) FL-MTX accumulation. (B) 
shows the time course of FL-MTX 
accumulation in control tubules 
and tubules exposed to 100 µM 
SNP from time zero on. SNP 
significantly reduced luminal 
fluorescence intensity at all times 
(P<0.001). Values are means ± 
SEM for 6-16 tubules from a 
single fish. Significantly lower 
than the control value (**: 
P<0.001). 
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Figures 2.1 and 2.2 indicate that SNP and ET-1 have similar effects on Mrp2-
mediated transport of FL-MTX. To determine whether NO release was a 
consequence of ET-1 exposure, tubules were exposed to 10 nM ET-1 in the 
absence or presence of L-NMMA, a NOS inhibitor. Figure 2.3 shows that L-
NMMA by itself had no effect on FL-MTX transport, but that this NOS inhibitor 
attenuated the effect of ET-1. Thus, ET-1 activated NOS. In killifish tubules, ET-1 
interacts with a basolateral ETB receptor and to reduce Mrp2-mediated transport by 
acting through PKC (13). In this study the effects provided by ET-1 were prevented 
using the ETB receptor antagonist, RES-701-1, or PKC-selective inhibitors BIM, 
calphostin C or staurosporine. To determine where NO generation was placed in 
the signaling pathway, we examined the abilities of RES-701-1 and the PKC-
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 Figure 2.3 Inhibition of NOS 
blocks the action of ET-1 on FL-
MTX transport. Tubules were 
incubated for 30 min in medium 
containing 1 µM FL-MTX alone 
(control) or with 10 nM ET-1, 50 
µM NG-methyl-L-arginine (L-
NMMA) or ET-1 plus L-NMMA. 
Confocal images were collected 
and analyzed as described in 
Methods. Values are means ± SE 
for 11-20 tubules from a single 
fish. Significantly lower than the 
control value (**: P<0.001). Co
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Figure 2.4 The ETB receptor 
antagonist, RES701-1, does not 
protect against inhibition of 
Mrp2-mediated FL-MTX 
transport by NO. Tubules were 
incubated for 30 min in medium 
containing 1 µM FL-MTX alone 
(control) or with 100 nM SNP or 
SNP plus 100 nM RES701-1. 
Confocal images were collected 
and analyzed as described in 
Methods. Values are means ± SE 
for 10-11 tubules from a single 
fish. Significantly lower than the 
control value (**: P<0.001). 
 
 
 
 
selective inhibitor, BIM, to attenuate the effects of SNP on FL-MTX transport. 
RES-701-1 did not alter the effects of SNP on transport (figure 2.4), but BIM 
protected completely (figure 2.5), indicating that NO generation came after ETB 
receptor binding, but before PKC activation. 
We recently found that in killifish tubules ET release and subsequent signaling 
could be activated by two types of external stimuli: elevated extracellular Ca2+ and 
several, structurally unrelated nephrotoxicants (25). The present experiments 
indicate that each of these act through NO. Figure 2.6 shows that L-NMMA 
prevented the decrease in luminal FL-MTX accumulation caused by increasing the
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Figure 2.5 A PKC-selective 
inhibitor, BIM, protects against 
inhibition of Mrp2-mediated 
FL-MTX transport by NO. 
Tubules were incubated for 30 
min in medium containing 1 
µM FL-MTX alone (control) or 
with 100 µM SNP, 100nM BIM 
or SNP plus BIM. Confocal 
images were collected and 
analyzed as described in 
Methods. Values are means ± 
SE for 9-15 tubules from a 
single fish. Significantly lower 
than the control value (**: 
P<0.01). 
 
 
Figure 2.6 L-NMMA protects 
against inhibition of Mrp2-
mediated FL-MTX transport by 
elevated medium Ca2+. Tubules 
were incubated for 30 min in 
medium containing 1.5 mM 
Ca2+ and 1 µM FL-MTX 
(control), 3 mM Ca2+ and 1 µM 
FL-MTX and 3 mM Ca2+, 1 µM 
FL-MTX and 50 µM L-
NMMA. Confocal images were 
collected and analyzed as 
described in Methods. Values 
are means ± SE for 18 tubules 
from a single fish. Significantly 
lower than the control value 
(**: P<0.001). 
 
 
 
 
 
 
medium Ca2+ concentration from 1.5 mM in controls to 3 mM in treated tubules. 
Table 2.1 shows the results of a series of experiments in which nephrotoxicants 
reduced FL-MTX transport mediated by Mrp2. The data for the aminoglycoside 
antibiotics, gentamicin and amikacin, and for the radiocontrast agent, diatrizoate, 
confirm previous findings (25). For these drugs, effects on Mrp2-mediated 
transport were shown to be due to stimulation of ET release by the tubules and 
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 Table 2.1 Inhibition of FL-MTX transport by nephrotoxicants and protection by 50 µM L-
NMMA. 
 
 Control Nephrotoxicant Nephrotoxicant +  L-NMMA 
Gentamicin (10 µM) 2160 ± 140 1550 ± 130   * 2200 ± 230  
Amikacin (10 µM) 2650 ± 120 1460 ± 120 ** 2600 ± 130  
Diatrizoate (10 µM) 1670 ± 130 1020 ± 160 ** 1640 ± 160  
HgCl2 (0.1 µM) 2140 ± 160 1280 ± 170 ** 2170 ± 130  
CdCl2 (10 µM) 2300 ± 180 1130 ± 150 ** 1850 ± 190  
 
Values are expressed as means ± SE luminal fluorescence intensity of 11-21 tubules. L-NMMA, 
NG-methyl-L-arginine. None of the nephrotoxicants altered cellular fluorescein methotrexate (FL-
MTX) accumulation. Significantly lower than the control value (*: P<0.05, **: P<0.001).  
 
 
 
subsequent ET action through the ETB receptor and PKC (25). Additional 
experiments with killifish tubules have disclosed a similar mechanism of action for 
low concentrations of the heavy metal salts, HgCl2 and CdCl2 (Terlouw SA and 
Miller DS, unpublished observations). Table 2.1 shows that for all of these 
nephrotoxicants, including HgCl2 and CdCl2, inhibition of NOS by L-NMMA 
prevented the reduction in Mrp2-mediated transport. Thus, the effects of elevated 
medium Ca2+ and the nephrotoxicants appear to involve generation of NO. 
 
 
Figure 2.7 The NO-donor SNP 
(100 nM) and several nephro-
toxicants (10 µM diatrizoate, 10 
µM CdCl2, 10 µM amikacin and 
10 µM gentamicin) stimulate NO 
production. Tubules were 
preincubated for 1 h in medium 
containing 10 µM 4-amino-5-
methylamino-2',7'-difluorofluo-
rescein (DAF-FM) diacetate. 
After loading, tubules were 
transferred to confocal chambers 
containing medium without 
(control) and with effectors. After 
5 min, confocal images were 
collected and analyzed as 
described in Methods. Values are 
means ± SE for 11-14 tubules 
from two fishes. Significantly 
lower than the control value (**: 
P<0.001). 
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Figure 2.8: The stimulation of 
NO production caused by 
exposure to 10 nM ET-1 was 
blocked 50 µM L-NMMA (A). 
The stimulation of NO production 
caused by exposure 10 µM 
gentamicin (Gent) could also be 
blocked by 100 nM RES-701-1 
(B). Tubules were preincubated 
for 1 h in medium containing 10 
µM DAF-FM diacetate. After 
loading, tubules were transferred 
to confocal chambers containing 
medium without (control) and 
with effectors. After 5 min, 
confocal images were collected 
and analyzed as described in 
Methods. Values are means ± SE 
for 11-14 tubules from two fishes. 
Significantly lower than the 
control value (*: P<0.01, **: 
P<0.001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To test this supposition directly, we measured NO generation in intact killifish 
tubules using a fluorescence-based technique. The technique relies on the formation 
of a highly fluorescent product when DAF-FM reacts with NO. The indicator is 
introduced to the tubule as a non-fluorescent ester, DAF-FM diacetate, which is 
membrane-permeable and which is hydrolyzed intracellularly to DAF-FM. Figure 
2.7 shows that the average fluorescence intensity was low in control tubules, but 
that it increased several fold in tubules exposed to the NO generator, SNP (100 
µM). Roughly the same magnitude of increase was also found for tubules exposed 
to diatrizoate, CdCl2, amikacin and gentamicin at concentrations that reduce FL-
MTX transport mediated by Mrp2. ET-1 also generated NO (figure 2.8A) and this 
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 production was blocked by the NOS inhibitor, L-NMMA. Finally, figure 2.8B 
shows that NO production induced by gentamicin was blocked by the ETB receptor 
antagonist, RES-701-1. Together these data demonstrate that ET-1 and the 
nephrotoxicants stimulated NO production in the tubules. 
 
 
Discussion 
 
Using killifish renal proximal tubules, we previously demonstrated that ET, 
acting through an ETB receptor and PKC reduced transport mediated by Mrp2, i.e., 
luminal accumulation of FL-MTX (13). In the present study, we used Mrp2-
mediated transport of FL-MTX to monitor activity of this ET-fired, intracellular 
signaling pathway, the aim being to examine further the chain of events that 
connect ETB receptor binding at the basolateral membrane to reduction of transport 
at the luminal membrane. We show here that exposing tubules to SNP, an NO 
donor, also signaled a reduction in transport. Importantly, exposure to L-NMMA, a 
NOS inhibitor, blocked the action of ET-1 on transport. Since the effects of SNP on 
transport were blocked by BIM, a PKC selective inhibitor, but not by RES-701-1, 
an ETB receptor antagonist, generation of NO occurred after receptor signaling but 
before PKC activation. Several additional observations are consistent with this 
proposed sequence of events. Experiments using a fluorescence-based NO assay 
showed that ET-1 and the nephrotoxicants stimulated NO production by intact 
tubules. For ET-1, NO production was blocked by an inhibitor of NOS; for the 
nephrotoxicant, gentamicin, NO production was blocked by an ETB receptor 
antagonist. A scheme of the proposed signaling pathway is shown in figure 2.9. 
The present data are the first to describe an ET-NO-PKC signaling axis in renal 
proximal tubule. In agreement with our findings, activation of NOS was found after 
ETB receptor stimulation in the thick ascending limb and this was associated with 
inhibited chloride transport (19;20). In OK cells, a proximal tubule cell line from 
opossum, Liang and Knox described a NO-PKC-Na+,K+-ATPase signaling pathway 
(9). Such a pathway was not present in LLC-PK1 cells, a proximal tubule cell line 
from pig (9). Obviously, species differences or differences in culture conditions 
could underlie the differences in signaling found in the two cell lines. 
Liang and Knox have suggested that NOS might activate PKC through guanylate 
cyclase (9). Results indicating cyclic GMP generation following NO synthesis 
confirm this suggestion (24;30). Interestingly, it was recently shown that one 
member of the MRP family, viz. MRP5, transports cGMP (7). It is possible that 
Mrp2 transports the cyclic nucleotide as well, and that cGMP might compete with 
FL-MTX for efflux resulting in a decreased FL-MTX transport. In this regard, our 
preliminary experiments show that in killifish tubules 8-Br-cGMP is a potent 
inhibitor of FL-MTX transport from cell to lumen and that at least a portion of that 
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Figure 2.9 Scheme illustrating the proposed sequence of events by which nephrotoxicants reduce 
Mrp2-mediated transport in isolated renal proximal tubules. Nephrotoxicants cause a transient 
opening of Ca2+ channels, which increases intracellular Ca2+ concentration and stimulates ET 
release. The hormone binds to a basolateral ETB receptor, which activates NOS, increases NO 
production and activates PKC. PKC activation rapidly reduces transport by Mrp2. 
 
 
inhibition is removed when tubules are pretreated with an inhibitor of PKG 
(Notenboom S and Miller DS, unpublished observations). The latter suggests 
activation of guanylate cylclase by PKC rather than the opposite, since the effect of 
NO generation by the NO-donor, SNP, was completely reversed by inhibiting PKC. 
Whether guanylate cyclase is directly or indirectly responsible for a diminished 
transport of organic anions by Mrp2, will be investigated in further research.  
Although it is not clear whether proximal tubules are capable of generating NO 
under basal conditions, they certainly can produce large amounts of the substance 
when stimulated (10). In this regard, proximal tubules express several NOS 
isoforms including, iNOS and eNOS and NO production increases upon exposure 
to a variety of stimuli, including, LPS, cytokines, hypoxia and several nephrotoxic 
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 chemicals (10). The present results indicate that when killifish proximal tubules 
were exposed to radiocontrast agents, aminoglycoside antibiotics or heavy metal 
salts, NO production increased. In addition, for each of the compounds Mrp2-
mediated transport decreased and for each this decrease was prevented when the 
tubules were also exposed to a NOS inhibitor, L-NMMA. We have recently found 
that each of the nephrotoxicants tested reduce Mrp2-mediated transport in killifish 
tubules by inducing ET release and activating ETB receptor-PKC signaling (13;25). 
Nephrotoxicant action appeared to be Ca2+-dependent, since nifedipine, an L-type 
Ca2+ channel blocker, protected and since elevated medium Ca2+ also stimulated ET 
release and signaling. The present results indicate that exposure of tubules to 
nephrotoxicants or elevated medium Ca2+ also produces NO as an intermediate step 
in signaling (figure 2.9).  
Production of NO as a consequence of nephrotoxicant-triggered signaling 
provides a toxicological context in which to consider the present and previous 
results. NO production has been implicated in renal diseases and in the action of 
several nephrotoxic compounds (8). For example, hypoxic/ischemic injury is 
prevented by L-NAME and enhanced by SNP (29) and iNOS appears to be the 
critical isoform involved (11;17). In renal proximal tubule cells, NO induces 
apoptosis and potentiates immunosupressant-induced apoptosis (1;6). ET signaling 
and NO production are implicated in HgCl2-induced acute renal failure (28). In this 
regard, although short term exposure of killifish tubules to the relatively low 
concentrations of nephrotoxic compounds used in the present study produced no 
evidence of cellular toxicity [as measured by the ability to actively transport 
fluorescein on the classical organic anion system (Ref. 25 and Notenboom S and 
Miller DS, unpublished observations)], our initial experiments show that longer 
exposures are clearly toxic and that L-NMMA can protect (Notenboom S and 
Miller DS, unpublished observations). Experiments are underway to determine 
whether toxicity is a result of signaling through the ET-ETB receptor-NOS-PKC 
pathway or whether a separate sequence of events leads to NO production and 
subsequent toxicity. 
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 Summary 
 
In killifish renal proximal tubules, endothelin-1 (ET-1), acting through a 
basolateral ETB receptor, nitric oxide synthase (NOS), and PKC, decreases cell-to-
lumen organic anion transport mediated by the multidrug resistance protein isoform 
2 (Mrp2). In the present study, we examined the roles of guanylyl cyclase and 
cGMP in ET signaling to Mrp2. Using confocal microscopy and quantitative image 
analysis to measure Mrp2-mediated transport of the fluorescent drug, fluorescein 
methotrexate (FL-MTX), we found that oxadiazole quinoxalin (ODQ), an inhibitor 
of NO-sensitive guanylyl cyclase, blocked ET-1 signaling. ODQ was also effective 
when signaling was initiated by nephrotoxicants (gentamicin, amikacin, diatrizoate, 
HgCl2 and CdCl2), which appear to stimulate ET release from the tubules 
themselves. ODQ blocked the effects of the NO donor, sodium nitroprusside, but 
not of the phorbol ester which activates PKC. Exposing tubules to 8-bromo-cGMP 
(8Br-cGMP), a cell permeable cGMP analog, decreased luminal FL-MTX 
accumulation. This effect was abolished by bisindolylmaleimide (BIM), a PKC 
inhibitor, but not by L-NMMA, an NOS inhibitor. Together, these data indicate that 
ET regulation of Mrp2 involves activation of guanylyl cyclase and generation of 
cGMP. Signaling by cGMP follows NO release and precedes PKC activation. 
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Introduction 
 
Multidrug resistance proteins (MRPs) are ATP-driven xenobiotic export pumps 
that belong to the ATP-binding cassette superfamily (ABC superfamily). These 
transporters were initially found to be expressed in tumor cell lines resistant to 
chemotherapeutics. However, they also contribute to important xenobiotic defense 
mechanisms in barrier and excretory tissues. P-glycoprotein (ABCB1), breast 
cancer related protein (BCRP, ABCG2) (16; 31) and members of the ABCC 
subfamily (the MRPs) limit xenobiotic absorption from the gut and xenobiotic 
entry into the central nervous system (3; 5; 20). They are also present in liver and 
kidney, organs important for the excretion of potentially toxic xenobiotics, 
xenobiotic metabolites and endogenous waste products (19; 26). The apical 
localization of P-glycoprotein and MRP2 in hepatocytes and renal proximal tubule 
epithelial cells is consistent with their importance in excretory transport into bile 
and urine. In addition, some MRPs may play a role in cellular signaling by 
transporting second messengers like cyclic nucleotides and leukotrienes (2; 13; 34).  
We previously used intact killifish (Fundulus heteroclitus) renal proximal 
tubules to demonstrate that Mrp2 function is regulated by the vasoactive peptide 
endothelin (ET) working through a basolateral ETB receptor, nitric oxide synthase 
(NOS), nitric oxide (NO), and protein kinase C (PKC) (18; 23; 33). Firing this 
signaling pathway rapidly reduced transport mediated by Mrp2. Importantly, this 
autocrine/paracrine signaling pathway was also triggered by acute exposure to low 
levels of nephrotoxicants, which caused Ca2+-dependent release of ET (33).  
The present study is concerned with the mechanism by which NO activates PKC 
in killifish renal proximal tubules. Specifically, we found that inhibition of 
guanylyl cyclase blocked ET-signaling whether initiated by ET-1 or by 
nephrotoxicants. In addition, 8-bromo-cGMP (8Br-cGMP) reduced Mrp2-mediated 
transport and this effect was blocked when PKC was inhibited, but not when NOS 
was inhibited. Thus, guanylyl cyclase appears to be involved in signaling by ET 
and the nephrotoxicants; generation of cGMP follows NO release and precedes 
PKC activation. 
 
 
Methods 
 
Chemicals 
Fluorescein methotrexate (FL-MTX), bisindolylmaleimide (BIM), and NG-
Methyl-L-arginine acetate salt (L-NMMA) were purchased from Molecular Probes 
(Eugene, OR). RES-701-1, an ETB receptor antagonist was obtained from 
Peninsula Laboratories (Belmont, CA). Sodium nitroprusside (SNP) and oxadiazole 
quinoxalin (ODQ) were purchased from Calbiochem (San Diego, CA). Phorbol 12-
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 myristate 13-acetate (PMA) was obtained from Alexis biochemicals (San Diego, 
CA) and from Sigma Chemicals (St. Louis, MO). 8Br-cGMP and its Rp isoform, 
HgCl2 and CdCl2, gentamicin, amikacin, and diatrizoic acid were purchased from 
Sigma Chemicals (St. Louis, MO). All other chemicals used were obtained at the 
highest purity available commercially. 
 
Animals and tissue preparation 
Killifish were collected by local fishermen in the vicinity of Mount Desert 
Island, Maine and maintained at the Mount Desert Island Biological Laboratory in 
tanks with natural flowing seawater. Renal tubular masses were isolated in a marine 
teleost saline based on that of Forster and Taggart (4), containing (in mM) 140 
NaCl, 2.5 KCl, 1.5 CaCl2, 1.0 MgCl2 and 20 Tris) at pH 8.0. All experiments were 
carried out at 18-20 °C. Under a dissecting microscope each mass was teased with 
fine forceps to remove adherent hematopoietic tissue. Individual killifish proximal 
tubules were dissected and transferred to a foil-covered Teflon chamber containing 
1.5 ml of marine teleost saline with 1 µM FL-MTX and added effectors. The 
chamber floor was a 4 x 4 cm glass coverslip to which the tubules adhered lightly 
and through which the tissue could be viewed by means of an inverted microscope. 
Tubules were incubated at room temperature for 30 minutes until steady state was 
reached for FL-MTX. Analysis of tubule extracts by HPLC showed no metabolic 
degradation of FL-MTX when incubated with killifish proximal tubules for periods 
of at least 1 hour (17; 29). 
 
Confocal microscopy 
The chamber containing renal tubules was mounted on the stage of an Olympus 
FluoView inverted confocal laser scanning microscope and viewed through a 40x 
water immersion objective (numerical aperture 1.15). Excitation was provided by 
the 488 nm line of an argon ion laser. A 510 nm dichroic filter and a 515 nm long-
pass emission filter were used. Neutral density filters and low laser intensity were 
used to avoid photobleaching. With the photomultiplier gain set to give an average 
luminal fluorescence intensity of 1500 to 3000 (on a scale of 0-4096), tissue auto-
fluorescence was undetectable. To obtain an image, dye-loaded tubules in the 
chamber were viewed under reduced, transmitted light illumination, and a single 
proximal tubule with well-defined lumen and undamaged epithelium was selected. 
The plane of focus was adjusted to cut through the center of the tubular lumen and 
an image was acquired by averaging four scans. The confocal image was viewed on 
a high-resolution monitor and saved to an optical disk or Zip disk. In previous 
studies, it has been shown that there is a linear relationship between fluorescence 
intensity and dye concentration (22). However, because of the many uncertainties 
in relating cellular fluorescence to actual compound concentration in cells and 
tissues with complex geometry, data are reported here as average measured pixel 
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intensity rather than estimated dye concentration. Fluorescence intensities were 
measured from stored images using Scion image version 1.8 for Windows as 
described previously (17; 21). Briefly, two or three adjacent cellular and luminal 
areas were selected from each tubule, and the average pixel intensity for each area 
was calculated. The values used for that tubule were the means of all selected areas 
after subtraction of the pixel intensity of the bathing medium, which was 
considered as background. 
 
Data analysis 
Data are given as mean ± SE. Mean values were considered to be significantly 
different, when P<0.05 by use of the unpaired t-test, or by a one-way ANOVA 
followed by Bonferroni’s multiple comparison test. Software used for statistical 
analysis was GraphPad Prism (version 3.00 for Windows; GraphPad Software, San 
Diego CA). 
 
 
Results 
 
The present experiments were conducted using isolated renal proximal tubules 
from a marine teleost fish, the killifish, to determine whether guanylyl cyclase and 
cGMP are involved in the regulation of Mrp2-mediated transport. This comparative 
animal model has proven to be a powerful tool for the study of secretory transport 
in an intact proximal tubule (24). As in mammalian proximal tubules, killifish 
express high levels of Mrp2 in the luminal membrane of renal proximal tubule 
cells. Moreover, intact killifish tubules exhibit Mrp2-mediated transport of a 
number of fluorescent substrates, e.g., FL-MTX, that can be visualized and 
measured using confocal microscopy (17; 18; 21). Figure 3.1A shows a typical 
confocal image of a control killifish tubule after 30 min (steady state) incubation in 
medium with 1 µM FL-MTX. Autofluorescence was not detectable. The 
fluorescence distribution pattern is the same as shown previously, with 
fluorescence intensity in lumen>cells>medium (17; 18). This pattern is indicative 
of a two-step process, involving uptake at the basolateral membrane mediated by an 
as yet uncharacterized transporter for large organic anions and secretion into the 
lumen mediated by a teleost form of Mrp2 (for data on substrate and inhibitor 
specificities as well as immunostaining with Mrp2 antibodies, see Refs. 18 and 33). 
Using an Sf9 overexpression system, we previously proved that FL-MTX is a 
substrate for MRP2 (32). Interference of other members of the Mrp family with FL-
MTX transport in this model is unlikely, although other Mrp’s are known to share 
numerous substrates. However, Mrp5 and Mrp6 are located in the basolateral 
membrane and not in the apical membrane of renal proximal tubules, whereas 
Mrp1 and Mrp3 are not expressed in renal proximal tubules (26). Furthermore, we
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Figure 3.1 Representative confocal images of killifish proximal tubules after incubation in marine 
teleost saline with 1 µM fluorescein methotrexate (FL-MTX) for 30 min in the absence (A) and 
presence of the cGMP analog 8-bromo-cGMP (8Br-cGMP; B). Treatment with 1 µM 8Br-cGMP 
reduced luminal fluorescence, indicating that FL-MTX secretion on multidrug resistance protein 
isoform 2 (Mrp2) was inhibited.  
 
 
can exclude the contribution of Mrp4 because preliminary results from our group 
show that FL-MTX is not a substrate for MRP4 (Smeets PHE and Russel FGM, 
unpublished observations), and MRP4-mediated transport is insensitive to 
leukotriene C4 (34), which is an excellent inhibitor of FL-MTX secretion in killifish 
proximal tubules (17; 18). 
To determine whether ET signaling involved activation of guanylyl cyclase, we 
examined the effects of the NO-sensitive-guanylyl cyclase inhibitor ODQ on FL-
MTX transport and its modulation by ET-1. Figure 3.2 shows that exposure to 10 
nM ET-1 resulted in a decrease in luminal accumulation of FL-MTX by about 50% 
and an unchanged cellular accumulation, a result consistent with previous 
experiments (18). This inhibition pattern is consistent with that observed in earlier 
experiments after exposure to specific Mrp2 inhibitors such as leukotriene C4 (17; 
18) and taken to mean that FL-MTX efflux into the lumen is not an important 
determinant of steady-state cellular FL-MTX accumulation. Indeed, time course 
experiments showed a rapid increase in cellular and luminal fluorescence in control 
tubules that reached a steady state after 10 min. For tubules exposed to 10 nM ET-1 
from time zero on, cellular fluorescence approximated control values, but luminal 
fluorescence was significantly lower than controls except at the earliest time 
measured (18). This indicates that the steady-state cellular levels of FL-MTX are 
set independently of events at the luminal membrane. Exposing tubules to 10 µM 
ODQ by itself did not affect luminal FL-MTX accumulation and thus transport. 
When tubules were exposed to ET-1 plus ODQ no significant reduction in luminal
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Figure 3.2 Prevention of the 
inhibitory effect of endothelin-1 
(ET-1) on FL-MTX transport by 
the guanylyl cyclase inhibitor 
oxadiazole quinoxalin ODQ. The 
inhibitory effect caused by 10 nM 
ET-1 on FL-MTX transport is 
prevented by 10 µM ODQ, 
indicating cGMP generation 
following ET-1 release. Values 
are means ± SE for 10-15 tubules 
from 1 fish. Significantly lower 
than the control value (***: 
P<0.001).  
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accumulation of FL-MTX was found. None of these treatments affected cellular 
FL-MTX accumulation again indicating that steady-state cellular levels of FL-
MTX seem to set independently of events at the luminal membrane. Since we 
previously demonstrated that several nephrotoxicants also fired ET signaling in the 
tubules (33), we also determined whether nephrotoxicant effects on signaling and 
FL-MTX transport could be blunted by ODQ. Consistent with previous results (23; 
33), exposing tubules to gentamicin, amikacin, diatrizoate, HgCl2, and CdCl2 
significantly reduced luminal accumulation of FL-MTX (table 3.1); cellular 
accumulation was not affected (not shown). The concentrations of nephrotoxicants 
used here do not reduce transport of FL by the classical Na-dependent organic 
anion system (33) and do not reduce mitochondrial membrane potential measured 
 
 
Table 3.1 Inhibition of FL-MTX transport by nephrotoxicants and protection by 10 µM ODQ. 
 
 Control Nephrotoxicant Nephrotoxicant +10 µM ODQ 
Gentamicin (10µM) 2160 ± 230 690 ± 150 * 1990 ± 240 
Amikacin (10 µM) 1670 ± 260 830 ± 150 * 1920 ± 220 
Diatrizoate (10 µM) 1670 ± 260 370 ±   80 * 1480 ± 190 
HgCl2 (100 nM) 1770 ± 170 620 ± 160 * 1810 ± 300 
CdCl2 (10 µM) 1770 ± 170 420 ± 100 * 1240 ± 270 
 
Values are means ± SE expressed as luminal fluorescence intensity of 10-14 tubules. FLMTX, 
fluorescein methotrexate; ODQ, oxadiazole quinoxalin. None of the nephrotoxicants altered 
cellular FL-MTX accumulation. Significantly lower than the control value (*: P<0.001).  
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Figure 3.3 Effects of guanylyl 
cyclase inhibitor, ODQ, on FL-
MTX transport inhibited by nitric 
oxide (NO) and PKC stimulation. 
The inhibitory effect caused by 
100 µM sodium nitroprusside 
(SNP) on FL-MTX transport is 
prevented by 10 µM ODQ (A). 
However, the inhibitory effect 
caused by 100 nM PMA on FL-
MTX transport could not be 
prevented by 10 µM ODQ (B). 
Together these data indicate that 
cGMP generation follows NO 
release and precedes PKC 
stimulation. Values are means ± 
SE for 10-14 tubules from 1 fish. 
Significantly lower than the 
control value (***: P<0.001).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
using a fluorescent indicator dye (Notenboom S, Miller DS, Russel FGM., and 
Masereeuw R, unpublished observations). Importantly, when tubules were 
pretreated with 10 µM ODQ, none of the nephrotoxicants significantly reduced 
luminal FL-MTX accumulation. Thus, inhibiting guanylyl cyclase blocked 
signaling through the ETB receptor-NOS-PKC pathway irrespective of whether the 
stimulus was hormone or nephrotoxicant. We used ODQ as a pharmacological tool 
to determine the position of guanylyl cyclase in the signaling chain. Figure 3.3 
shows that ODQ attenuates the reduction in luminal FL-MTX accumulation caused 
by the NO donor, SNP, but has no effect on the reduction caused by the PKC 
activator, PMA. Thus, activation of guanylyl cyclase appears to follow NO release 
and precedes PKC activation. 
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Figure 3.4 Dose-dependent 
inhibitory effect of 8Br-cGMP (A) 
and its inactive Rp-isoform (Rp-
8Br-cGMP; B) on FL-MTX 
transport. Values are means ± SE 
for 15-19 tubules from 1 fish. 
Significantly lower than the 
control value (*: P<0.05, **: 
P<0.01, ***: P<0.001).  
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Next we examined the effects of cGMP analogs on FL-MTX transport. Figure 
3.1B shows that incubating tubules in medium with 1 µM 8Br-cGMP (a membrane 
permeant analog that activates PKG) reduced luminal but not cellular FL-MTX 
accumulation. Quantitation of images indicated that the reduction in luminal 
accumulation was concentration dependent, with a significant decrease seen with 
0.1 µM cyclic nucleotide and more than a 50% decrease with 1 µM (figure 3.4A). 
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 Figure 3.5 Consequences of PKC 
and NO synthase (NOS) 
inhibition on FL-MTX transport 
reduced by cGMP. The inhibitory 
effect caused by 1 µM 8Br-
cGMP, but not by its inactive Rp-
isoform on FL-MTX transport is 
prevented by 100 nM 
bisindolylmaleimide (BIM; A). 
The inhibitory effect caused by 1 
µM 8Br-cGMP could not be 
prevented by 50 µM NG-Methyl-
L-arginine (L-NMMA; B). 
Together these data indicate that 
cGMP generation precedes PKC 
stimulation and follows NO 
release. Values are means ± SE 
for 9-19 tubules from 1 fish. 
Significantly lower than the 
control value (*: P<0.05, ***: 
P<0.001).  
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Rp-8Br-cGMP, which does not activate PKG, also reduced luminal accumulation 
of FL-MTX (figure 3.4B), but was less effective.  
If 8Br-cGMP reduced Mrp2-mediated transport of FL-MTX through signaling 
rather than by competition for transport, its effects should be attenuated when the 
signaling chain is broken by inhibiting a downstream step, i.e., PKC activation. 
Figure 3.5 shows a series of experiments designed to test this possibility. First, 
inhibition of PKC by BIM abolished the effects of 1 µM 8Br-cGMP on luminal FL-
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MTX accumulation (figure 3.5A). Second, inhibition of NOS by L-NMMA did not 
alter the effects of 8Br-cGMP (figure 3.5B). These results are consistent with 8Br-
cGMP modifying transport through signaling at a step downstream of NOS but 
upstream of PKC. Third, in contrast, BIM exposure did not alter the effects of Rp-
8Br-cGMP (figure 3.5A), suggesting that this compound reduced transport by 
interacting with Mrp2. However, pilot experiments using MRP2 transfected Sf9 
vesicles, as previously described by Terlouw et al. (32), showed no inhibition of 
FL-MTX transport (pmol FL-MTX mg protein-1⋅min-1) by 10 µM 8Br-cGMP (82.1 
± 11.3; n = 3), 100 µM 8Br-cGMP (186 ± 47.6; n = 3), 10 µM Rp-8Br-cGMP (147 
± 32.5; n = 3), 100 µM 8Br-cGMP (165 ± 16.4; n = 3) compared to the control 
(91.7 ± 46.3; n = 3) (data not shown).  
 
 
Discussion 
 
Cyclic GMP is an intracellular second messenger involved in hormonal signaling 
throughout the body. Cyclic GMP is generated from GTP by guanylyl cyclases, 
which are present as membrane bound and soluble forms (1). The soluble forms 
produce cGMP in response to several signals including NO (25; 36). Cyclic GMP 
itself acts through cGMP-dependent protein kinase G (PKG), cyclic nucleotide-
gated channels, cAMP-dependent protein kinase, and phosphodiesterase (15). Here 
we provide evidence that NO-dependent guanylyl cyclase and cGMP are involved 
in the regulation of Mrp2-mediated transport in the renal proximal tubule. We 
previously showed that ET acting through a basolateral ETB receptor, NOS, and 
PKC, decreases cell-to-lumen organic anion transport mediated by Mrp2 (18; 23). 
Figure 3.6 summarizes this sequence of events. Transport is also reduced by several 
nephrotoxicants, which cause Ca2+-dependent ET release from the tubules; ET then 
activates signaling by an autocrine/paracrine mechanism (33).  
The present study shows that ODQ, an inhibitor of guanylyl cyclase, blocked ET 
signaling to Mrp2. ODQ was effective irrespective of the source of the initial 
signal, i.e, hormone or nephrotoxicant. ODQ also blocked the effects of the NO 
generation by sodium nitroprusside, but not the effects of PKC activation by PMA. 
8Br-cGMP reduced Mrp2-mediated transport and this effect was blocked by PKC 
inhibition, but not by NOS inhibition. Although the Rp-isoform of 8Br-cGMP, 
which does not activate PKG, also reduced transport on Mrp2, this effect was not 
altered by BIM. Thus, it is likely that the Rp-isoform, unlike the parent compound, 
affected transport by interacting directly with the transporter. Together, the data 
indicate that ET signaling involves activation of guanylyl cyclase and generation of 
cGMP. This step in signaling occurs after NO generation by NOS and before PKC 
activation.  
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 Figure 3.6 Scheme illustrating the proposed sequence of events by which nephrotoxicants reduce 
Mrp2-mediated transport in isolated renal proximal tubules. Nephrotoxicants cause a transient 
opening of the Ca2+-channels, which increases intracellular Ca2+ concentration and stimulates ET 
release. The hormone binds to a basolateral ETB receptor, which activates NOS, increases NO 
production, activates soluble guanylyl cyclase (sGC), increase cGMP production and activates 
PKC. PKC activation rapidly reduces transport by Mrp2. 
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Although our result indicated that cGMP activates PKC other protein kinases 
may still be involved as intermediate steps. Possible candidates are PKA and PKG. 
However, PKA activation does not appear to be involved, since we previously 
found no effect of a PKA-selective inhibitor on ET-1 signaling (18). Our attempts 
to demonstrate activation of PKG as an intermediate step were not successful since 
each of the several PKG-selective inhibitors tested inhibited transport on Mrp2 
themselves (Notenboom S and Miller DS, unpublished observations). It is likely 
that these drugs affected transport by direct interaction with the transporter, since 
all inhibitors were organic anions. Additional experiments will be needed to clarify 
at the molecular level the events between cGMP production and PKC activation 
and the events between PKC and Mrp2 inhibition. A possible candidate for the 
latter is phosphorylation of Mrp2 PSD-95/Disc-large/zona occluding-1 (PDZ) 
domains. Hegedüs et al. (7) suggested that PKC is involved in the Mrp2 targeting 
and recycling through phosphorylation of MRP2 PDZ domain, which influences 
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the interaction between Mrp2 and its anchoring PDZ proteins and thereby its 
transport function. 
Signaling through cGMP has been implicated in the mechanisms of action of 
several nephrotoxicants. Tack et al. (30) showed that a single dose of cyclosporine 
A transiently increases glomerular cGMP in rat. In this process, activation of ETB 
receptors and the NO pathway are also involved. Signaling through NO and cGMP 
also affects renal tubular transport, e.g. sodium transport in rabbit proximal tubule 
(25), and Na+-K+-ATPase in rat proximal tubule (36). Cyclic GMP has been 
implicated in the regulation of other transport processes in the kidney, although not 
directly linked to NO production or to PKC stimulation. For example Hirsch et al. 
(8-10) described that cGMP is involved in the regulation of Ca2+- and K+-channels 
in a human proximal tubule cell line, while others (28) showed that cGMP is 
involved in the regulation of the organic cation transporters, rOCT1 and hOCT2. 
cGMP has also found to be involved in the regulation of vascular tone in which the 
ETB receptor is included. Here also binding of ET-1 to the ETB receptor leads to the 
production of NO and subsequent cGMP. However cGMP in turn inhibits ET-1 
release, suggesting a complex signaling mechanism for relaxation of pulmonary 
vessels (14). A comparable negative feedback system between cGMP and ET-1 
secretion is not present in our system, since the inhibitory effect of cGMP could be 
completely prevented by the PKC inhibitor BIM. A role for cGMP in renal toxicity 
is not yet established. It was shown previously that cytotoxicity of oxidant stress 
resulted in upregulation of NOS with excessive production of NO (6). The 
nephrotoxicants, cyclosporin A, FK506 (11) and the heavy metal HgCl2 (35) have 
all been implicated in acute renal failure through increased NO production. The 
biological actions of NO are mediated often by cGMP. Hosogai et al. (12) found 
that exposure to cyclosporin A resulted in a decrease in cGMP-phosphodiesterase 
activity and an increase in guanylate cyclase activity, implying a role for cGMP in 
cyclosporine A induced nephrotoxicity. Next to the activity of the soluble guanylyl 
cyclases and phosphodiesterases, excretion and reabsorption of cGMP in the 
proximal tubule might influence transport processes important for fluid balance and 
possibly for Mrp2 regulation (13; 27; 34).  
In summary, cGMP plays a role in the short-term regulation of Mrp2 by the 
following sequence of events: nephrotoxicants trigger a calcium influx, ET is 
released and binds to the ETB receptor, the ETB receptor triggers nitric oxide 
release by activating nitric oxide synthase, subsequently soluble guanylyl cyclase is 
activated, the cGMP produced stimulates PKC, eventually leading to the inhibition 
of Mrp2-mediated transport. In conclusion, cGMP plays a role in the ET-signaling 
pathway, first described by Masereeuw et al. (18) in killifish proximal tubule, next 
to its diverse actions throughout the body.  
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 Summary 
 
We previously showed that the function of renal Multidrug resistance protein 2 
(Mrp2; Abcc2) is reduced by endothelin-1 (ET-1) signaling through an ETB 
receptor, NOS, cGMP and protein kinase C and that this pathway was rapidly 
activated by several nephrotoxicants (19; 23; 24; 38). The present study was 
conducted to determine the long-term effects on Mrp2-mediated transport (luminal 
fluorescein methotrexate accumulation) of short-term (30 min) exposure to ET-1 
and the aminoglycoside antibiotic, gentamicin. Our data show that over the 3 h 
following exposure proximal tubules recovered fully from the initial decrease in 
Mrp2-mediated transport and that transport activity was not changed 9 h later. 
However, 24 h after exposure, luminal accumulation of an Mrp2 substrate had 
increased by 50%. Increased transport at 24 h was accompanied by an increased 
transporter protein content of the luminal plasma membrane as measured by 
immunostaining. Blocking ET-1 signaling at the ETB receptor or downstream at 
NOS or guanylyl cyclase abolished both stimulation of transport and increased 
transporter expression. Thus, regardless of whether signaling was initiated by a 
short exposure to ET-1 or to a nephrotoxicant, the time course of the Mrp2 
response to ETB signaling was the same and was multiphasic. Finally, when tubules 
were exposed to gentamicin for 30 min and removed to gentamicin-free medium 
for 24 h they were less sensitive to acute gentamicin toxicity than paired controls 
not initially exposed to the drug. Thus, short-term exposure to ET-1 or gentamicin 
resulted in long-term protection against a second insult. 
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Introduction 
 
ATP-driven drug efflux pumps, e.g., P-glycoprotein and Multidrug resistance 
protein 2 (Mrp2), play an important role in the absorption, distribution and 
excretion of endogenous compounds, drugs and their metabolites (31; 34). In 
vertebrate renal proximal tubule, Mrp2 has been localized to the luminal pole of the 
epithelial cells (33), the correct location to provide the final step in transport of 
many anionic xenobiotics from blood to urine. The efflux pump handles a wide 
range of substrates and its activity and expression level in the kidney is influenced 
by hormones, local mediators, nuclear receptors, protein kinases, and disease 
conditions (37). As with drug metabolizing enzymes, e.g., cytochrome P450s and 
transferases (13; 30), pump activity is regulated in response to exposure to 
substrates and physiological state. 
We previously showed in intact killifish renal proximal tubules that Mrp2 
activity, as measured by luminal accumulation of a fluorescent MTX derivative 
(FL-MTX), is rapidly reduced by subnanomolar to nanomolar concentrations of 
ET-1 acting through an ETB receptor, NOS, cGMP and PKC. Surprisingly, acute 
exposure of tubules to several nephrotoxicants, i.e. aminoglycoside antibiotics, 
radiocontrast agents and heavy metal salts, also reduces FL-MTX transport, and 
blocking ET signaling at any point in the chain abolishes the nephrotoxicant effects 
on transport (23; 24; 38). From these experiments, it was also clear that the 
nephrotoxicants caused Ca2+-dependent release of ET from the tubules and that 
released ET activated intracellular signaling by an autocrine mechanism. In 
contrast, after long-term, continuous exposure (6-24 hours) to the nephrotoxic 
heavy metal salt CdCl2, transport activity and immunostaining of Mrp2 at the 
luminal membrane of the proximal tubules had increased (36). This long-term 
induction of Mrp2 may function as a compensatory mechanism for the initially 
reduced efflux of potentially toxic compounds, serving a protective route. 
The present study addresses the issue of whether short-term signaling through 
the ET-activated pathway has longer-term consequences to tubular function. Our 
results show that after 30 min exposure to ET-1 or the aminoglycoside antibiotic, 
gentamicin, Mrp2-mediated transport initially declined; this is in agreement with 
previous studies (23; 38). When tubules were removed to ET-1- and gentamicin-
free medium, transport recovered over the next several hours. Twenty-four hours 
after exposure, Mrp2-mediated transport and Mrp2 protein expression were 
significantly higher than controls. These increases in transport and Mrp2 expression 
were abolished when ET signaling was disrupted. Finally, short-term gentamicin 
exposure and subsequent recovery for 24 h was protective against acute gentamicin 
tubular toxicity. Thus, short-term signaling has long-term consequences with regard 
to transport function and nephrotoxicant resistance.  
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 Material and methods 
 
Chemicals 
Fluorescein methotrexate (FL-MTX), fluorescein, Mito Tracker® Red CM-
H2XRos and Alexa Fluor® 488 goat anti-rabbit IgG (rabbit polyclonal antibodies) 
were obtained from Molecular Probes (Eugene, OR). NG-methyl-L-arginine (L-
NMMA) was purchased from Alexis biochemicals (San Diego, Ca). RES-701-1 
was purchased from Peninsula Laboratories (Belmont, CA). Oxadiazole quinoxalin 
(ODQ) was obtained from Calbiochem (San Diego, Ca). Modified medium 199 
with Earle’s salts (M199) was purchased from Sigma Chemical (St. Louis, MO). 
Rabbit polyclonal antibodies against Mrp2 (k78 mrp2) and Mrp4 (anti-Mrp4) were 
obtained as described previously (39; 40). 
All other chemicals used, were obtained at the highest purity available 
commercially. 
 
Animals and tissue preparation 
Killifish (Fundulus heteroclitus) were collected by local fishermen in the 
vicinity of Mount Desert Island, Maine and maintained at the Mount Desert Island 
Biological Laboratory in tanks with natural flowing seawater. Renal tubular masses 
were isolated in a marine teleost saline based on that of Forster and Taggart, 
containing (in mM) 140 NaCl, 2.5 KCl, 1.5 CaCl2, 1.0 MgCl2 and 20 
tris(hydroxymethyl)-aminomethane (Tris) at pH 8.0 (6). Isolation and short-term 
exposure were carried out at 18-20 °C. Under a dissecting microscope, each mass 
was teased with fine forceps to remove adherent hematopoietic tissue. Individual 
killifish proximal tubules from several fish were dissected, pooled and transferred 
to a well plate containing 3 ml marine teleost saline in presence or absence of 10 
µM gentamicin. After 30 min exposure tubules were washed in marine teleost 
saline and transferred to recovery medium, i.e. modified medium 199 with Earle’s 
salts (M199) supplemented with (in mM, unless stated otherwise) 30.0, NaCl, 4.2 
NaHCO3, 1.0 L-glutamine, 25.0 HEPES, 14.75, NaOH (pH 7.5, 347 mosmol/kg 
H2O), and 20 mg/l tetracycline, 10 µg/ml insulin, 5 µg/ml hydrocortisone, and 10% 
flounder serum (28) with added effectors. The viability of teleost tubules is not 
preserved at 18-20 °C past 6 h, but can be extended to 48 h by reducing the 
incubation temperature to13.5°C (Miller, unpublished observations). After 1.5, 3, 
12, or 24 h of recovery at 13.5°C tubules were washed in marine teleost saline and 
transferred to a foil covered Teflon chamber containing 1 ml of marine teleost 
saline with 1 µM FL-MTX. The chamber floor was a 4 x 4 cm glass coverslip to 
which the tubules adhered lightly and through which the tissue could be viewed by 
means of an inverted microscope. Tubules were incubated at room temperature for 
30 minutes until steady state was reached for FL-MTX. Analysis of tubule extracts 
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by HPLC showed no metabolic degradation of FL-MTX when incubated with 
killifish proximal tubules for periods of at least 1 h (18; 35). 
In toxicity experiments, isolated killifish tubules were transferred to a well plate 
containing marine teleost saline in presence or absence of 10 µM gentamicin. After 
30 min exposure, tubules were washed in marine teleost saline and transferred to 
the recovery medium. After 24 h of recovery at 13.5°C tubules were exposed to 
100 µM gentamicin for 2 h and subsequently washed in marine teleost saline and 
transferred to a foil covered Teflon chamber containing 1 ml of marine teleost 
saline with an indicator of tubular function. We used transepithelial transport of the 
fluorescent agent fluorescein and the mitochondrial marker, Mito Tracker® Red 
CM-H2Xros, as two functional indicators of tubule viability. Both were measured 
using confocal microscopy and quantitative image analysis. 
 
Confocal microscopy 
The chamber containing renal tubules was mounted on the stage of an Olympus 
FluoView inverted confocal laser scanning microscope and viewed through a 40x 
water immersion objective (numerical aperture 1.15). Excitation was provided by 
the 488 nm line of an argon ion laser. A 510 nm dichroic filter and a 515 nm long-
pass emission filter were used. Neutral density filters and low laser intensity were 
used to avoid photobleaching. With the photomultiplier gain set to give an average 
luminal fluorescence intensity of 1500 to 3000 (on a scale of 0-4096), tissue auto-
fluorescence was undetectable. To obtain an image, dye-loaded tubules in the 
chamber were viewed under reduced, transmitted light illumination, and a single 
proximal tubule with well-defined lumen and undamaged epithelium was selected. 
The plane of focus was adjusted to cut through the center of the tubular lumen and 
an image was acquired by averaging four scans. The confocal image was viewed on 
a high-resolution monitor and saved to an optical disk. In previous studies, it has 
been shown that there is a linear relationship between fluorescence intensity and 
dye concentration (21). However, because of the many uncertainties in relating 
cellular fluorescence to actual compound concentration in cells and tissues with 
complex geometry, data are reported here as a percentage of average measured 
pixel intensity compared to control rather than estimated dye concentration. 
Fluorescence intensities were measured from stored images using Scion image 
version 1.8 for Windows as described previously (18; 20). Briefly, two or three 
adjacent cellular and luminal areas were selected from each tubule, and the average 
pixel intensity for each area was calculated for measurement of fluorescein and FL-
MTX transport. The values used for that tubule were the means of all selected 
areas.  
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 Measurement of mitochondrial respiration 
Mito Tracker® Red CM-H2Xros was used for determination of mitochondrial 
respiration. We used the optical sectioning capabilities of the confocal microscope 
to measure the dye fluorescence intensity inside tubular cells. Essentially all of the 
cellular fluorescence was in discrete structures, suggesting mitochondrial 
accumulation (26). 
 
Immunohistochemistry 
Isolated killifish proximal tubules were exposed to 10 µM gentamicin or 10 nM 
ET-1 for 30 min and transferred to gentamicin and ET-1 free medium for a 24 h 
recovery period. Subsequently tubules were processed in PBS for immunostaining: 
fixation with 2% (v/v) formaldehyde/0.1% (v/v) glutaraldehyde; permeabilization 
with 1% (v/v) Triton X-100; 90 min exposure to primary antibody (k78 1:50 for 
Mrp2, or anti-Mrp4, 1:10); 60 min exposure to secondary antibody (Alexa488-
labeled goat anti-rabbit IgG, 1:20). Antibody binding was detected with the Zeiss 
confocal laser scanning microscope using an 20x objective and staining was 
quantified using ImageJ 1.30v (NIH, USA). A grid, consisting of 655.02 µm2 
squares, was placed on top of the confocal images to semi-quantify the fluorescent 
staining. Only there where the grid crossed luminal staining fluorescence intensities 
were measured. The value used for that tubule was the average of the values 
measured in this tubule.  
 
Data analysis 
Data are given as mean percentage of control fluorescence ± SE, unless indicated 
otherwise. Mean values were considered to be significantly different when P<0.05 
by use of the unpaired t-test or by a one-way ANOVA followed by Bonferroni’s 
multiple comparison test. Software used for statistical analysis was GraphPad 
Prism (version 3.00 for Windows; GraphPad Software, San Diego CA, USA). 
 
 
Results 
 
Isolated renal tubules from killifish, have proven to be a powerful model for the 
study of excretory transport in an intact proximal tubule (27). Unlike mammalian 
proximal tubules, the broken ends of teleost proximal tubules reseal after isolation, 
thus, forming a closed fluid filled luminal compartment. This enables study of 
cellular uptake and luminal accumulation of fluorescent compounds using imaging 
techniques. As in mammalian proximal tubules, killifish express high levels of 
Mrp2 in the luminal membrane of renal proximal tubule cells. Moreover, killifish 
tubules exhibit Mrp2-mediated transport of a number of fluorescent substrates, e.g., 
FL-MTX, that can be visualized and measured in intact individual tubules using
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Figure 4.1 Changes in Mrp2-mediated transport in response to a short exposure to endothelin-1 
(ET-1). Tubules were incubated for 30 min in the absence (control) or presence of 10 nM ET-1 
and then transferred to ET-free medium for the indicated time. Representative confocal images of 
control (A) and ET exposed (B) killifish proximal tubules after 24 h in ET-free medium after 
incubation in marine teleost saline with 1 µM fluorescein methotrexate (FL-MTX) for 30 min. 
FL-MTX accumulation in cells and tubular lumens was then determined (C). At every time point 
measured, the luminal values of control tubules were set at 100%.Values are means ± SE for 24-
128 tubules from 9-10 fish. Significantly different from the control value (***: P<0.001). 
 
 
confocal microscopy (18-20). Figure 4.1A-B show a typical confocal image of a 
killifish tubule after 30 min (steady state) incubation in medium with 1 µM FL-
MTX following 24 h of recovery. The fluorescence distribution pattern is the same 
as shown previously after short-term exposure, i.e., fluorescence intensity in 
lumen>cells>medium (18; 19). We have demonstrated that this pattern is indicative 
of a two-step process, involving uptake at the basolateral membrane mediated by
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Figure 4.2 Changes in Mrp2-
mediated transport in response to 
a short exposure to gentamicin 
(Gent). Tubules were incubated 
for 30 min in the absence 
(control) or presence of 10 µM 
gentamicin and then transferred to 
gentamicin-free medium for the 
indicated time. FL-MTX 
accumulation in cells and tubular 
lumens was then determined. At 
every time point measured, the 
luminal values of control tubules 
were set at 100%. Values are 
means ± SE for 14-138 tubules 
from 4-14 fish. Significantly 
different from the control value 
(***: P<0.001).  
 
 
an, as yet, uncharacterized transporter for large organic anions and secretion into 
the lumen mediated by a teleost form of Mrp2 (for data on substrate and inhibitor 
specificities as well as immunostaining with Mrp2 antibodies, see Refs 18; 19; 38). 
Using an Sf9 overexpression system, we previously showed that FL-MTX is a 
substrate for MRP2 (36). Although MRPs are known to share many substrates, 
interference of other members of the MRP family with FL-MTX transport in this 
model is unlikely. Mrp5 and Mrp6 are located in the basolateral membrane and not 
in the apical membrane of renal proximal tubules, whereas Mrp1 and Mrp3 are not 
expressed in renal proximal tubules (31). Furthermore, we can exclude the 
contribution of Mrp4 because results from our group show that FL-MTX is not a 
substrate for MRP4 (Smeets and Russel, unpublished observations), and MRP4-
mediated transport is insensitive to leukotriene C4 (39), which is an excellent 
inhibitor of FL-MTX secretion in killifish proximal tubules (18; 19).  
To determine whether short-term ET-1 signaling has long-term effects, we 
exposed tubules to ET-1 for 30 min, removed them to ET-free medium and assayed 
Mrp2 transport function at several times after transfer. Figure 4.1C. shows that 1.5 
h after transfer the tubules exhibit significantly reduced transport. This result is in 
agreement with previous experiments from this laboratory where tubules were 
exposed continuously to ET-1 in transport experiments lasting up to 90 min (19). 
However, with time in the ET-free medium, transport increased, and 3 h and 12 h 
values were nearly identical to tubules not exposed to ET-1 (controls). Moreover, 
24 h after ET-1 exposure, luminal accumulation of FL-MTX had increased by 
about 50% (P<0.001; figure 4.1). Neither short-term exposure to ET-1 nor short-
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Figure 4.3 Effect of gentamicin 
exposure on fluorescein (FL) 
transport. A. Tubules were 
incubated for 30 min in the 
absence (control) or presence of 
different concentrations of 
gentamicin, after which FL 
accumulation in cells and tubular 
lumens was determined. B. 
Tubules were incubated for 30 
min in the absence (control) or 
presence of 10 µM gentamicin and 
then transferred to gentamicin-free 
medium for the indicated time. FL 
accumulation in cells and tubular 
lumens was then determined. 
Values are means ± SE for 11-39 
tubules from 3 fish. Significantly 
different from the control value (*: 
P<0.05, **: P<0.01). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
term exposure followed by recovery affected cellular accumulation of FL-MTX. 
 that several tubular nephrotoxicants 
(am
Thus, both the short-term and long-term effects of 30 min ET-1 exposure were 
evident with FL-MTX as substrate. 
We previously demonstrated
inoglycoside antibiotics, radio contrast agents and heavy metal salts) were 
capable of mimicking the effects of ET-1 on FL-MTX transport. Each of these 
activated the ET signaling pathway by a Ca2+-dependent mechanism causing ET 
release from the tubules. None of them interacted with Mrp2 directly (23; 38). 
When we incubated tubules in medium containing the aminoglycoside antibiotic, 
gentamicin (10 µM), transferred them to gentamicin-free medium and monitored 
FL-MTX transport, we found the same pattern of effects as observed with ET-1 
(figure 4.2). Thus, both ET-1 and gentamicin had a triphasic effect on FL-MTX:
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Figure 4.4 ETB receptor, nitric 
oxide (NO), and cGMP are 
involved in the up-regulation of 
Mrp2 mediated transport of FL-
MTX after short-term exposure to 
gentamicin and recovery. Tubules 
were incubated for 30 min in the 
absence (control) or presence of 10 
µM gentamicin (Gent) and then 
transferred to gentamicin-free 
medium (recovery) for 24 h. As 
indicated, the recovery medium 
contained 100 nM of an ETBR 
antagonist, RES701-1 (RES), 50 
µM of an NOS inhibitor, NG-
methyl-L-arginine (L-NMMA), or 
10 µM oxadiazole quinoxalin 
(ODQ), a soluble guanylyl cyclase 
inhibitor. Fl-MTX accumulation in 
cells and tubular lumens was then 
determined. The up-regulation of 
FL-MTX transport after 24 h 
recovery caused by 30 min 
exposure to 10 µM gentamicin was 
prevented by RES701-1 and L-
NMMA to the recovery medium 
(A). Also ODQ was able to prevent 
this up-regulation (B). The 
inhibitors alone had no effect (A 
and B). The luminal values of the 
control tubules were set to 100%. 
Values are means ± SE for 12-48 
tubules from 3-6 fish. Significantly 
higher than the control value (***: 
P<0.001). 
 
 
 
short-term reduction, followed by recovery, and finally significantly increased 
transport. Note that when fluorescein (FL) was used as a substrate, there was no 
initial decrease in transport with 10 µM gentamicin (figure 4.3A) and no increase 
24 h after gentamicin exposure (figure 4.3B). However, with short-term exposure 
to higher concentrations of gentamicin (figure 4.3A) and with 24 h continuous 
exposure to 10 µM gentamicin (preliminary data not shown), a decrease in FL 
transport was seen, indicating toxicity.  
We used a pharmacological approach to further examine the intracellular events 
signaling the increase in FL-MTX transport 24 h after a short exposure to ET-1 or 
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gentamicin. For this purpose, specific antagonists were used to block steps in the 
common signaling pathway. Figure 4.4 shows that blocking the ETB receptor with 
RES701-1, blocking NOS with L-NMMA or blocking guanylyl cyclase with ODQ 
abolished the long term effects of short-term exposure to gentamicin. None of the 
inhibitors affected FL-MTX transport by itself (figure 4.4 and Refs. 23 and 24). 
Thus, at a minimum, the long-term effects of short-term exposure to ET-1 or 
gentamicin appear to be a consequence of signaling through the ETB receptor, NOS 
and cGMP.  
The increase in luminal accumulation of FL-MTX 24 h after short-term 
exposures to ET-1 or gentamicin may have resulted from increased transporter 
expression or increased transport activity with no increase in expression. To 
determine whether the expression level was altered, we used immunofluoresence to 
examine the long-term effects on Mrp2. Figure 4.5 shows representative confocal 
images of killifish tubules immunostained for Mrp2. In agreement with previous 
studies in mammalian and killifish renal tissue, this transporter localized to the 
luminal (brush border) membrane of the tubule epithelial cells (19; 32; 33; 36; 38). 
Figure 4.5 also shows representative confocal images of tubules exposed to 
gentamicin or ET-1 for 30 min and then assayed 24 h later. In these tubules, Mrp2 
immunofluoresence appears to be more intense than in controls (no ET-1 or 
gentamicin exposure). Quantitation of Mrp2 immunofluoresence bears out this 
impression. Both ET-1 and gentamicin increased luminal membrane 
immunofluorescence by about 25% (P<0.01). In contrast, no such increase was 
found when tubules were stained for Mrp4, which, as in mammalian renal proximal 
tubules (39), is also localized to the luminal membrane of killifish renal proximal 
tubule cells (figure 4.5E). Consistent with the transport data presented above, 
inhibiting NOS with L-NMMA blocked the increase in Mrp2 expression caused by 
30 min exposure to ET-1 or gentamicin (figure 4.6). 
Thus, one consequence of short-term exposure to ET-1 or gentamicin is an 
increase in Mrp2 expression and function 24 h later. To determine whether the 
response to nephrotoxicants was also affected, we used MitoTracker® Red CM-
H2XRos in tubules exposed to 100 µM gentamicin to assess mitochondrial 
respiration. This concentration of nephrotoxicant is an order of magnitude higher 
than that which alters Mrp2-mediated transport though ET signaling, and was 
found to affect tubular viability (figure 4.3). The advantage of using MitoTracker® 
Red CM-H2XRos is that the probe is highly stable. It is oxidized within cells and 
then selectively sequestered in mitochondria of actively respiring cells. Probes 
often used for measuring mitochondrial membrane potential, e.g. JC-1 and 
Safranine O, cannot be used in our model because they are substrates for efflux 
carriers present in the apical membrane of the tubular cells. In this experiment,
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Figure 4.5 Increased luminal plasma 
membrane Mrp2 protein 24 h after 30 min 
exposure to 10 µM gentamicin (Gent) or 10 
nM ET-1. (A) Quantitation of luminal plasma 
membrane immunostaining of Mrp2; (B) 
Representative image of control tubule; (C) 
tubule exposed to gentamicin; (D) tubule 
exposed to ET-1; (E) quantitation of Mrp4 
immunostaining. Functional up-regulation of 
Mrp2-mediated transport was confirmed by 
an increased expression of Mrp2 in the 
luminal membrane of the proximal tubule 
after 24 h recovery of short-term exposure to 
10 µM gentamicin or 10 nM ET-1 (C and D, 
resp.) compared to control tubules (B). In (A) 
this is semi-quantified. Mrp4, however, was 
not affected by recovery to short-term 
exposure to 10 µM gentamicin or 10 nM ET-
1 (E). Values are means ± SE for 31-108 
tubules from 10-31 fish. Significantly 
different from the control value (**: P<0.01). 
Co
ntr
ol
Ge
nt
ET
-1
0
40
80
120
Mrp4 E
Fl
uo
re
sc
en
ce
 in
te
ns
ity
(%
 o
f c
on
tr
ol
)
74     Chapter 4 
Figure 4.6 Blocking NOS prevents the 
increase in Mrp2 immunostaining 24 h after 
30 min exposure to 10 µM gentamicin (A) or 
10 nM ET-1 (B). Values are means ± SE for 
12-48 tubules from 12-31 fish (***: 
significantly higher than the control value; 
P<0.001). 
Co
ntr
ol
Ge
nt
L-
NM
MA
Ge
nt+
L-
NM
MA
0
40
80
120
Mrp2 *** A
Fl
uo
re
sc
en
ce
 in
te
ns
ity
(%
 o
f c
on
tr
ol
)
Co
ntr
ol
ET
-1
L-
NM
MA
ET
-1+
L-
NM
MA
0
40
80
120
Mrp2 B***
Fl
uo
re
sc
en
ce
 in
te
ns
ity
(%
 o
f c
on
tr
ol
)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
tubules were pre-exposed to 0 (controls) or 10 µM gentamicin for 30 min and then 
incubated in gentamicin-free medium for 24 h. Subsequently, they were challenged 
with a 2 h exposure to 100 µM gentamicin and changes in mitochondrial 
respiration was measured using 500 nM of Mito Tracker® Red CM-H2XRos and 
confocal imaging after 30 min incubation with the probe. In tubules not pre-
exposed to the low concentration of gentamicin (controls), 100 µM gentamicin 
significantly decreased mitochondrial respiration (P<0.05). This effect was roughly 
half of that seen when control tubules were exposed to 1 mM NaCN for 2 h (figure 
4.7). In contrast, no such gentamicin-induced reduction in mitochondrial respiration 
was observed in tubules that had been pre-exposed to 10 µM gentamicin. Thus, at 
least for one nephrotoxicant and one measure of toxicity, gentamicin pre-exposure 
and subsequent recovery was protective.   
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Figure 4.7 A short exposure to gentamicin protects against acute gentamicin toxicity 24 h later. 
Tubules were incubated for 30 min in the absence (control) or presence of 10 µM gentamicin and 
transferred to gentamicin-free medium for 24 h. Tubules were then exposed to 100 µM 
gentamicin or 1 mM NaCN (positive control) for 2 h. Mitochondrial respiration was measured 
using Mito Tracker® Red CM-H2XRos. Values are means ± SE for 10-15 tubules from 3 fish. 
Significantly lower than the control value (*: P<0.05, ***: P<0.001). 
 
 
Discussion 
 
In killifish renal proximal tubules, ET-1 signals a decrease in Mrp2 transport 
function by acting through an ETB receptor, NOS, cGMP, and PKC. Moreover, 
exposure to any of several nephrotoxicants causes release of ET from the tubules 
with subsequent activation of signaling and reduced Mrp2 function (19; 36; 38). 
These inhibitory effects on Mrp2-mediated transport was observed within 15 min 
of exposure and were maximal within 60 min. After 60 min exposure, the Mrp2 
protein content of the luminal plasma membrane is not changed, suggesting that 
transporter activity in the luminal plasma membrane was modified or transporter 
was removed to a subapical compartment that was not resolved at the light 
microscope level (38). In the present study, we investigated the effects of exposing 
renal proximal tubules to ET-1 or to gentamicin for a short time (30 min) and then 
returning them to ET-1- and gentamicin-free medium. The data show that over the 
3 h following exposure, tubules recovered fully from the initial decrease in Mrp2-
mediated transport and that transport activity was not changed 9 h later. However, 
24 h after exposure, luminal accumulation of FL-MTX had increased by 50%. 
Increased transport at 24 h was accompanied by an increased transporter protein 
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content of the luminal plasma membrane measured by immunostaining. This 
finding could not be confirmed using immunoblots. Immunoblot analysis is not 
feasible in this situation, because of the small amount of membrane protein isolated 
from killifish tubules. A recent direct comparison of quantitative immunostaining 
with immunoblot analysis, however, indicates that the results obtained with the two 
methods are comparable (2). Furthermore, preliminary data in rats treated with 
gentamicin in vivo showed a clear up-regulation of Mrp2 in the apical membrane of 
renal proximal tubule confirming the findings of our killifish experiment in a 
different species (Notenboom et al., unpublished findings). 
Blocking ET-1 signaling at the ETB receptor, or downstream at NOS, abolished 
both stimulation of transport and increased transporter expression. Thus, regardless 
of whether signaling was initiated by a short exposure to ET-1 or by a 
nephrotoxicant, the time course of the Mrp2 response to ETB signaling was the 
same. It was multiphasic, involving reduced Mrp2-mediated transport, recovery to 
control levels, and a delayed increase over control levels 24 h after exposure. Non-
specific leakage of the fluorescent dye can be excluded because luminal FL-MTX 
accumulation is concentrative with respect to medium, and leakage of the dye at the 
tight junctions would decrease the luminal concentrating ability of the tubules. 
Note that FL transport in killifish renal tubules was constant over the entire 
exposure/recovery time course (figure 4.3) as observed previously (36). This 
fluorescent organic anion is avidly transported from bath to tubular lumen by an 
organic anion transport system that does not include Mrp2 (18). Thus, there was no 
generalized increase in tubule xenobiotic transporter function. Furthermore, 24 h 
after exposure we did not detect any qualitative change in luminal plasma 
membrane content of Mrp4. This indicates no increase in expression of luminal 
membrane transporters in general or in the expression of MRP subfamily members 
in particular. 
The increase in Mrp2 transport function (~50%) 24 h after exposure to ET-1 or 
gentamicin was accompanied by a less than proportional increase in transporter 
content in the plasma membrane (~25%). Assuming a one-to-one correspondence 
between transport activity and transporter content, this difference suggests that 
multiple mechanisms contribute to the increase in transporter function. These might 
include: 1) de novo synthesis of Mrp2, 2) increased insertion of Mrp2 into the 
apical membrane, 3) reduced Mrp2 retrieval from the apical membrane and 4) 
functional activation of membrane-bound transporter. Mrp2 activity is known to be 
modulated by transcriptional and post-transcriptional mechanisms. For example, 
several ligand activated nuclear receptors have been shown to transcriptionally 
regulate the activity of xenobiotic metabolizing enzymes and xenobiotic 
transporters, including Mrp2, in liver, intestine and blood-brain barrier (2; 12; 15). 
These include the pregnane X nuclear receptor (PXR) and the constitutive 
androstane receptor (CAR), both of which are activated by a wide range of 
xenobiotics. Teleost fish do express a PXR homolog (17; 22), but it is not known to 
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 what extent (if any) gentamicin or ET-1 affects PXR activity in any species. In 
addition, in mammalian hepatocytes, both PKC and PKA have been implicated in 
bidirectional, regulated trafficking of Mrp2 between intracellular stores and the 
canalicular membrane (4; 14; 29). Furthermore, Hegedus et al. (8) suggested that 
PKC is involved in the Mrp2 targeting and recycling through phosphorylation of 
the PDZ domain, which influences the interaction between Mrp2 and its anchoring 
PDZ proteins and thereby its transport function. PKA activation does not appear to 
be involved in short-term exposure, since we previously found no effect of a PKA-
selective inhibitor on ET-1 signaling (19). Preliminary data using a canine kidney 
cell line over-expressing MRP2 pointed to an increased insertion of the transport 
protein in the luminal membrane after 1 h gentamicin exposure and 24 h recovery 
or 24 h gentamicin exposure, whereas overall MRP2 expression remained 
unchanged (Notenboom et al, unpublished). Additional experiments are needed to 
further characterize in the killifish renal proximal tubule model the mechanisms 
that link ET-NOS-cGMP-PKC signaling and Mrp2 up- and down-regulation.  
Up-regulation of Mrp2 may be interpreted as part of a mechanism called 
preconditioning. Thus an up-regulation of Mrp2 and other adaptive mechanisms 
after recovery protects the tissue against a second exposure to gentamicin. This 
phenomenon has been observed for ischemia in heart, liver and kidney (1; 10; 11; 
25). Mrp2 serves a protective function through the elimination of potentially 
harmful chemicals. Indeed, Mrp2 up-regulation was also observed after long-term 
exposure to cadmium (36) and after ischemia (16). Since Mrp2 handles many 
potentially toxic compounds, like xenobiotics and their metabolites (31), up-
regulation of the transport protein may be part of a protective pathway of proximal 
tubules following harmful events. 
Finally, use of gentamicin and other aminoglycoside antibiotics has been 
associated with severe proximal tubular nephrotoxicity, which limits their clinical 
use. Although such irreversible toxicity has been historically associated with 
multiple administration of high doses (3), gentamicin can alter renal function even 
at low dose levels (7). The present data show for the first time that low-level, short-
term, gentamicin exposure could have beneficial side effects, possibly by triggering 
a survival/protective pathway. Certainly, ET signaling and gentamicin 
preconditioning affect more than Mrp2 expression and function. It will be 
important to determine which of these changes in gene expression or 
enzyme/transporter function confers increased resistance to aminoglycoside 
antibiotic toxicity. Note that the present experiments, in which Mrp2 transport 
function was the end-point, provide an additional example of context-dependent 
signaling, as demonstrated recently for protein kinases (5; 9). In this regard, we 
have been able to document three patterns of effects following tubule exposure to 
gentamicin (and other nephrotoxicants): 1) inhibition of transport with short-term 
exposure (23; 24; 36; 38), 2) toxicity with long-term, continuous exposure 
(unpublished observations), and 3) increased transport with long-term exposure to 
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low concentrations of nephrotoxicants (36) or with short-term exposure followed 
by a period of recovery (present study). 
In conclusion, renal proximal tubules exposed to gentamicin or ET-1 and 
allowed to recover for 24 h, display an increase in Mrp2-mediated transport and 
Mrp2 expression in the luminal membrane. These increments are a result of 
intracellular signaling consequences caused by short-term nephrotoxicant exposure 
in the renal proximal tubule. Several signaling molecules were identified as 
participants in this pathway leading to the following sequence of events: Short-term 
exposure to gentamicin triggers ET-1 release, ET-1 binds to the ETB receptor, 
subsequently NOS is stimulated resulting in the activation of soluble guanylyl 
cyclase. The produced cGMP might cause de novo synthesis of Mrp2, stimulation 
of Mrp2 insertion in the luminal membrane and/or inhibition of Mrp2 retrieval 
from the luminal membrane, eventually leading to increased Mrp2-mediated 
transport through increased Mrp2 insertion in the luminal membrane in the renal 
proximal tubule. Thus, short-term signaling (nephrotoxicant exposure) has long-
term consequences for renal proximal tubule functioning. 
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 Summary 
 
The aim of this pilot study was to define the importance of ABC transporter 
expression in renal regeneration after nephrectomy in the little skate and in the 
nephrogenic zone of fish. This fundamental study is a first attempt to gain insight in 
how renal stem cells are established in the adult kidney and are mobilized after 
injury.  
Here we characterized the localization of Mdr1 P-gp, Mrp2, Mp4 and Bcrp in 
interstitial tissue, the inducible nephrogenic zone and mature tissue using light 
microscopy and immunohistochemistry in little skate (Leucoraja erinacea), spiny 
dogfish (Squalus acanthias) and zebrafish (Danio rerio). 
Our observations suggest preservation of Mdr1 P-gp, Mrp2 and possibly Mrp4 at 
the luminal membrane of kidney tubules in elasmobranch and teleost fish. In 
addition a Bcrp-like protein is conserved in single cells of the hematopoietic tissue 
of teleost as is Mrp2 in the contralateral operated skate kidney. These cells are 
possible candidates for progenitor cells. However, further research is needed to 
identify these cells in the vicinity of nephrogenic tissue. Blood staining with May-
Grünwald Giemsa in combination with antibodies directed against several CD 
markers and other progenitor cell markers, such as Pax-2, will be used for this 
purpose. 
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Introduction 
 
Our knowledge of the pathogenesis of renal failure has increased in recent years. 
Acute renal failure may result from sepsis, hypoxia, and exposure to nephrotoxic 
agents, whereas proteinuria is a major determinant of chronic renal failure. Patients 
are almost continuously exposed to drugs that must be excreted by the kidney, 
which may cause additional harm. Nevertheless, a previously healthy kidney has a 
high capacity to regenerate: in most patients who develop severe acute tubular 
necrosis, necessitating hemodialysis treatment, renal function will improve 
completely. Renal regeneration may result from dedifferentiation, cell division and 
cell spreading of neighbouring viable tubular epithelial cells. Alternatively, stem 
cells may be involved either residing within the kidney or derived from circulating 
bone marrow mesenchymal stem cells (1; 11; 16; 32). The role of stem cells in 
diseases has recently received great emphasis. A single metanephric mesenchymal 
cell can generate all the epithelial cells of the nephron (except the collecting duct 
which is generated from the ureteric bud), indicating that the embryonic kidney 
contains epithelial stem cells (1). By using in situ hybridization to detect Y-
chromosomes it was demonstrated that stem cells engraft into the kidney of female 
mice recipients of male bone marrow grafts (32), which was confirmed in male 
patients with acute tubular necrosis who had received a kidney transplant from a 
female donor (14). These pluripotent hematopoietic stem cells can contribute to the 
formation of kidney cells, including tubular epithelial cells, podocytes, mesangial 
cells and myofibroblasts (2; 11). In the elasmobranch kidney (little skate; 
Leucoraja erinacea) it was previously demonstrated that partial nephrectomy is 
followed by regrowth of new nephrons, most likely from progenitor cells resident 
in the adult kidney (10). Most recently, Maeshima et al. (22) showed that slow-
cycling cells present in rat kidney tubules acted as progenitor-like cells, which 
actively proliferate and eventually differentiate into epithelial cells during tubular 
regeneration. Their origin, however, resident or extra-renal remains unclear. 
There are indications that the differentiation of stem cells may be regulated by 
members of the ATP-binding cassette (ABC) superfamily of transmembrane 
transporters (4; 48). A high expression of these transporters has been associated 
with a maintenance of primitive stem cell characteristics. The ATP-driven 
transporters are involved in the trafficking of biologic molecules across cell 
membranes by coupling ATP hydrolysis to the transport of specific substrates. 
Their overexpression in tumor cells is associated with multidrug resistance, which 
is a major complication for successful cancer chemotherapy. Among the proteins 
implicated in this process is the multidrug resistance-1 (MDR1/ABCB1) gene 
product, P-glycoprotein (MDR1 P-gp) (5), and the breast cancer resistance protein 
(BCRP/ABCG2)(36; 48). Both proteins are expressed in tissues with protective 
functions, such as the apical surface of cells in kidney, liver and intestine, or the 
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 endothelium forming the blood-brain barrier (9; 17; 23; 42). In addition, the kidney 
contains two other luminally expressed ABC transporters, the multidrug resistance 
proteins (MRP2/ABCC2 and MRP4/ABCC4), which determine the rate-limiting 
step in urinary excretion of various xenobiotics. All four transporters handle a wide 
range of structurally divergent organic chemicals, although with different 
specificities. ABC transporters have been highly conserved during evolution, and it 
was previously demonstrated that orthologs of human ABC transporters are present 
in kidneys of lower vertebrates as well (25; 26; 28). The aim of this study was to 
define the importance of ABC transporter expression in renal regeneration after 
nephrectomy in the little skate and in the nephrogenic zone of several fish species. 
This fundamental study is a first attempt to gain insight in how renal stem cells are 
established in the adult kidney and are mobilized after injury.  
 
 
Methods 
 
Materials and animals 
The polyclonal antibody raised against rabbit Mrp2 and rat Mrp4 were provided 
by our laboratory (43; 44). The monoclonal antibody C219 against mouse Mdr1 P-
gp was purchased from Sigma (St Louis, Mo or Munich, Germany) and the 
monoclonal BCRP from Alexis Biochemicals (Lausen, Switzerland). DAPI (4´,6-
diamidino-2-phenylindole) for nuclear staining was obtained from Molecular 
Probes (Leiden, the Netherlands).The secondary antibodies labelled with Cy3 
where purchased from DakoCytomation (Hamburg, Germany). All other chemicals 
used were obtained at the highest purity available. 
Female skates, Leucoraja erinacea (Mitchell 1825), were netted in Frenchman 
Bay, Maine, or or purchased from the Marine Station Woods Hole, MA, USA and 
kept as described (10). Spiny dogfish, Squalus acanthias, were obtained from the 
similar locations as the female skate. The zebrafish, Danio rerio, were purchased 
from a local supplier (Dortmund, Germany) and raised in aquaria at 28oC. 
 
Tissue preparation 
The renal reduction model, developed and described by Elger et al (10), was used 
to investigate the expression of ABC transporters during regeneration 
histologically. In brief, in this model two thirds of one kidney of the elasmobranch 
(little skate; Leucoraja erinacea) was removed by cauterization. Ten days after this 
partial nephrectomy an intraperitoneal injection of 5-bromo-2’-deoxyuridine 
(BrdU) was given to determine the proliferative activity of the renal tissue. The 
kidneys were fixed by vascular perfusion, using fixation fluid containing 
paraformaldehyde (3-4%) and picric acid (0.5%) in 0.1 M Sörensen phosphate 
buffer supplemented with sucrose, sodium chloride and trimethylamine-N-oxide 
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(TMAO) to a final osmolality of the vehicle of approximately 950 mOsm. 
Following this fixation the kidneys were excised. 
Next to elasmobranch fish, teleost fish are also known to maintain nephrogenic 
properties throughout their life (10; 15; 35). Therefore, kidneys of two teleost fish 
(spiny dogfish, Squalus acanthias and zebrafish, Danio rerio) were also fixed by 
vascular perfusion and dripping, respectively. The fixation fluid contained 4% 
paraformaldehyde and 0,5 % picric acid in Sörensen buffer with enhanced 
osmolality (see above). For the fixation of zebrafish kidneys several fixatives were 
tested next to 4% paraformaldehyde, namely Dubosq-Brasil (80% ethanol, 1.6% 
paraformaldehyde, 2% picric acid), modified Carnoy’s fixative (60% Methanol, 
30% chloroform, 10% acetic acid, 0.1% picric acid) and 4% paraformaldehyde 
with 0.1% glutaraldehyde. The 4% paraformaldehyde fixation solution resulted in 
the best preservation of the kidney tissue and epitopes of the proteins to be 
investigated, important for the identification of precursor cells.  
 
Histology 
The excised kidneys were postfixed in fresh fixation fluid for 1 h. Subsequently, 
each kidney was cross-sectioned in 8-10 blocks (little skate and spiny dogfish) or 2-
4 blocks (zebrafish), and processed for paraffin embedding or cryosections. Serial 
cross-sections (2-3 µm) were prepared in which the developmental stages of the 
nephrons and other structures were identified using Masson Goldner trichrome 
staining. 
Subsequently, the expression of Mdr1 P-gp, Mrp2, Mrp4, and Bcrp was 
determined in parallel sections. In addition, a few sections were used for 
immunostaining with paired box 2 (Pax-2; Zymed, Germany), another progenitor 
cell marker. Before immunostaining, the paraffin sections were deparaffinized, 
rehydrated and heated in 0.1M citrate buffer (pH 6.0) for 20 min. Cryo sections did 
not need this pretreatment. Subsequently, primary antibodies were incubated 
overnight at 4°C (1:40 for Mdr1 P-gp, 1:20 - 1:60 for Mrp4, 1:100 for Mrp2, 1:25 
for Bcrp and 1:100 for Pax-2), followed by washing steps and incubation with the 
secondary Cy3- labelled antibody (1:500) directed against rabbit IgG (Mrp2, Mpr4, 
Pax-2) or mouse IgG (Mdr 1 P-gp, Bcrp). Nuclei of cells were stained using DAPI. 
The sections were investigated and photographed with a Zeiss Axioplan II light 
microscope equipped with a digital camera Axiocam (Carl Zeiss, Göttingen, 
Germany) (Nephrology, Hannover), or with a Zeiss Axiovert 200M light 
microscope equipped with Apotome and CCD camera Axiocam MR (Carl Zeiss, 
Göttingen, Germany) for multiodimensional image acquisition (MPI Dortmund).  
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 Results 
 
The aim of this pilot study was to see whether ABC proteins could be possible 
markers for progenitor cells involved in kidney regeneration. Although previous 
investigations have indicated that antibodies developed against mammalian Mdr1 
P-gp, Mrp4 and Mrp2 cross-react with the teleost (killifish; fundulus heteroclitus) 
(25; 26; 28), optimal immunostaining conditions for these antibodies and the 
antibody against human BCRP were determined in all three species. Our first step 
was to assess whether markers directed against mammalian Mrp2, Mrp4, Mdr1 P-
gp and Bcrp would also react with their fish homologues. Next, the expression of 
the different transporters was investigated in the nephron segments and the 
interstitial tissue, consisting of distinct compartments enriched in cells of the 
erythroid and myeloid cell lineages. Eventually we performed most 
immunostainings in pretreated paraffin sections, since we observed a loss of tissue 
structure in the cryo sections.  
 
Nephron segments 
Expression of Mdr1 P-gp was found in the luminal membrane of the proximal 
tubule (PII) in little skate and in the zebrafish (figure 5.1). Mrp2 was differently 
expressed among the three species. In the little skate, Mrp2 expression was found 
in the luminal membrane of the proximal tubule (PIIb) and possibly early distal 
tubule (figure 5.2A). In dogfish shark, luminal immunostaining of Mrp2 was found 
in the proximal tubule (PIIb) and late distal tubule / collecting duct (figure 5.2B). In 
zebrafish, Mrp2 immunostaining was found luminally in the neck segment of the 
proximal tubule and collecting duct (figure 5.2C). Expression of Mrp4 was not 
 
 
Figure 5.1 Localization of Mdr1 P-gp in the luminal membrane of the proximal tubule (PIIa) of 
little skate (yellow; A) and of zebrafish (red; B) as indicated by the arrows. A is a cryo section 
with DAPI staining (blue), B is a paraffin section. UR = urether. 
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Figure 5.2 Mrp2 expression in the luminal 
membrane of proximal tubule (PIIb) in the 
mesial zone of skate kidney (yellow; A). 
Mrp2 expression in late distal tubule in 
dogfish shark (red; B). Mrp2 expression in 
neck segment (N) and collecting duct (CD) 
of the zebrafish (red; C). Lens culinaris 
agglutinin (LCA) (green) was used in the 
latter to stain the apical side of proximal 
tubule PI. A, B and C are paraffin sections. 
 
 
 
 
 
 
 
clear due to high background, but seems to be present in the luminal membrane of 
the collecting tubule and duct in little skate and spiny dogfish. In the zebrafish, 
Mrp4 expression was found exclusively in the urether, although due to high 
background this might be non-specific binding (observations not shown). In none 
of the three species a clear expression of Bcrp in nephron segments was detected.  
 
Interstitial tissue 
In order to find possible progenitor cells we looked at the interstitial tissue. The 
elaborate interstitial tissue of the mature kidney of spiny dogfish (figure 5.3A and 
B), little skate (figure 5.4A) and zebrafish (figure 5.5A) contains distinct 
compartments enriched in cells of the erythroid and myeloid cell lineages, a 
possible niche for progenitor cells. No expression of Mdr1 P-gp or Mrp4 was found 
in the interstitial tissue, neither in the vicinity of normal nephrogenesis nor 
nephrogenesis induced by damage.  
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 Figure 5.3 The elaborate interstitial tissue of the mature kidney of spiny dogfish contains distinct 
compartments enriched in cells of the erythroid and myeloid cell lineages. Presence of similar 
compartments were seen in little skate and zebrafish. (Paraffin sections, Masson Goldner stain). 
 
 
 
Figure 5.4 Histology of operated skate 
kidney showing regenerating tubules and 
augmented interstitial tissue (A). Numerous 
cells reactive with antibody against Mrp2 
were present in the ipsilateral operated 
remnant kidney, next to the luminal staining 
of PIIb (red; B). In the contralateral non-
operated kidney, reactive cells were 
occasionally found at the base and in intra-
epithelial position of proximal tubule 
segments as indicated by the arrow 
(red/orange; C), next to luminal staining of 
PIIb. A, B and C are paraffin sections. 
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Figure 5.5 Hematopoietic tissue in the 
kidney of adult zebrafish between proximal 
tubules (A). A subpopulation of the 
hematopoietic tissue binds the antibody 
against human BCRP, a marker of stem and 
progenitor cells (white; B and C). A, B and 
C are paraffin sections. 
 
 
 
 
 
 
 
 
 
 
 
 
Mrp2 immunostaining was detected sparsely in hematopoietic tissue of the shark 
and in the contralateral non-operated kidney of the partly nephrectomized little 
skate (figure 5.4C). Most positive cells were occasionally found at the base and in 
intraepithelial position of the proximal tubule segments. In the ipsilateral operated 
kidney, abundant Mrp2-positive cells were present in the interstitium and a lower 
number of cells in tubules (figure 5.4B). The high number of these cells suggests 
that most of these cells are lymphoid cells due to inflammatory processes, in 
contrast to progenitor cells that are expected to be scarcely present. Bcrp, the most 
likely candidate marker for a renal progenitor cell, was detected in zebrafish and 
dogfish shark (only zebrafish shown in figure 5.5B and C), located on the 
membrane of relatively few big cells with big nuclei in the hematopoietic tissue in 
the kidney.  
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 Discussion 
 
As our data show, Mdr1 P-gp-, Mrp4-, Mrp2- and Bcrp-like proteins are present 
in the kidney, in either segments or single cells. A Mdr1 P-gp protein was 
expressed in the luminal membrane of proximal tubule PIIa of the teleost and 
elasmobranch. A similar proximal expression was also found in the mammalian 
kidney and killifish kidney, another teleost (25; 26; 28), suggesting a high 
preservation of this protein during evolution. Similar results were found for Mrp2, 
which was also present in the proximal tubule of the kidney in both the teleost and 
elasmobranch. However, in contrast to the mammalian expression which is only in 
the proximal tubule (37), immunostaining of Mrp2 was found in the late distal 
tubule and collecting duct as well. Mrp4 was expressed in the luminal membrane of 
the collecting duct tubule in the little skate and in spiny dogfish and was found 
exclusively in the urether of the zebrafish, which is highly different from results 
found in renal mammalian tissue (7; 43). However, despite several pre-treatments, 
the Mrp4 antibody had to be used in relatively high concentrations leading to high 
background signal, which might have prevented the detection of weak Mrp4 
immunostaining in other segments or interstitium and led to non-specific staining 
of nephron segments. In none of the three species clear expression of Bcrp in 
nephron segments was detected. In contrast, in mouse kidney Bcrp was found to be 
highly expressed in the luminal membrane of the proximal tubule (M Huls, 
unpublished observations). 
In order to find a possible involvement of ABC proteins in the regulation of 
renal progenitor cells, we screened for single cells expressing Mdr 1 P-gp, Mrp2, 
Mrp4 and Bcrp proteins. ABC proteins likely protect these cells from harmful 
effects of xenobiotics and metabolic wastes by efflux or transport of modulators 
important to maintain the niche and/or signaling resulting in nephrogenesis. Both 
MDR1 P-gp and BCRP are described as markers for (side) populations consisting 
of rhodamine 123 or hoechst 33342 extruding stem cells/progenitor cells present in 
different tissue types (4; 13; 24; 46). However, Mdr1 P-gp was not detected in the 
interstitium of any of the three species tested. Similar results for the absence of 
Mdr1 P-gp was also found in rat liver progenitor cells were Mrp1 and Mrp3 were 
highly expressed in contrast to Mdr1 P-gp (34). Even though we did find Bcrp on 
the membrane of relatively few large cells with big nuclei in the heamotopoietic 
tissue in the kidney of both dogfish shark and zebrafish we still need to be careful 
with the interpretation of these results, since the antibody was raised against human 
BCRP and is also reported to be present in lymphoid cells (36; 45; 48). 
Furthermore, Mrp2 is known to be expressed in lymphoid and myeloid cells (19; 
31; 39), maybe partly explaining the massive influx of Mrp2 positive cells in the 
operated skate kidney. However, a presence of Mrp2 in progenitor cells cannot be 
excluded, since positive cells in the contralateral non-operated kidney were
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occasionally found at the base and in intraepithelial position of the proximal tubule 
segments, an ideal position for regeneration. In addition, Steinbach et al. (39) did 
report presence of Mrp2 in CD34+ cells. 
At present, Bcrp and Mrp2 seem to be the most likely candidates to be present 
on progenitor cells involved in nephrogenesis of the ABC transporters we tested. 
More work is needed to identify and locate the Mrp2 and/or Bcrp positive cells in 
the vicinity of nephrogenic tissue. Until now it still remains unclear whether 
progenitor cells are extrarenal or resident. Although studies in mice and man 
proved that circulating pluripotent stem cells from either hemotopoietic or 
mesenchymal origin are able to contribute to the formation of kidney cells (11; 14; 
18; 27), other evidence suggest the presence of a niche of resident cells in the adult 
kidney to contribute to regeneration of the kidney next to circulating extrarenal 
cells. Oliver et al. (30) suggest that the renal papilla is a niche for adult stem cells. 
They found that a low-cycling cell population in the papilla, that persists 
throughout life, are involved in renal repair due to their ability to enter the cell 
cycle, migration to the repair site and their plasticity enabling them to turn in more 
than one cell type including epithelial cells. Also Elger et al. (10) described a 
specific nephrogenic zone where extra new tubules were generated following 
partial nephrectomy. In addition, it can not be excluded that bone marrow cells 
reside in the kidney and turn into kidney progenitor cells triggered by injury (29). 
In our results, the precise origin of the blast-like cells that react with antibody 
against Mrp2 and Bcrp remains unclear. It will be very interesting to locate these 
cells directly in the vicinity of neo-nephrogenesis and identify the precise type of 
and their origin with a blood staining (May-Grünwald Giemsa) and known cell 
markers for mesenchymal, hematopoietic and progenitor cells.  
One known progenitor cell marker is paired box 2 (Pax-2). Pax-2 has been 
reported to be present in the pronephros of the zebrafish (12; 38), is proven to be 
important for normal kidney development (6; 8; 47) and has been implicated in 
regenerating processes of the tubular cells (21). Preliminary results in little skate 
showed presence of the progenitor marker Pax-2 in nephrogenic tissue 
(observations not shown). Another candidate marker is the transcription factor Wnt, 
which enables self-renewal of hematopoietic stem cells (33). Activation of the Wnt 
pathway contributes to kidney tubulogenesis (20) and renal fibrosis (40). The 
transcription factor Oct-4 may be an additional promising stem cell marker, that 
could help to identify the progenitor cells (3; 41) 
In conclusion, our observations suggest preservation of Mrp2, Mrp4 and Mdr1 
P-gp at the luminal membrane of kidney tubules in elasmobranch and teleost fish. 
In addition, Bcrp is conserved in single cells of the hematopoietic tissue of teleost 
as is Mrp2 in the contralateral non-operated kidney. These cells are possible 
candidates for progenitor cells, however, further research is needed to identify these 
cells in the vicinity of nephrogenic tissue and in non-growing kidneys. Blood 
staining with May-Grünwald-Giemsa in combination with antibodies directed 
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 against several CD markers and or progenitor markers, such as Pax-2, will be used 
for this purpose. 
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 Summary 
 
Previous studies with mutant transport deficient rats (TR-), in which the 
multidrug resistance protein 2 (Mrp2) is lacking, have emphasized the importance 
of this transport protein in the biliary excretion of a wide variety of glutathione 
conjugates, glucuronides and other organic anions. Mrp2 is also present in the 
luminal membrane of proximal tubule cells of the kidney, but little information is 
available on its role in the renal excretion of xenobiotics. Here we compared renal 
transport of the fluorescent Mrp2 substrates calcein, fluo-3 and lucifer yellow (LY) 
between perfused kidneys isolated from Wistar Hannover (WH) and TR- rats. 
Isolated rat kidneys were perfused with 100 nM of the non-fluorescent calcein-AM 
or 500 nM fluo3-AM, which enter the tubular cells by diffusion and are hydrolyzed 
intracellularly into the fluorescent anion. The urinary excretion rates of calcein and 
fluo-3 were 3-4 times lower in perfused kidneys from TR- rats as compared to WH 
rats. In contrast, the renal excretion of LY (10 µM, free anion) was somewhat 
delayed, but appeared unimpaired in TR- rats Membrane vesicles from Sf9 cells 
expressing human MRP2 or human MRP4 indicated that MRP2 exhibits a 
preferential affinity for calcein and fluo-3, whereas LY is a better substrate for 
MRP4. We conclude that the renal clearance of the Mrp2 substrates calcein and 
fluo-3 is significantly reduced in TR- rat, whereas for LY the absence of the 
transporter may be compensated for by (an)other organic anion transporter(s) 
among which Mrp4.  
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Introduction 
 
ATP-Binding Cassette (ABC) proteins play an important role in the cellular 
defence against xenobiotics and their metabolites by active secretion of these 
compounds into bile, urine and intestinal lumen. Overexpression of the ATP-driven 
transporters in tumor cells is associated with multidrug resistance, which is a major 
complication for successful cancer chemotherapy. The proteins couple ATP 
hydrolysis to the transport of specific substrates, and include P-glycoprotein, which 
transports uncharged compounds and organic cations, and the multidrug resistance 
proteins (MRPs), with a preference for organic anions (for reviews, see Refs.2; 5 
and 13). The canalicular membrane of hepatocytes contains an isoform of MRP, 
called MRP2 or canalicular multispecific organic anion transporter (cMOAT) (29). 
In mutant transport deficient (TR-) rats and Eisai hyperbilirubinemic rats (EHBR), 
the mRNA levels of Mrp2 are very low and the protein itself is absent (11; 24). In 
TR- rats this is due to a single nucleotide deletion in the gene resulting in a frame 
shift, which leads to an early stop codon. A human counterpart of the TR- rat is the 
Dubin-Johnson syndrome patient, who is lacking MRP2 (30). This defect is 
associated with a deficiency in the biliary excretion of a wide variety of glutathione 
conjugates, glucuronides and other organic anions. 
Although the function of MRP2 in the liver has been studied extensively, the 
protein is also present in the luminal membrane of small intestine (27; 36) and 
proximal tubule cells of the kidney (33), but little information is available on the 
mechanism governing renal and intestinal excretion of anionic xenobiotics by 
MRP2. All three organs have a main task in the excretion of xenobiotics and 
multispecific organic anion transporters are supposed to play a key role in this 
process. Using killifish renal proximal tubules, we previously characterized an 
ATP-dependent efflux mechanism for the organic anions fluorescein-methotrexate 
(FL-MTX) and lucifer yellow (LY) (18; 20). With a polyclonal antibody directed 
against rabbit Mrp2, an ortholog of the transporter could be identified in killifish at 
the proximal tubule brush-border membrane (21). These findings are consistent 
with a teleost form of Mrp2 which mediates transport in killifish proximal tubules. 
Its importance in overall renal organic anion secretion is, however, still undefined. 
It has been demonstrated that the renal excretion of α-naphtyl-β-D-glucuronide (4), 
leukotriene C4 (12) or glutathione-bimane (35) is not impaired in the TR- rat, 
whereas the biliary excretion of these compounds is markedly reduced. This 
indicates that (an)other MRP-like transport mechanism(s) exist for the renal 
excretion of organic anions, which compensate for the absence of Mrp2. A possible 
candidate may be Mrp4, which was recently identified by us as a novel organic 
anion transporter in the apical membrane of rat and human proximal tubule (37). 
In the present study, we compared the renal excretion of three fluorescent 
anionic Mrp2 substrates in perfused kidneys isolated from normal Wistar Hannover 
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 (WH) rats and TR- rats. Our results indicate that the excretion of calcein and fluo-3 
is significantly reduced in TR- rat kidneys, whereas LY excretion appeared 
unimpaired.  In membrane vesicles from insect cells expressing human MRP2 and 
MRP4, calcein and fluo-3 were transported almost exclusively by MRP2. LY 
appeared to be a better substrate for MRP4 as compared to MRP2. This suggests 
that for renal LY excretion, Mrp4 may compensate for the lack of Mrp2 in TR- rat. 
 
 
Materials and methods 
 
Materials 
Sodium pentobarbital was obtained from Apharmo (Arnhem, The Netherlands), 
Pluronic F108 was from BASF (Arnhem, The Netherlands), and heparin, 
aldosterone and inulin were from Organon (Oss, The Netherlands). LY-CH 
dilithium salt, tetramethylrhodamine isothiocyanate-dextran (TRITC-dextran, Mw. 
4,400), and dextran (Mw. 60,000-90,000) were purchased from Sigma (St. Louis, 
Mo., USA). Lysine-vasopressin was obtained from Sandoz Pharma Ltd. (Basel, 
Switzerland), angiotensin II from Beckman (Palo Alto, USA) and Synthamin 14 
was from Travenol (Thetford, Norfolk, UK). Bovine serum albumin (BSA) was 
obtained from Boehringer Mannheim (Mannheim, Germany). Fluorescein 
methotrexate (FL-MTX), fluo-3, fluo-3-acetoxymethylester (fluo-3-AM), calcein-
acetoxymethylester (calcein-AM), and calcein were from Molecular Probes 
(Eugene, OR). All other chemicals were of analytical grade and purchased from 
Merck (Darmstadt, Germany) or Sigma (St.Louis, MO). The p-glycoprotein 
inhibitor, PSC-833, was a gift from Novartis (Arnhem, The Netherlands). The 
Groningen Yellow/transport mutant rat strain (GY/TR-; TR- rats) was kindly 
provided by the group of Jansen (4) and bred in Nijmegen. 
 
Kidney isolation and perfusion 
Rat kidneys were isolated and perfused as described in detail previously (3). 
Briefly, male Wistar-Hannover or TR- rats (225-275 g) were anesthetized 
intraperitoneally with pentobarbital (6 mg/100 g) and furosemide was injected 
intraperitoneally (1 mg/100 g) to prevent deterioration of the distal nephron. 
Heparin (125 I.U./100 g) was injected in the femoral vein. The ureter of the right 
kidney was cannulated and the renal artery via the mesenteric artery without 
interruption of the blood flow. The kidney was then excised and placed in a fluid 
bath with a constant temperature of 37.5 °C. The perfusate reservoir was placed 
also in a waterbath of 37.5 °C and fluid was gassed with 95% O2 / 5% CO2. The 
perfusion fluid had the following composition (mM, except indicated otherwise): 
NaCl 114.0, KCl 5.2, CaCl2 1.8, MgCl2 1.0, NaHCO3 22.5, Na2HPO4 0.84, 
KH2PO4 0.28, glucose 5.0, urea 4.0, pluronic F108 25.0 g ⋅ l-1, glutathione 0.33, 
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inositol 0.083, cysteine 0.50, glycine 2.3, Na-pyruvate 2.0, Na-acetate 1.22, Na-
propionate 0.21, inosine 1.0, alanine 5.0, glutamine 0.11, L-glutamine acid 2.0, 
ascorbic acid 0.01, Na-lactate 1.0, choline chloride 1.0 mg/l, insulin 4 I.U./l, 
aldosterone 2.0 µg ⋅ l-1, lysine-vasopressin 0.01 I.U. ⋅ l-1 and angiotensin II 15.0 ng ⋅ 
l-1. To this solution 1.0 % Synthamin 14, a mixture of 15 amino acids, was added. 
Pluronic F-108 was used as oncotic agent in the normal perfusion medium, whereas 
a combination of 3.3% dextran and 2% BSA was used in Pluronic-free perfusion 
fluid. For the determination of glomerular filtration rate, either inulin was added to 
the perfusion fluid in pluronic experiments (100 µg ⋅ ml-1) or TRITC-dextran in 
dextran/BSA experiments (10 µg ⋅ ml-1). Because inulin would bind to BSA in 
pluronic-free perfusion medium, TRITC-dextran was used. In our perfused kidney 
preparation, perfusion medium was recirculated at a constant flow rate (15 ml ⋅ 
min-1) with a perfusate pressure of approximately 90 mmHg. During the first 5 min 
of perfusion, the venous effluent was discarded and after this period the perfusion 
fluid was recirculated and the kidney was allowed to stabilize for 30 min. Then the 
experiment was started with a 30 min baseline period, after which the experiment 
was started by the addition of 0.23 mg FL-MTX resulting in an initial perfusate 
concentration of 1 µM, calcein-AM with an initial perfusate concentration of 100 
nM, fluo-3-AM (initial perfusate concentration 500 nM) or LY (initial perfusate 
concentration of 10 µM). During the baseline period the perfusate volume was 500 
ml from which a sample of 5 ml was drawn. After the baseline period, the 
experimental fluid was connected to the kidney, with a total volume of 250 ml in 
which FL-MTX, calcein-AM, fluo-3-AM or LY were already dissolved. The 
experimental period was 120 min. Urine samples were collected during control and 
experimental periods over 10 min intervals. Perfusate samples (300 µl) were drawn 
at the midpoint of each urine collection interval. Two additional perfusate samples 
were taken: one at the beginning of the experimental period (t = 0), and one at the 
end of the experiment. Urine and perfusate samples were analyzed directly after the 
experiment. Perfusion fluid during experimental period, and perfusion and urine 
samples were protected from light. 
 
 
Uptake of fluorescent substrates in membrane fractions of Sf9-cells overexpressing 
MRP2 and MRP4 
Cells from Spodoptera frugiperda (Sf9) expressing human MRP2 and MRP4 
were generated by infection of cells using a recombinant baculovirus encoding 
MRP2 and MRP4 as described previously (37). For controls, Sf9 cells were 
infected with a baculovirus encoding the ß-subunit of rat H+/K+-ATPase. Crude 
membrane fractions from infected Sf9 cells were isolated. Protein concentration 
was determined using the BioRad protein assay (BioRad Laboratories, Veenendaal, 
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 The Netherlands). Uptake of fluorescent substrates was measured using a rapid 
filtration technique (38).  
 
Analytical methods 
Urine and perfusate samples were analyzed for glucose, using the GLUCO-
QUANT kit from Boehringer (Mannheim, Germany), and alkaline phosphatase, 
according to (26), to assess proximal tubule function. Inulin was determined 
according to a previously published method (9). The concentration of FL-MTX, 
calcein, fluo-3, LY or TRITC-dextran in perfusate and urine samples were 
determined by means of fluorescence spectrophotometry. To this end, an aliquot of 
50 µl of the perfusate sample was taken and adjusted to 600 µl with analysis buffer 
(Sörensen buffer, pH 7.36). Urine samples were diluted 10 times with buffer, from 
which an aliquot of 25 µl was taken and adjusted to 600 µl with 50 µl blank 
perfusion fluid and 525 µl buffer. Fluorescence in these prepared samples was 
measured using a Perkin Elmer LS50 luminescence spectrophotometer 
(Beaconsfield, Buckinghamshire, UK). For FL-MTX measurements, excitation and 
emission wavelengths were 491 and 516 nm, for calcein 488 and 518 nm, 
rexpectively, for fluo-3 506 and 524 nm, for LY 425 and 525 nm, respectively, and 
for the determination of TRITC-dextran the wavelengths were set to 511 and 575 
nm, respectively. In all cases, a band width of 5 nm was used. Concentrations were 
calculated by comparing fluorescence intensity (in photomultiplier units) with a 
calibration curve of spiked samples of blank perfusion fluid with different 
concentrations of FL-MTX, calcein, fluo-3, LY or TRITC-dextran.  
 
Data analysis 
In membrane transport experiments, net ATP-dependent uptake was calculated 
by subtracting values in the absence of ATP from those in the presence of ATP. 
Furthermore, uptake values were corrected for control uptake measured in vesicles 
expressing the β-subunit of H+,K+-ATPase. All data are expressed as mean ± S.D., 
unless stated otherwise. Statistical differences between means were determined 
with Student's t-test. Statistical differences between multiple means were 
determined with a one-way analysis of variance followed by the least significant 
difference post test. Means were considered significantly different when P<0.05.  
 
 
Results 
 
In recent studies using killifish proximal tubules we showed that FL-MTX is a 
substrate for Mrp2, and its luminal secretion was sensitive to inhibition by 
leukotriene C4, chlorodinitrobenzene (CDNB) and estradiol-17-ß-D-glucuronide 
(18; 20). Here, we investigated the secretion of this fluorescent substrate by Mrp2
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Table 6.1. Functional parameters of isolated perfused kidneys from WH and TR- rats during 
control perfusionsa
 
Parameter WH control TR- control 
GFR (µl ⋅ min-1) 280 ± 40 366 ± 17* 
diuresis (µl ⋅ min-1) 19.2 ± 1.4 19.1 ± 1.2 
CEALP (µM PNP) 2.0 ± 0.4 1.6 ± 0.9 
FEglucose (%) 4.1 ± 0.6 3.5 ± 1.0 
FRwater (%) 93.9 ± 0.1 94.8 ± 0.1** 
RPP (mmHg) 89 ± 7 87.6 ± 0.5 
 
a Values are presented as mean ± SD of three perfused kidney experiments over the period 30-120 
min. Kidneys were perfused for 150 min as described in Materials and methods without addition 
of substrate. GFR = glomerular filtration rate, CEALP = cumulative excretion of alkaline 
phosphatase, PNP = para-nitrophenyl, FE = fractional excretion, FR = fractional reabsorption, 
RPP = renal perfusion pressure. Significantly different from perfused control WH-rat kidney (*: 
P<0.05, **: P<0.01). 
 
 
in the isolated perfused rat kidney. The viability of the perfused rat kidneys was 
assessed by monitoring fractional excretion of glucose, cumulative excretion of 
alkaline phosphatase, fractional reabsorption of water, urine flow and pH, 
glomerular filtration rate (GFR) and renal perfusate pressure. Based on these 
criteria, kidneys from WH rats as well as TR- rats showed good function over the 2-
h time course of the clearance experiments (table 6.1). Our attempts to measure 
active secretion of FL-MTX in perfused rat kidneys were unsuccessful. After 
perfusing WH rat kidneys for 2 h with 1 µM FL-MTX, a clearance over glomerular 
filtration ratio of 0.61 ± 0.11 (n = 3) was observed, indicating net reabsorption of 
the fluorescent dye. Most likely, the bulky organic anion is not able to enter tubule 
cells from the basolateral side of the cells.  
To overcome cell entry problems as observed for FL-MTX, we used an esterified 
fluorescein derivative, calcein-AM. This hydrophobic nonfluorescent precursor 
enters the tubule cells by simple diffusion and is, subsequently, cleaved into calcein 
by cytoplasmic esterases. Evers et al. (6) showed that this organic anion is actively 
secreted by MRP2 in stably transfected cells. After addition of 100 nM calcein-AM 
to perfusion medium, the renal excretion rate of calcein was measured in urine and 
depicted in figure 6.1 (upper panel) as a function of perfusion time. Evidently, the 
renal excretion of the organic anion was delayed and reduced in TR- rats, indicating 
the contribution of Mrp2 in renal clearance of calcein. Kidney functional 
parameters in calcein-AM perfusion experiments were not significantly different in 
TR- rats as compared to WH rats (table 6.2). The precursor, calcein-AM, is also a 
good substrate for P-glycoprotein (10). To avoid efflux of calcein-AM by P-
glycoprotein, we performed perfusion experiments in the presence of 10 µM PSC-
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Figure 6.1 Renal excretion rate of calcein as a function of time. A concentration of 100 nM of the 
hydrophobic, nonfluorescent, compound calcein-AM was added to normal perfusion medium 
(upper panel) or Pluronic-free medium (lower panel) and secretion of the fluorescent calcein into 
urine was measured in WH rat kidneys (z,{) and  in TR- rat kidneys (,). Data are means of 
four to five experiments ± SD. Significantly different from WH (*: P<0.05, **: P<0.01). 
 
 
833, however, no differences in calcein excretion were found in comparison with 
the perfusions in absence of PSC-833 (data not shown). 
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Table 6.2 Functional parameters of isolated perfused rat kidneys with 100 nM calcein-AM in 
normal perfusion medium and/or after perfusion with Pluronic-free mediuma  
 
 Normal medium  Pluronic-free medium 
Parameter WH calcein-AM 
TR- 
calcein-AM 
WH calcein-
AM 
TR- 
calcein-AM 
GFR (µl ⋅ min-1) 300 ± 60 350 ± 80  550 ± 300 430 ± 3b* 
diuresis (µl ⋅ min-1) 18 ± 4 18 ± 3  34 ± 11* 27 ± 6 
FRwater (%) 93.9 ± 0.6 94.6 ± 0.9  94.4 ± 1.2 94.3 ± 1.2b
RPP (mmHg) 89 ± 7 93 ± 3  93 ± 14 91 ± 14 
 
a Values are presented as mean ± SD of four experiments over the period 30-120 min. b n = 3. 
GFR = glomerular filtration rate, FR = fractional reabsorption, RPP = renal perfusion pressure. 
Significantly different from perfused WH and TR- rat kidney in normal medium (*: P<0.05). 
 
 
It was demonstrated that Pluronic copolymers inhibit MRP1-mediated transport 
(25), although others found no significant effect on MRP1 or even an increase in 
MRP2-mediated transport (6). Since Pluronic F108 was added to perfusion medium 
as a colloid oncotic agent and to increase perfusion fluid viscosity, we investigated 
the effect of the copolymer on renal calcein excretion. For comparison, a 
combination of dextran (3.3% w/v) and BSA (2% w/v) were used as colloid 
osmotic agents. The results shown in figure 6.1 (lower panel) indicate that the renal 
excretion rate is somewhat faster during the first 60 min of the experiment. 
However, no differences in maximum calcein excretion rate was observed between 
the two perfusion media in WH rat kidneys. Although differences in GFR and 
urinary excretion rate were observed, kidney viability was not altered by the change 
in colloid osmotic agent (table 6.2). GFR values were increased in pluronic-free 
medium, either due to a decreased vascular resistance of the kidney when perfused 
with an albumin solution or due to a reduced oncotic pressure resulting in an 
increase in net filtration Starling forces (15). In TR- rat kidneys perfused with 
Pluronic-free medium, a steady-state calcein excretion rate of approximately 13 
pmol ⋅ min-1 was observed after 80 min of perfusion. This was higher than the 
maximum excretion rate observed for calcein in normal medium perfusions, 
however, a steady-state was not yet achieved after 120 min of perfusion. Most 
likely, the faster onset of calcein excretion in Pluronic-free medium is responsible 
for this difference. Also renal perfusion flow was somewhat lower in normal 
medium as compared to Pluronic-free medium (varying between 11-15 ml/min in 
normal medium versus 15-20 ml/min in Pluronic-free medium). 
In addition to calcein, the calcium-dependent fluorescent indicator, fluo-3, was 
found to be an Mrp2 substrate (28). In agreement with calcein, fluo-3 excretion was 
significantly reduced in perfused kidneys from TR- rats compared with WH rats
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Figure 6.2 Renal excretion rate of fluo-3 as a function of time. A concentration of 500 nM of the 
hydrophobic, nonfluorescent, ester derivative fluo-3-AM was added to perfusion medium (upper 
panel) or the free fluorescing organic anion fluo-3 (lower panel) and secretion of fluo-3 into urine 
was measured in WH rat kidneys (z,{) and in TR- rat kidneys (,). In the upper panel, data 
are expressed as renal excretion rate, in the lower panel clearance over GFR was calculated. Data 
are means of four experiments ± SD. Significantly different from WH (**: P<0.01). 
 
 
after perfusion with the non-fluorescent precursor, fluo-3-AM (figure 6.2, upper 
panel). The use of the hydrophobic acetoxymethyl ester derivative was necessary 
for tubular cell loading of fluo-3, because the organic anion itself was not secreted 
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Table 6.3 Functional parameters of isolated perfused rat kidneys with 500 nM fluo-3-AM or 
500 nM fluo-3 in normal perfusion mediuma  
 
Parameter WH  Fluo-3-AM 
TR-  
Fluo-3-AM 
WH  
Fluo-3 
TR-  
Fluo-3 
GFR (µl ⋅ min-1) 280 ± 50 330 ± 20 320 ± 40 340 ± 30 
diuresis (µl ⋅ min-1) 18 ± 3 21 ± 6 19 ± 2 18.8 ± 0.7 
FRwater (%) 93.6 ± 1.0 93.6 ± 1.7 94.0 ± 0.5 94.5 ± 0.5 
RPP (mmHg) 79 ± 5 76 ± 8 82 ± 4 81 ± 4 
 
a Values are presented as mean ± SD of 4 different experiments over the period 30-120 min. GFR 
= glomerular filtration rate, FR = fractional reabsorption, RPP = renal perfusion pressure. 
 
 
in the perfused rat kidney. Most likely, the basolateral membrane functions as a 
diffusional barrier for fluo-3. Figure 6.2 (lower panel) shows that after perfusion of 
the kidneys with 500 nM fluo-3, an overall clearance over GFR of approximately 
0.6 was calculated in both the WH and TR- rat kidneys. This indicates that, similar 
to FL-MTX, a net reabsorption of fluo-3 was observed. No differences in kidney 
function during fluo-3 or fluo-3-AM perfusions were detected for both rat strains 
(table 6.3). 
The reduced excretion of calcein and fluo-3 in TR- rat kidneys in comparison 
with WH rat kidneys appears to be due to the absence of Mrp2, and not a result of a 
reduced hydrolysis rate of the hydrophobic precursors into the fluorescent organic 
anions. Figure 6.3 shows the concentration of calcein (upper panel) and fluo-3 
(lower panel) detected in perfusion medium in time after perfusion with the 
acetoxymethyl esters. No significant differences in concentrations of the 
hydrolyzed organic anions appearing in the recirculating medium between the two 
rat strains were detected. 
In a previous study, we showed that the renal secretion of the anionic fluorescent 
dye, LY, was sensitive to inhibition by leukotriene C4 and CDNB (18), suggesting 
the involvement of Mrp2 in luminal LY secretion. Figure 6.4 shows LY/inulin 
clearance ratios for kidneys perfused with buffer containing 10 µM LY. After 
exposing WH rat kidneys to a perfusate concentration of 10 µM LY, the LY/inulin 
clearance ratio exceeded unity, indicating net secretion of the fluorescent dye. In 
agreement with previous results (18), the clearance ratio increased during the first 
40 min of the experiment and then gradually declined. In TR- rat kidneys, however, 
the clearance ratio increased slower and a maximum was observed 10 minutes later 
than in WH rats (at 70 min of perfusion) followed by a gradual decline. For both rat 
strains the renal clearance ratio at maximum averaged about 2. No differences in 
kidney function during LY perfusions were detected for both rat strains (table 6.4). 
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Figure 6.3 Appearance of calcein (upper panel) and fluo-3 (lower panel) in kidney perfusate after 
perfusion with calcein-AM or fluo-3-AM. A concentration of 500 nM of the hydrophobic, 
nonfluorescent, compound calcein-AM or fluo-3-AM was added to perfusion medium and 
appearance of the fluorescent calcein or fluo-3 into perfusion medium was measured in WH rat 
kidneys (z) and in TR- rat kidneys ({). Data are means of three experiments ± SD. 
 
 
We recently demonstrated that renal proximal tubule expresses another apical 
organic anion ABC transporter, MRP4, which substrate specificity overlaps with 
that of MRP2 (37). To investigate whether Mrp4 may compensate for the lack of 
Mrp2 in TR- rat kidney, uptake studies were performed with membrane vesicles 
isolated from Sf9-MRP4 cells and compared with studies performed using Sf9- 
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Figure 6.4 Renal clearance over glomerular filtration clearance (GFR) of LY as a function of 
time. A concentration of 10 µM LY was used in WH rat kidneys (z) and in TR- rat kidneys (). 
Data are means of four experiments ± SD. Significantly different from WH (*: P<0.05). 
 
 
 
Table 6.4 Functional parameters of isolated perfused rat kidneys with 10 µM Lucifer Yellow  
in normal perfusion mediuma  
 
Parameter WH  Lucifer Yellow 
TR-  
Lucifer Yellow 
GFR (µl ⋅ min-1) 320 ± 80 300 ± 10 
diuresis (µl ⋅ min-1) 15 ± 3 18 ± 4 
FRwater (%) 94.5 ± 0.6 93.9 ± 0.1 
RPP (mmHg) 87.1 ± 0.4 79 ± 5* 
 
a Values are presented as mean ± SD of four experiments over the period 30-120 min. GFR = 
glomerular filtration rate, FR = fractional reabsorption, RPP = renal perfusion pressure. 
Significantly different from perfused WH-rat kidney in normal medium (*: P<0.05). 
 
 
 
MRP2 membrane vesicles. The net ATP-dependent uptake of 10 µM calcein was 
clearly observed for Sf9-MRP2 vesicles (figure 6.5) but was undetectable in Sf9-
MRP4 vesicles. For Fluo-3, a 4-fold higher uptake was found for Sf9-MRP2 
vesicles as compared to Sf9-MRP4 vesicles. On the other hand, Sf9-MRP4 vesicles 
exhibited a 4-fold higher LY uptake in comparison with Sf9-MRP2 vesicles.  
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Figure 6.5 Net ATP-dependent uptake, 
corrected for control uptake, of fluorescent 
substrates in Sf9-MRP2 (gray bars) and Sf9-
MRP4 (black bars) vesicles. Membrane 
vesicles were incubated at 37 °C for 20 
minutes with 10 µM calcein, 10 µM Fluo-3 
and 100 µM LY and an ATP regenerating 
system. Data are given as mean ± SD, n = 3.  
 
 
 
 
 
 
Discussion 
 
Many of the transport systems for organic anions in the apical membrane of 
renal proximal tubule have initially been characterized in membrane vesicle studies 
(for recent reviews see Refs. 19 and 31). Nevertheless, remarkably little 
information is available on the function of Mrp2 in the kidney, whereas the 
characteristics of Mrp2-mediated secretion in liver canalicular membranes have 
been studied extensively in normal and TR- rats. A major cause for this discrepancy 
is that isolated brush-border membrane vesicles of proximal tubule cells are 
exclusively oriented right-side out (7) and are, therefore, unsuitable for measuring 
ATP-dependent uptake as the ATP-binding site can only be reached by ATP when 
it is exposed to the extravesicular space.  
In the present study, we investigated Mrp2-mediated renal excretion of 
fluorescent substrates using isolated perfused rat kidney, which allows an accurate 
determination of renal drug clearance under controlled conditions (16; 17). 
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Although we have previously shown that FL-MTX is a good substrate for Mrp2 
using membrane vesicles from Sf9-cells over-expressing recombinant rabbit Mrp2 
(34), our attempts to use the compound in perfused rat kidneys were unsuccessful. 
In killifish proximal tubules we clearly observed a two-step process in FL-MTX 
secretion: first uptake into the tubular cells against the electrochemical gradient, 
and second efflux into the tubular lumen by Mrp2 (20). In contrast, in the present 
study FL-MTX was not secreted by perfused rat kidney, most likely because this 
large anionic compound is not taken up from the peritubular side. Apparently, a 
basolateral uptake system for large lipophilic organic anions similar to that in 
killifish proximal tubules is not present in rat kidney. To overcome cell entry 
problems as observed for FL-MTX, the cell permeant derivatives calcein-AM and 
fluo-3-AM were applied. Renal secretion of the fluorescent organic anions, calcein 
and fluo-3, was clearly impaired in isolated TR- rat kidneys. These results are in 
agreement with previous findings that calcein and fluo-3 are actively transported by 
MRP2 (6; 28). The steady increase in renal dye excretion in TR- rats may be a 
result of glomerular filtration of free calcein and fluo-3 in the recirculating system. 
It is unclear by what mechanism hydrolyzed organic anions appear in perfusion 
medium. Probably a carrier-mediated process is involved in efflux of the anionic 
compounds in perfusate, although passive back-diffusion cannot be excluded 
because the concentration gradient is in favor of this process. Using a polarized 
canine renal cell line (MDCKII) stably expressing MRP2, Evers et al. (6) found a 
stimulation of calcein transport by Pluronic L61, suggesting that the cells retained 
the precursor, calcein-AM, better. This was unexpected because others already 
reported a clear inhibition of MRP1-mediated transport by Pluronic block 
copolymers (25). Our results demonstrate that neither a stimulatory nor an 
inhibitory effect of the copolymer Pluronic F108 could be detected. In presence of 
the copolymer, present in normal perfusion medium, the renal excretion rate of 
calcein was somewhat lower as compared to the perfusions with Pluronic-free 
medium. This can be explained by the low urinary flow and GFR in normal 
medium as compared to Pluronic-free medium. 
In TR- rat kidneys the efflux of LY was only delayed in comparison with WH 
rats but not reduced. This is in contrast to our previous findings for LY in killifish 
renal proximal tubules, where its secretion was found to be sensitive to the Mrp2 
inhibitors, leukotriene C4, CDNB and 17ß-estradiol-17β-D-glucuronide (18; 21). It 
has been shown that TR- rats have a dramatically reduced hepatic excretion of the 
conjugates α-naphtyl-β-D-glucuronide and leukotriene C4, whereas their urinary 
excretion was almost unimpaired (4; 12). Therefore, it may very well be possible 
that the absence of Mrp2 from the kidney can be compensated for by (an)other 
Mrp-like organic anion transporter(s). Mrp4 seems to be a good candidate, beacuse 
it is expressed in the apical membrane of renal proximal tubule, but not in 
hepatocyte canalicular membranes (37). However, the organic anion transport 
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 proteins (Oatp’s), Oatp1, Oatp3, Oat-k1 and Oat-k2, are also localized to the apical 
membrane of rat proximal tubules (1; 22; 23; 37). These transporters accept Mrp2 
substrates, like dinitrophenol-glutathione and methotrexate (14; 32; 37). 
Nevertheless, the Oatp’s probably have a preference for transport in the uptake 
direction (reabsorption), rather than that they are involved in excretion (8). In the 
present study we demonstrated that Mrp4 indeed might compensate for the lack of 
Mrp2 in TR- rat kidneys, In close agreement with our findings in perfused rat 
kidney, MRP2 shows a preferential affinity for calcein and fluo-3, whereas LY is a 
better substrate for MRP4. Van Aubel et al. (37) showed previously that there is no 
difference in Mrp4 protein expression in isolated brush-border proximal tubular 
membranes of TR- rat as compared to control rats. Apparently, the basal expression 
level of Mrp4 in rat kidney is sufficient to compensate for the loss of Mrp2 in renal 
LY handling. In contrast, calcein and fluo-3 excretions are equally reduced in TR- 
rats as compared to controls, but calcein seems not to be a substrate for MRP4 
whereas fluo-3 is a poor substrate for the transporter. This might be a result of 
differences between rat Mrp4 and human MRP4 substrate specificity. Evidently, 
more research is needed to define the relative importance of all above mentioned 
organic anion transporters in the facilitated efflux of anionic xenobiotics into the 
urine. Moreover, in this study we used marker compounds unimportant for Dubin-
Johnson patients. In a forthcoming study we will investigate the renal handling of 
clinically relevant drugs known to be substrates for Mrp2 (e.g. pravastatin, 
temocaprilate, cefpiramide, ceftriaxone, p-aminohippurate). 
In conclusion, the results of the present study demonstrate that, in contrast with 
earlier findings (4; 12; 35), the renal secretion of some organic anions is clearly 
impaired in TR- rats implying the contribution of Mrp2. For LY absence of Mrp2 
from the kidney may be compensated for by (an)other organic anion transporter(s), 
among which is Mrp4. However, the clearance of the fluorescent substrates, calcein 
and fluo-3, is significantly reduced in TR- rats. 
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Increased apical insertion of the multidrug 
resistance protein 2 (Mrp2/Abcc2) in renal 
proximal tubules by gentamicin 
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 Summary 
 
We showed previously, using killifish proximal tubules, that the functional 
expression of the efflux transporter Mrp2 is regulated by a signaling pathway, 
triggered by short-term exposure to the nephrotoxicant gentamicin and acting 
through the vasoactive hormone endothelin. Here the influence of gentamicin on 
the functional expression of MRP2/Mrp2 was studied in MRP2-transfected Madin 
Darby Canine Kidney type II (MDCKII) cells and in rat kidney. Transport of 
glutathione-methylfluorescein (GS-MF, cells) or calcein (isolated perfused rat 
kidney) were measured to monitor transporter activity.  
MDCKII cells were exposed to different concentrations of gentamicin (100 - 
1000 µM) for either 1 h, 24 h or for 1 h followed by 24 h recovery. No effect was 
observed for gentamicin on initial transport rate of GS-MF or MRP2 expression 
after 1 h exposure. However, after 24 h of exposure to gentamicin or after a 24 h 
recovery period following 1 h exposure an increase in GS-MF transport was seen, 
which was significant with 500 and 1000 µM. This up-regulation was confirmed by 
a 2-fold increased expression of MRP2 in the apical membrane, whilst the absolute 
expression of MRP2 in total cell lysates stayed the same. In isolated perfused 
kidneys of rats exposed to 100 mg/kg bodyweight gentamicin for 7 consecutive 
days, an increase in the urinary excretion rate of calcein was found, which was 
prevented by the addition of a dual endothelin-receptor antagonist bosentan. No 
effect of gentamicin on Mrp2 mRNA expression was found. We conclude that an 
increased shuttling of the transporter to the apical membrane takes place in 
response to gentamicin exposure, which is triggered by endothelin. 
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Introduction 
 
The renal proximal tubule fulfills an important role in the elimination of anionic, 
cationic and neutral waste products, varying from endogenous (metabolic) waste 
products to xenobiotics. One of the transporters involved in the active secretion of 
organic anions in the pre-urine is the multidrug resistance protein 2 (MRP2; 
ABCC2). MRP2 is located at the brush border membrane of the proximal tubule, 
and transports a wide variety of organic anionic conjugates, amphiphilic anions and 
neutral substrates (reviewed in Russel et al., see Ref. 33).  
When the function of MRP2 is disturbed, pathological situations can occur. Low 
expression or absence of MRP2 causes conjugated hyperbilirubinemia and pigment 
disposition in the liver as observed in patients with the autosomal recessively 
inherited Dubin-Johnson (29; 38) and decreased renal excretion capacity for a 
number of known Mrp2 substrates in an Mrp2-deficient TR- rat (22). On the other 
hand, disease conditions like cholestasis result in a decreased expression of Mrp2 in 
the rat liver, whereas the expression of the transporter protein in the kidney is up-
regulated (40) 
Less dramatic changes in Mrp2 can be observed after exposure to exogenous 
factors like the aminoglycoside antibiotic, gentamicin. Using a killfish renal model, 
we observed a rapid effect of gentamicin on Mrp2 without affecting tubular 
functioning (23; 27; 28; 42). The activity of the ATP-driven drug transporter is 
reduced upon exposure to gentamicin in which a signaling pathway is involved 
triggered by the release of endothelin (ET) and acting through an ETB receptor and 
the second messengers nitric oxide synthase (NOS), cGMP and protein kinase C 
(PKC). Remarkably, however, was an observed increase of Mrp2-mediated 
transport and Mrp2 protein expression in tubules after a 24 h recovery period 
following this short-term exposure compared to non-exposed tubules. These 
increases in transport and Mrp2 expression were abolished when ET signaling was 
disrupted. Moreover, short-term gentamicin exposure and subsequent recovery for 
24 h was protective against acute gentamicin tubular toxicity (26).  
Gentamicin is widely used because of its broad spectrum, low levels of 
resistance and low costs. Its clinical use, however, is hampered by its nephrotoxic 
and ototoxic potential (3; 12). Renal damage is predominantly a result of specific 
accumulation of gentamicin within the cells lining proximal tubules. The 
mechanism of nephrotoxicity supported by most data starts with binding of 
gentamicin to acidic phospholipids or megalin at predominantly the brush border 
membrane and subsequent endocytosis (9; 25; 43). Once inside the cell gentamicin 
may be routed to the Golgi apparatus (34), where it is known to cause disruption of 
ion gradients across the plasma lemma including excessive calcium influx (14; 49), 
reduction of the activity of lysosomal enzymes and inhibition of membrane bound 
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 transporters (11; 36; 42). But, relatively high doses of gentamicin and multiple day 
dosing were used to accomplish general toxicity. 
In the present study we used Madin-Darby canine kidney cells type II (MDCKII 
cells) and a rat renal perfusion set-up as model systems to investigate the effect of 
non-cytotoxic concentrations of gentamicin on MRP2/Mrp2 regulation in more 
detail. We found that, in agreement with our killifish data, long-term treatment of 
renal tubular cells with gentamicin and/or short-term treatment followed by 24 h 
recovery resulted in significantly higher MRP2/Mrp2-mediated transport and Mrp2 
protein expression compared to controls. This functional up-regulation results from 
an increased expression of the transport protein in the apical membrane.  
 
 
Methods 
 
Chemicals 
Gentamicin, fetal bovine serum and non-essential amino acids were obtained 
from ICN biomedicals (Zoetermeer, NL). Dulbecco’s modified eagle culture 
medium with Glutamax-I (DMEM Glutamax-I), 25 mM HEPES and pyridoxine, 
and Hank’s Balanced Salt Solution (HBSS) were purchased from Gibco (Paisly, 
UK). Bovine serum albumin (BSA) was obtained from Boehringer Mannheim 
(Mannheim, Germany). Sodium pentobarbital was purchased from Apharmo 
(Arnhem, The Netherlands), Pluronic F108 from BASF (Arnhem, The 
Netherlands), and heparin, aldosterone and inulin from Organon (Oss, The 
Netherlands). Lysine-vasopressin was obtained from Sandoz Pharma Ltd. (Basel, 
Switzerland) and angiotensin II from Beckman (Palo Alto, USA). Calcein-
acetoxymethylester (calcein-AM) and 5-chloromethylfluorescein diacetate 
(CMFDA) were purchased from molecular probes (Leiden, the Netherlands). MK-
571 was purchased from Cayman Chemical (Ann, Arbor, MI) and 
chlorodinitrobenzene (CDNB) from Sigma (Zwijndrecht, the Netherlands). 
Bosentan was a kind gift of Actelion Pharmaceuticals Ltd. (Allschwil, 
Switzerland). All other chemicals used were of analytical grade and obtained at the 
highest purity available.  
 
Cell culture 
Madin Darby Canine Kidney cells type II (MDCKII wt) and Opossum Kidney 
(OK) cells were obtained from the American Type Culture Collection (Manassasa, 
VI). MRP2- transfected MDCKII cells (MDCKII+MRP2) were a kind gift of the 
Netherlands Cancer Institute (13). Both MDCKII cell lines were cultured in 
DMEM, with glutamax-I, 25 mM HEPES and Pyroxine supplemented with 5% 
fetal bovine serum and 1% non-essential amino acids, at 37°C and 5% CO2 in a 
humid atmosphere. OK cells were cultured in DMEM, with glutamax-I, 25 mM 
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HEPES and Pyroxine supplemented with 10% fetal bovine serum. For all 
experiments MCKII wt, MRP2-transfected MDCKII and OK cells were used in the 
passage range 28-38, 231-251 and 12-15, respectively. For transport experiments, 
LDH measurements or membrane isolations cells were seeded in a density of 5*104 
/ 2 cm2 in 24-well plates (Greiner Labortechnik, Frickenhausen, Germany) or in 
density 1.5*106 / 24 mm transwell polycarbonate membrane filters (0.4 µm pore 
size, Corning Costar inc., Corning, NY) and refreshed every other day until they 
reached confluency after 5-8 days. In the transwell system, confluency was tested 
by measuring electrical resistance. Confluent monolayers were subsequently 
exposed to different concentrations of gentamicin ranging from 100-1000 µM. 
Different exposure times were used for each gentamicin concentration i.e. 1 h, 24 h 
and 1 h followed by 24 h recovery. After exposure, cell layers were used for 
immunoblotting, toxicity or transport studies. 
 
Rat kidney isolation and perfusion.  
For long-term experiments, male Wistar-Hannover (WH) rats (225-275 g) were 
exposed to gentamicin for 7 consecutive days through intraperitoneal injection of 
100 mg/ml per kg bodyweight. These injections took place under a slightly sedated 
condition. Subsequently, rat kidneys were isolated and perfused as described in 
detail previously (8; 22). In short, male WH rats were anesthetized intraperitoneally 
with pentobarbital (6 mg/100 g) followed by an intraperitoneal injection of 
furosemide (1 mg/100 g) to prevent deterioration of the distal nephron. Heparin 
(125 I.U./100 g) was injected in the femoral vein. Without interruption of the blood 
flow, the renal artery via the mesenteric artery and the ureter of the right kidney 
were cannulated. The kidney was then excised and placed in a fluid bath with a 
constant temperature of 37.5 °C. The perfusate reservoir was also placed in a 
waterbath of 37.5 °C and fluid was gassed with 95% O2 / 5% CO2. The perfusion 
fluid had the following composition (mM, except indicated otherwise): NaCl 114.0, 
KCl 5.2, CaCl2 1.8, MgCl2 1.0, NaHCO3 22.5, Na2HPO4 0.84, KH2PO4 0.28, 
glucose 5.0, urea 4.0, pluronic F108 25.0 g ⋅ l-1, glutathione 0.33, inositol 0.083, 
cysteine 0.50, glycine 2.3, Na-pyruvate 2.0, Na-acetate 1.22, Na-propionate 0.21, 
inosine 1.0, alanine 5.0, glutamine 0.11, L-glutamine acid 2.0, ascorbic acid 0.01, 
Na-lactate 1.0, choline chloride 1.0 mg/l, insulin 4 I.U./l, aldosterone 2.0 µg ⋅ l-1, 
lysine-vasopressin 0.01 I.U. ⋅ l-1 and angiotensin II 15.0 ng ⋅ l-1. To this solution 
8.5% Travasol® (Baxter, Clintech Benelux NV/SA, Brussels), a mixture of amino 
acids, was added. Perfusion medium was recirculated at a constant flow rate (15 ml 
⋅ min-1) with a perfusate pressure of approximately 90 mmHg. During the first 5 
min of perfusion, the venous effluent was discarded and after this period the 
perfusion fluid was recirculated and the kidney was allowed to stabilize for 30 min. 
Then transport experiments were started after a baseline period of 45 min during 
which gentamicin was added to the perfusion medium in case of short-term 
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 exposure. After the experiment the remaining kidneys were used for RNA and 
protein isolations.  
 
Toxicity studies 
Cells: To test possible toxic effects of gentamicin on the cell monolayers we 
measured lactate dehydrogenase (LDH) activity in the cells and supernatant after 
exposure. LDH is a cytosolar enzyme that converts pyruvate into lactate in the 
presence of NADH, and is released from the cell after cell damage. A decrease in 
NADH over time was taken as a measure for LDH activity. After adding 1.6 mM 
Na-pyruvate and 0.2 mM NADH, LDH activity in cell and supernatant was 
measured at 340 nm for 3 min using the Thermomax microplate reader and 
SOFTmax software (Molecular Devices Corporation, Mento Park, USA).  
Rat: In the rat perfusion model diminished renal proximal tubule function was 
taken as a measure for functional toxicity. Urine and perfusate samples obtained 
during transport experiments were analyzed for glucose, using the GLUCO-
QUANT kit from Boehringer (Mannheim, Germany), and alkaline phosphatase, 
according to Mircheff et al. (24), to assess this proximal tubule function. 
 
Transport studies 
All transport experiments, were carried out under dimmed light conditions. For 
transport experiments in cell monolayers, CMFDA was used as a source for an 
Mrp2 fluorescent substrate (32). In the rat perfusion model, calcein-AM was used 
as a substrate (22). Both lipophilic compounds readily diffuse into cells where they 
become fluorescent and hydrophilic through the cleavage of the acetate groups by 
unspecific cytosolic esterases. For CMFDA the diacetate-containing compound as 
well as to the esterase-modified compound are conjugated with glutathione by 
glutathione-S-transferase. The resulting substrates are the fluorescent glutathione-
methylfluorescein (GS-MF) and calcein.  
Cell: For transport experiments in wells, cell monolayers were washed twice 
with HBSS + 10 mM hepes, pH 7,4 (HBSS/HEPES) at room temperature. 
Subsequently, cells were loaded with 5 µM CMFDA - / + inhibitors in 
HBSS/HEPES for 30 min to 1 h at 10°C while shaking. After loading, cells were 
washed twice with 10°C HBSS/HEPES. The transport experiments were initiated 
by adding 500 µl HBSS/HEPES 37°C to the cell monolayer. After 0, 1, 2.5, 5, 10 
and 30 min this supernatant was removed and saved for fluorescence analysis. 
Subsequently the cell monolayers were permeabilized for 15 min using 0.1% triton 
in HBSS/HEPES and resulting cell samples were saved for fluorescence analysis. 
For transwell experiments, monolayers were washed twice with 37°C 
HBSS/HEPES. To initiate the transport, both the apical (1.5 ml) and basolateral 
(2.6 ml) side were exposed to 5 µM CMFDA in HBSS/HEPES (37°C ). At 
different time points, varying from 0, 5, 10 and 30 min, samples were taken from 
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the apical and basolateral side to determine fluorescence intensities. To prevent 
floating of cell layers due to hydrostatic pressure, loss of sample volume was 
corrected by replacing the removed volume with 5 µM CMFDA in 37°C 
HBSS/HEPES. After the last time sample was taken monolayers were 
permeabilized using 1.5 ml 0.1% Triton X-100 in HBSS/HEPES. Both 
fluorescence intensity and protein content of resulting cell samples were measured. 
For protein determination a Biorad assay (Bio-Rad laboratories, München, 
Germany) was used.  
Rat: Transport studies in the rat were started after a baseline period of 45 min 
through the addition of 100 µM, calcein-AM with an initial perfusate concentration 
of 100 nM. The experimental period was 150 min. Urine samples were collected 
during baseline and experimental periods over 10 min intervals and analysed 
directly after the experiment.  
For determination of fluorescence intensities in all samples, a Perkin Elmer 
LS50B luminescence spectrometer (Norwalk, CT) was used. For measurement of 
GS-MF excitation and emission wavelengths were set to 475 nm (slit width = 2.5 
nm) and 517 nm (slit width = 2.5 nm), respectively, and for calcein to 488 nm (slit 
width = 5 nm) and 518 nm (slit width = 5 nm). Urine samples were diluted 10 times 
with HBSS/HEPES. For calcein measurements, concentrations were calculated by 
comparing fluorescence intensity (in photomultiplier units) with a calibration curve 
of spiked samples of blank perfusion fluid with different concentrations of calcein 
and corrected for glomerular filtration rate. For GS-MF a sup:cell ratio was used. 
 
Membrane isolation and immunoblotting 
Cell: A specific biotinylation and immunoblotting assay was used to detect 
MRP2 in the apical membrane as described by van Balkom et al. (45). For this 
purpose gentamicin treated transwell monolayers were used and apical membrane 
samples were denatured following isolation by incubation in 1x laemmlli buffer for 
10 min at 65°C. Samples were subjected to 6% SDS-polyacrylamide gel 
electrophoresis and transferred to Hybond-ECL nitrocellulose membrane 
(Amersham, Buckinghamshire, UK). Reversible staining of the membrane with 
Ponceau Red was used to confirm transfer of the proteins. Next the nitrocellulose 
membrane was blocked in TBS-T (20 mM Tris-HCl, 73 mM NaCl, 0.15% Tween-
20, pH 7,6) containing 5% non-fat dried milk (NFDM), for 1 h at room 
temperature, after which the membranes were incubated with a primary antibody 
directed against hMRP2 (k22-MRP2) (37), 1:1000 in TBS-T overnight at 4°C. 
Subsequently the membranes were washed twice in TBS-T, blocked in TBS-T 
containing 5% NFDM, washed twice in TBS-T again and incubated with affinity-
purified horseradish peroxidase-conjugated goat anti-rabbit IgG (Sigma 
Imunochemicals, St. Louis, MO) diluted 1:5000 in TBS-T for 1 h at room 
temperature. After washing the membranes twice with TBS-T, Mrp2 proteins were 
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 visualized with enhanced chemiluminescence (Pierce, Rockford, IL). For semi-
quantification we measured the pixel intensity of the bands using Scion image 
version beta 4.02 for Windows (Scion Corp. Frederick, Maryland).  
Rat: Perfused kidneys were snap frozen in liquid nitrogen. Subsequently the 
kidneys were pulverized using a Mikro-dismembrator U (B. Braun Biotech Int., 
Allentown, Pennsylvania) set at 200 rpm for 30 sec and quickly dissolved in TS 
buffer containing protease inhibitors (250 mM sucrose and 10 mM Tris-HCl at pH 
7.4, supplemented with phenylmethylsulfonyl fluoride (PMSF; 0.1 mM) aprotinin 
(5 µg/ml), leupeptin (5 µg/ml), pepstatin (1 µg/ml) and E64 (10 µM)). After slow 
defrosting on ice, kidney samples were vortexed and centrifuged for 30 min 
(12000g, 4°C). The supernatant was centrifuged again at 105000g for 75 min at 
4°C using a Beckman XL-80 ultracentrifuge after which, the pellet containing 
membrane fraction was dissolved in TS buffer with protease inhibitors. These 
membrane samples were analyzed using immunoblotting with M2III6 (Abcam Ltd., 
Cambridge, UK) to detect Mrp2. 
 
RNA isolation and mRNA expression 
For mRNA isolation homogenized rat kidneys were resuspended in TRIzol 
Reagent (Life Technologies, Breda, The Netherlands). Reverse transcription was 
subsequently performed on 1 µg of total RNA using random primers in a final 
volume of 100 µl (Reverse Transcription System, Promega). Synthesized cDNA 
was used for quantitative real-time polymerase chain reaction (RQ-PCR) according 
to the TaqMan protocol in optical tubes (Applied Biosystems, Foster City, CA). Rat 
Mrp2 and Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were amplified 
with a predeveloped Gene Expression Assay, provided by Applied Biosystems 
(Mrp2; Rn00563231_m1, GAPDH; Rn99999916_s1). For this assay 12.5 µL PCR 
mastermix, 5 µL cDNA, 18 µM for each primer and 5 µM TaqMan with aFAM TM 
reporter dye at the 5’ end and a nonfluorescent quencher at the 3’ end was used. 
The amplification was performed after an initial warm-up phase of 2 min at 50ºC 
for optimal PCR Master Mix activity and 10 min at 95ºC, which served as 
denaturing step. Forty amplification cycles were completed at 95ºC for 15 sec and 
60ºC for 1 minute. Finally, the cDNA was subjected to RT-PCR quantification 
using the ABI PRISM 7700 single reporter Sequence Detection System (Applied 
Biosystems, Foster City, CA).  
 
Data analysis 
Data are given as means ± SE. Mean values were considered to be significantly 
different, when P<0.05 by use of a two-way ANOVA corrected for repeated 
measurements, or by a one-way ANOVA followed by Bonferroni’s multiple 
comparison test. Software used for statistical analysis was GraphPad Prism® 
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(version 4.00 for Windows; GraphPad Software, San Diego CA) and SPSS (version 
10 for Windows Chicago, Il). 
 
Results 
 
MRP2 function and expression in cells 
Transport studies with MDCKII wt and MRP2-transfected MDCKII cells were 
performed to confirm that GS-MF is a good substrate for MRP2. To ensure optimal 
MRP2 routing to the apical membrane, all cell layers used for transport were 
cultured to confluency to obtain the necessary high polarity of the cells (13). The 
transport capacity of both cell lines is expressed as the relative fluorescence 
intensity in the supernatant (figure 7.1A) compared to the total amount of 
fluorescence present, measured after 30 min. Transport of GS-MF is roughly 4-fold
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Figure 7.1 Characterization of 
GS-MF efflux from MDCKII 
wild type (wt) and MRP2-
transfected MDCKII (MRP2) 
monolayers. Active time- 
dependent efflux of GS-MF is 
about 4-fold larger in MRP2 
transfected MDCKII compared to 
wt cells (A). Transport of GS-MF 
is inhibited by MK-571, CDNB 
and MK-571 + CDNB in both 
cell lines at 1 min of efflux (B). 
Efflux measured over time is 
depicted as mean percentage of 
extracellular fluorescence, where 
the total fluorescence, i.e. 
extracellular and intracellular, at 
30 min is set at 100%. Transport 
measured at a single time point is 
depicted as the ratio of 
extracellular and intracellular 
fluorescence measured at that 
time point. Values are means ± 
SE, n = 4-11. Significantly 
different from MRP2 control (+++: 
P<0.001) or control (*: P<0.05, 
**: P<0.001).  
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Figure 7.2 Effect of different gentamicin 
exposures in MDCKII wild type (wt) and 
MRP2-transfected MDCKII (MDCKII + MRP2) 
for either 1 h (A and B), 1 h followed by 24 h 
recovery (C and D) or 24 h (E and F) on Mrp2-
mediated transport. Efflux is increased after 24 h 
recovery following 1 h exposure to high 
concentrations of gentamicin in both cell lines. 
In addition, a similar increase in efflux was 
observed after 24 h exposure to gentamicin in 
opossum kidney (OK) cells (G). Values are 
means ± SE, n = 8-23, where GS-MF efflux was 
set to 100% in 0 µM gentamicin exposed cells. 
Significantly different from 0 µM gentamicin 
(*: P<0.05, **: P<0.01, ***: P<0.001).  
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increased in MRP2-transfected MDCKII cells as compared to MDCKII wt at early 
time points measured, and is still roughly 1.5-fold higher after 30 min of GS-MF 
efflux. At 10°C transport of GS-MF is clearly diminished (figure 7.1A). This 
indicates that a large proportion of the transport measured at 37°C in both cell lines 
is actively driven. Known inhibitors of MRP-mediated transport, CDNB and MK-
571 (33), both inhibit initial GS-MF efflux in wt and MRP2-transfected cells 
(figure 7.1B), although not synergistically.  
To determine the effects of different gentamicin treatments on MRP2-mediated 
transport, we measured initial GS-MF efflux in wells. After 1 h exposure to 500 
and 1000 µM gentamicin a slight increase of GS-MF efflux was observed in wt 
cells, although not statistically significant (figure 7.2A). Also in MRP2-transfected 
MDCKII cells no significant change in efflux was found, although a similar trend 
was visible (figure 7.2B). Note that initial transport rates in wild type cells were 
less than 10% of the rates of GS-MF efflux observed in transfected cells. When 
wild type cells were allowed to recover for an additional 24 h, a slight up-
regulation in GS-MF efflux was seen (figure 7.2C). In MRP2-transfected cells 
exposure to 500 and 1000 µM gentamicin for 1 h followed by a 24 h recovery 
period resulted in an even stronger increased efflux of GS-MF (figure 7.2D). After 
24 h exposure to several concentrations of gentamicin, a dose-dependent increase 
in GS-MF transport was observed for both cell lines, which was significant for 
MDCKII-MRP2 cells (figure 7.2E and F). Furthermore, another kidney cell line 
often used for renal drug transport studies, OK cells, showed a similar dose-
dependent increase in GS-MF transport upon exposure to gentamicin for 24 h 
(figure 7.2G). 
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Figure 7.3 Expression of MRP2 
determined by Western blotting. 
Functional data are supported by an 
increase in MRP2 at the luminal membrane 
after 24 h recovery following gentamicin 
exposure (B and D), while MRP2 in total 
membrane did not change (A and C) 
Values are means ± SE, n = 2-4, where 
pixel intensity (arbitrary units) was set at 
1.0 in the control. Significantly different 
from control (*: P<0.05, **: P<0.01). 
 
 
These increases in efflux were accompanied by an approximately 2-fold increase 
in 
he 24 h exposure to gentamicin to ensure 
tha
Mrp2 protein present in the apical membrane (P<0.05) (figure 7.3B and D). The 
total amount of MRP2 in the cell lysate, however, remained unchanged (figure 
7.3A and C), suggesting a functional up-regulation of MRP2 through increased 
shuttling towards the apical membrane after exposure to gentamicin for 24 h or 1 h 
followed by a recovery period of 24 h. 
An LDH assay was carried out after t
t leakage of GS-MF due to toxicity did not occur. LDH levels in the supernatant 
ranged between 1% and 3.6% for both MDCKII cell types and between 6.8% and 
8.0% for OK cells. These findings suggest that gentamicin does not affect cell 
viability. 
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Figure 7.4: Renal excretion rate 
of calcein as a function of time in 
isolated perfused rat kidneys. A 
concentration of 100 nM of the 
hydrophobic, non-fluorescent, 
compound calcein-AM was 
added to normal perfusion 
medium, and secretion of the 
fluorescent calcein into urine was 
measured in WH rat unexposed 
(control) and exposed to 100 µM 
gentamicin (Gent) for 45 min (A) 
or exposed to gentamicin, 
bosentan (Bos) or a combination 
during 7 consecutive days (B). 
Values are means ± SE, n = 4-12. 
Significantly different from 
control (**: P<0.01).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mrp2 function and expression in rat kidney 
olated from mutant transport-deficient 
rat
Previous studies with perfused kidneys is
s (TR-), in which Mrp2 is lacking, have emphasized that urinary excretion rates 
of calcein are significantly reduced as compared to normal (WH) rats (22). To 
elucidate the effects of gentamicin on renal transport of the fluorescent Mrp2 
substrate, isolated kidneys were exposed to 100 µM gentamicin for 45 min, after 
which urinary calcein excretion rate was assessed (figure 7.4A). In contrast to 
short-term exposure in killifish renal proximal tubules (42), no effect of gentamicin 
on Mrp2 function was found. On the other hand, a slight increase was seen in 
calcein transport following daily exposure to gentamicin (100 mg/kg bodyweight) 
during a period of 7 consecutive days (figure 7.4B). This effect is in agreement
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 Table 7.1 Functional parameters of isolated perfused rat kidneys in control rats (no additional 
treatment) and after exposure to gentamicin, bosentan or a combination of both for 7 days 
 
Parameter 
control 
 
(n = 11) 
100mg/kg 
gentamicin 
(n = 6) 
10mg/kg 
bosentan  
(n = 4) 
gentamicin+ 
bosentan 
(n = 4) 
GFR (µl ⋅ min-1) 308 ± 16 186 ± 23** 288 ± 22 164 ± 26** 
diuresis (µl ⋅ min-1) 19.0 ± 0.9 23.1 ± 2.3 17.7 ± 1.1 22.5 ± 5.3 
CEALP (µM PNP) 1.3 ± 0.3c 0.9 ± 0.3c 0.3 ± 0.1 1.4  0.6 
FEglucose (%) 4.0 ± 0.5
c 6.9 ± 0.8c 4.3 ± 0.5 6.2  1.2 
FRwater (%) 93.7 ± 0.2 87.0 ± 1.3** 93.8 ± 2.7 85.8 ± 2.6**
RPP (mmHg) 81.6 ± 1.6 78.0 ± 1.4 81.0 ± 2.0 81.5 ± 3.8 
 
b Values are presented as mean ± SE of 4-11 perfused kidney experiments over the period 30-120 
min. Kidneys were perfused for 150 min as described in Methods. c n = 3, GFR = glomerular 
filtration rate, CEALP = cumulative excretion of alkaline phosphatase, PNP = para-nitrophenyl, FE 
= fractional excretion, FR = fractional reabsorption, RPP = renal perfusion pressure. Significantly 
different from perfused control WH-rat kidney (**: P<0.001).  
 
 
with the present findings in cells and our studies in killifish renal tubules, where 
Mrp2-mediated transport and transport protein expression were significantly higher 
24 h after a short-term exposure to gentamicin for 30 min. In killifish renal tubules, 
intracellular events signaling the increase in Mrp2-mediated transport involved at 
least endothelin release, binding to the ETB receptor, and activation of NOS and 
cGMP (26). In rats, the up-regulation of Mrp2-mediated transport was also 
prevented by blocking ET signaling. The addition of bosentan, a dual endothelin 
receptor antagonist, resulted in a calcein excretion similar to control perfusions. 
Glomerular filtration rate and fractional water reabsorption were both decreased 
significantly after gentamicin exposure (table 7.1). This effect was not prevented by 
bosentan. No changes in glucose transport and alkaline phosphatase excretion were 
found, suggesting intact proximal tubular functioning.  
The increase in calcein transport in perfused rat kidneys due to long-term 
gentamicin exposure was accompanied by an increase in Mrp2 protein expression, 
as depicted in figure 7.5A and B. The addition of bosentan decreased the 
gentamicin induced up-regulation, which is in accordance with the calcein 
excretion. No effect of gentamicin exposure was observed on the mRNA level, 
excluding de novo synthesis of the transporter protein (figure 7.5C). 
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Figure 7.5 Representative Western blot of Mrp2 in 
rat kidneys and expression of Mrp2 measured by 
RQ-PCR. Gentamicin (Gent) up-regulates Mrp2 
present in the membrane, which is prevented by 
bosentan (Bos) (A and B). Actin was used as the 
internal control. Values are given as mean ± SEM 
in regard to actin expression (n = 4), where pixel 
intensity (arbitrary units) was set to 100% in 
controls. No effect of gentamicin on mRNA level 
of Mrp2 was seen (C) GAPDH expression was 
used as internal control. mRNA expression was 
plotted relative to GAPDH expression. Values are 
means ± SE (n = 3-4) in regard to GAPDH 
expression, where Mrp2 mRNA expression was set 
to 100% in controls. Significantly different from 
control (*: P<0.05). 
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Discussion 
 
MRP transporters play an important role in the effective elimination of toxic 
compounds and metabolites, and for the conservation of essential substances. The 
expression and transport activity of MRPs are highly regulated by signals like 
circulating hormones, activation of protein kinases and nuclear receptors and 
disease conditions, enabling the kidney to adapt to altered physiological conditions. 
The adaptive capacity of the kidney contributes to an effective elimination of 
endogenous compounds, xenobiotics and their metabolites, thereby reducing their 
potential toxicity (reviewed by van de Water et al., see Ref. 46). In the present 
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 study, we showed that the nephrotoxicant, gentamicin, is able to influence Mrp2-
mediated transport and expression in two mammalian kidney models. Twenty four 
h exposure to gentamicin or 1 h exposure to gentamicin followed by 24 h of 
recovery in MDCKII cells resulted in an increased transport by both endogenous, 
canine, Mrp2 and hMRP2. This induction is due to increased shuttling of the 
transporter protein to the apical membrane. These results were confirmed in a 
whole organ perfusion model, where long-term, in vivo, exposure to gentamicin 
also resulted in enhanced Mrp2-mediated transport and, simultaneously, in 
increased expression of the transport protein in the membrane. In good agreement 
with previous studies using killifish renal proximal tubule (26) these effects were 
triggered by endothelin, since receptor blocking prevented this functional up-
regulation.  
GS-MF and calcein proved to be appropriate substrates to measure MRP2/Mrp2-
mediated transport. In addition to MRP2/Mrp2, GS-MF and calcein are reported to 
be substrates for other MRPs, among which Mrp1 (48). However, involvement of 
other efflux transporters influencing GS-MF or calcein transport in our models 
seems highly unlikely. Because MDCKII and OK cells were grown in wells, 
basolateral transporters such as MRP1, MRP3 and MRP6 do not contribute to GS-
MF efflux, which also applies for urinary calcein efflux in perfused rat kidneys. In 
contrast, Mrp4 is apically expressed in renal proximal tubule and colocalizes with 
Mrp2 (44), but we showed previously that calcein is not a substrate for this 
transporter (22). Concerning GS-MF efflux, involvement of canine Mrp4 cannot be 
excluded, but its contribution is likely to be of minor importance as increased GS-
MF transport is accompanied by an increase in Mrp2 expression upon gentamicin 
treatment. Moreover, our findings in killifish renal tubules indicated that 
gentamicin did not affect Mrp4 expression (26). 
In contrast with our findings in killifish renal proximal tubule (27; 28; 42) we 
did not observe an initial decrease in MRP2-mediated transport after a short-term 
exposure to gentamicin. After 1 h exposure, concentrations up to 500 µM and 1000 
µM gentamicin in cells, or 100 µM in perfused rat kidney did not affect Mrp2-
mediated transport. Remarkably, these concentrations were found to be non-toxic 
for these mammalian models even after long-term exposure, whereas killifish renal 
proximal tubules already showed toxic signs after 24 h exposure to 10 µM 
gentamicin (Notenboom et al. unpublished observations).  
After gentamicin exposure, glomerular filtration rate and fractional water 
reabsorption were decreased in rat kidney (table 7.1), apparently by an ET receptor-
independent mechanism, since bosentan was unable to prevent these effects. 
However, proximal tubular function remained unaltered, indicating minor toxicity. 
This large difference in sensitivity between killifish and mammalian models can 
partly be explained by species differences and exposure routes. Gentamicin is well 
known for its nephrotoxicity in various in vitro and in vivo study reports. However, 
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relatively high doses of gentamicin and multiple day dosing were used to 
accomplish general toxicity in animal and cellular models (3; 16). 
In accordance with previous studies in which longer-term exposure to 
nephrotoxicants resulted in an increased Mrp2 expression (18; 21; 26; 41), we 
observed an increase in MRP2-mediated transport. The up-regulation of Mrp2-
mediated transport is, at least in part, due to an increased amount of Mrp2 in the 
apical membrane, if a one-to-one correspondence between transport activity and 
transporter content is assumed. The expression and transport activity of MRPs can 
be modulated by transcriptional and post-transcriptional mechanisms. Mechanisms 
that may lead to an increased apical expression, include de novo synthesis of Mrp2, 
increased insertion of Mrp2 into or a reduced Mrp2 retrieval from the apical 
membrane. Important signals in these events are provoked by hormones, protein 
kinases and nuclear receptors. Gentamicin is known to trigger several signaling 
molecules involved in the short-term and long-term regulation of Mrp2, including 
endothelin, nitric oxide, cGMP and PKC (23; 27; 28; 42). In mammalian 
hepatocytes, both PKC and protein kinase A (PKA) have been implicated in 
bidirectional, regulated trafficking of Mrp2 between intracellular stores and the 
canalicular membrane (4; 20; 32). This is in support of our data, since MRP2 
expression was increased in our cell system in the apical membrane but not in total 
cell lysates. Also the smaller increase of GS-MF efflux in MDCKII wt compared to 
the transfected cells support increased shuttling, assuming that vesicles responsible 
for Mrp2 trafficking are more heavily loaded with MRP2 in transfected cells than 
in wild-type cells. The absence of changes in the Mrp2 mRNA levels in rat support 
a similar conclusion. 
In addition, MAP (mitogen-activated protein) kinase pathways might be 
involved in the regulation of transport protein expression. Both gentamicin and ET-
1 have been associated with the regulation of MAP kinases extracellular signal 
regulated kinase 1 and 2 (5; 49), a family of kinases that regulate organic anion 
uptake in renal proximal tubules as well (35). Whether gentamicin provokes 
signaling of MRP2 through these kinases needs to be investigated. Furthermore, 
several ligand activated nuclear receptors have been shown to transcriptionally 
regulate the activity of xenobiotic transporters, including in liver, kidney and 
blood-brain barrier mostly accompanied by an increased activity of drug 
metabolizing enzymes (2; 6; 17). These include the pregnane X nuclear receptor 
(PXR) and the constitutive androstane receptor (CAR), both of which are activated 
by a wide range of xenobiotics (7; 17; 19). However, until now this up-regulation 
was exclusively studied in liver and not in kidney, and never in response to an 
aminoglycoside antibiotic. Interestingly, the endothelin receptor antagonist, 
bosentan, and its metabolites have been reported to activate PXR in kidney (47). 
Our data do not support such a transcriptional up-regulation of Mrp2, since the 
mRNA levels of the transporter remained unchanged.  
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 Up-regulation of Mrp2 in the kidney may be interpreted as part of a protective 
mechanism. Mrp2 serves a protective function through eliminating potentially 
harmful compounds. An up-regulation as observed after recovery following short-
term gentamicin exposure (present study and Ref. 26), after long-term exposure to 
cadmium as described previously (41) or after ischemia (21) strongly support the 
hypothesis that induction of Mrp2 is triggered to prevent (further) tubular injury. 
Also the prevention of toxicity due to a second toxic event following a recovery 
period of a short-term exposure, suggests a protective function (26). Furthermore, 
in cholestasis due to bile duct ligation, Mrp2 mRNA and protein expression in the 
liver of rats were found to be down-regulated but expression of the basolateral 
Mrp1, Mrp3 and Mrp4 proteins were induced (10; 31; 40) as was Mrp2 in the 
kidney. These up-regulated proteins may offer an alternative elimination route for 
accumulating bile salts and reducing tubular toxicity of a second toxic insult, as 
observed in killifish (26). However, it should be noticed that induced Mrp2-
mediated transport after gentamicin exposure appears to be associated with a 
protection of the proximal tubule but not of all renal functional parameters, as 
judged by the impaired glomerular filtration rate and fractional water reabsorption 
in the perfused kidney. 
MRP2 may also play an important role in the defense against oxidative stress. 
For example, Mrp2 transports gluthatione (GSH) conjugates, but also GSH itself 
and GSH disulfide, GSSG (reviewed by Russel et al., see Ref. 33), and is 
responsible for the maintenance of the GSH redox ratio (i.e. GSSG/GSH), which is 
essential for normal cellular function. The GSH redox ratio depends on the 
reversible conversion of GSH to GSSG, but enhanced efflux of GSSG, which 
accumulates when the activity of GSSG reductase becomes rate limiting, 
contributes to a steady state redox ratio as well. In contrast, a negative impact was 
found by Ji et al. (15) who stated that an increase in Mrp2 could harm the cell 
through GSH depletion, promoting cell injury through oxidative stress. In our 
models, however, no clear toxic signs were found although gentamicin is known to 
have a negative effect on the GSH content of the cell next to up-regulation of Mrp2 
(1; 30; 39). This suggests that Mrp2 can affect the detoxification of reactive 
electrophilic toxins through an interplay with the GSH and gluthatione S 
transferase–conjugating systems as speculated by Smitherman et al. (38). 
In conclusion, cultured mammalian renal proximal tubular cells exposed to 
gentamicin for 24 h or for 1 h followed by 24 h recovery, show an increase in 
MRP2-mediated transport and protein expression in the brush border membrane by 
an increased shuttling of the transport protein to the apical membrane. In perfused 
rat kidney a similar functional and expressional effect was reached after prolonged 
exposure to gentamicin for 7 consecutive days in vivo, in which endothelin-
signaling seems to be implicated. Up-regulation of this transport protein, involved 
in the excretion of many potentially toxic compounds, may be part of the strategy 
of the cell to cope with non-physiological situations ensuring cell survival. 
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As an excretory organ the kidney is part of the body’s detoxifying system. Renal 
tubular cells are equipped with a variety of transport systems to eliminate 
potentially harmful endogenous and exogenous toxicants, including the ATP-
dependent transporters multidrug resistance protein 2 (MRP2) and multidrug 
resistance 1 P-glycoprotein (MDR1 P-gp), that mediate efflux of amphiphilic 
compounds across the apical membrane into urine. The vasoactive hormone 
endothelin-1 (ET-1) has been known to be an important regulator of kidney 
function. In addition to its physiological role, ET-1 can be released by nephrotoxic 
compounds, thereby exerting several actions that promote kidney damage, 
including vasoconstriction, production of reactive oxygen species, release of 
growth and inflammatory factors, and inhibition of transporter activity as reviewed 
in chapter 1. However, dependent on exposure time, nephrotoxicants can also 
induce up-regulation of transporter activity, suggesting a protective effect of ET-1 
(chapter 1). The objective of the studies described in this thesis was to further 
elucidate the signal transduction mechanisms by which ET-1 regulates transporter 
function and to understand how this connects to nephrotoxicity or nephroprotection 
and whether ET receptor antagonists can be employed therapeutically.  
Chapters 2 and 3 describe the role of nitric oxide (NO) and cGMP in the 
sequence of events leading to inhibition of Mrp2-mediated transport in killifish 
proximal tubules, after short-term exposure to several unrelated nephrotoxicants. 
The following sequence of events were found to take place: influx of calcium, ET-1 
release, binding of ET-1 to the ETB receptor, stimulation of NO synthase (NOS) 
resulting in NO release, guanylyl cyclase stimulation resulting in cGMP release and 
protein kinase C (PKC) stimulation, finally resulting in the inhibition of fluorescein 
methotrexate (FL-MTX) mediated efflux. This is depicted in figure 8.1. 
Surprisingly, ET, NO, and cGMP are also involved in long-term consequences 
following short-term gentamicin exposure (chapter 4), in which the pathway gives 
rise to increased transport activity and apical membrane expression of Mrp2 in 
killifish proximal tubules. A similar induction of transport activity was observed in 
Madin Darby Canine Kidney type II (MDCKII) cells transfected with human 
MRP2 (chapter 7). Finally, this regulatory pathway could be confirmed in vivo in 
isolated perfused kidneys of rats treated with gentamicin (chapter 7).  
In this thesis the initial steps in the ET-mediated regulation of renal drug 
transport were explored in isolated killifish tubules (chapter 2, 3 and 4). In general, 
results observed in non-mammalian tissue are accepted with skepticism, because it 
is not always evident how representative they are for the human situation. Indeed, 
as described in chapter 7, no effects were found on Mrp2/MRP2-mediated transport 
after short-term exposure to gentamicin in the two mammalian models that were 
used i.e. MDCKII wild type and human MRP2 transfected MDCKII cells, and 
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isolated perfused rat kidney. Obviously, each of the models has its strengths and 
weaknesses, which should be taken into account.  
In chapters 2, 3 and 4 freshly isolated proximal tubules from killifish were 
employed to measure transport. Killifish kidneys contain a relatively high 
proportion of proximal tubules that, in contrast to mammalian tubules, form closed 
fluid filled compartments after isolation. This model is ideal for studying secretory 
transport into the tubular lumen and it is easily accessible for several effectors. 
Studies using killifish tubules indicated the luminal presence of Mrp2, Mdr1 P-gp, 
Mrp4 and a basolateral organic anion transporter (chapter 4, 7 and Refs. 18 and 29), 
which is in accordance with their localization in mammalian tubules (25; 26). 
Moreover, transport studies showed good resemblance between the mammalian and 
killifish transporters with respect to their substrate specificities (19; 20). Still, data 
concerning regulation processes observed in killifish needed to be confirmed in 
mammalian tissue, which is described in chapter 7. In this chapter, MDCKII and 
OK cell lines were used, originating from dog and opossum renal proximal tubule. 
Both cell lines possess general proximal tubular features (24), but it is unclear what 
the consequences of the immortalization procedure were for cell functioning. In 
other words minor changes in cell physiology could explain why relatively high, 
but still non-toxic, concentrations of gentamicin were required to trigger an effect. 
An advantage of the cell system was the availability of MDCKII cells transfected 
with MRP2, which resemble the human situation more closely. Although ideal for 
investigating transport characteristics, regulatory studies become more complex, 
since endogenous, canine, signaling pathways may not be able to regulate the 
artificially inserted human MRP2. Finally, the rat kidney was used to study 
transport at the organ level (chapter 6). In this model, the multiple and relatively 
high doses of gentamicin used, compared to the clinical situation, did not affect 
functional parameters as glucose transport and alkaline phosphatase (chapter 7). It 
is known that the doses of aminoglycoside antibiotics needed in animals such as 
mouse and rat to reach toxicity are higher than the doses described for patients to 
experience nephrotoxicity (30). Nevertheless, the mechanisms of toxicity are 
thought to be similar in all species studied, including humans (11).  
Data collected using all these renal models indicate that exposure to 
nephrotoxicants, like gentamicin, may have beneficial side effects. The studies 
described in chapters 4 and 7 suggest that gentamicin triggers a survival/protective 
pathway by enhancing Mrp2-mediated transport through the release of ET. This 
functional increase, observed after prolonged exposure to gentamicin or after 24 h 
recovery following short-term exposure, seems to be due to either increased 
insertion into the apical membrane and/or decreased retrieval of MRP2/Mrp2 from 
the membrane. Up-regulation of Mrp2 during the recovery period may be 
interpreted as part of a mechanism called preconditioning, because Mrp2 and 
possibly other adapted mechanisms protect the tissue against a second exposure to
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 Figure 8.1 Scheme illustrating the proposed sequence of events by which nephrotoxicants reduce 
Mrp2-mediated transport after short-term exposure and up-regulate Mrp2-mediated transport after 
long-term exposure, or short-term exposure followed by a 24 h recovery period. (A) 
Nephrotoxicants cause a transient opening of calcium channels, which increases intracellular Ca 
concentration and stimulates ET release. The hormone binds to a basolateral ETB receptor, which 
activates NOS, resulting in the production of NO. This in turn activates soluble guanylyl cyclase 
(sGC), increases cGMP production and activates PKC. PKC activation rapidly reduces transport 
by Mrp2. (B) Long-term exposure and short-term exposure to gentamicin results in up-regulation 
of MRP2/Mrp2-mediated transport due to increased insertion of MRP2/Mrp2 protein in and/or 
decreased retrieval from the membrane. In this process ET and possibly NOS and soluble 
guanylyl cylase are involved in a pathway favoring Mrp2 shuttling towards the membrane. 
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gentamicin (chapter 4). As explained in chapter 4, all the different effects on Mrp2-
mediated transport due to different time frames, provide an example of context-
dependent signaling. This has been demonstrated previously for protein kinases (3; 
8). This thesis has been able to document three patterns of effects following 
exposure to gentamicin and other nephrotoxicants (see figure 8.1): a) inhibition of 
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transport after short-term exposure (chapter 2 and 3), b) toxicity after long-term, 
continuous, exposure (chapter 4), and c) increased transport after long–term 
exposure to non-toxic concentrations of nephrotoxicants (chapter 7) or after short-
term exposure followed by a period of recovery (chapter 4 and 7).  
The question now remains how to view the role of ET in this potential context-
dependent signaling, and whether ET receptor antagonists can be useful as 
nephroprotectants. The initial inhibition of Mrp2- and Mdr1 P-gp-mediated 
transport was observed only in killifish tubules (chapter 2, 3, 4 and Refs. 18; 31 and 
32) and may be explained as an attempt of the cell to save ATP for cell survival. 
Mdr1 P-gp has a constitutive ATP-ase activity, which is stimulated during transport 
of substrates. Although MRP2 hydrolyzes less ATP than Mdr1 P-gp (7; 27; 28) a 
down-regulation of these transporters, and possibly other ATP consuming 
processes, might conserve energy for duties more immediately relevant for cell 
survival. In addition, ET might prevent oxidative stress through decreased efflux of 
GSH by inhibiting Mrp2 (9; 16), favoring the cells redox state. On the other hand, 
as suggested in chapter 1, these initial inhibiting effects of ET on proximal tubule 
functioning may also aggravate ET-mediated renal injury. A reduction in drug 
efflux may contribute to the progression of cellular damage as a result of 
accumulation of toxic compounds. In particular accumulation of glutathione 
conjugates and GSSG, normally efficiently transported by MRP2 may occur. 
MRP2 is able to transport GSSG out of the cell (chapter 1), thereby shifting the 
GSH/GSSG balance in favor of protection against oxidative stress (16; 34). Of 
course, it cannot be excluded that other transporters with certain substrate overlap, 
e.g. those belonging to the solute carrier (SLC) superfamily, may be able to take 
over the efflux function. On the other hand, the observed increase in MRP2/Mrp2-
mediated transport after prolonged exposure to nephrotoxicants (chapter 7 and Ref. 
31) and after short-term exposure followed by a period of recovery (chapter 4 and 
7) support the protective or survival pathway triggered by ET. This enhanced 
functional transport was accompanied by an increased expression of MRP2/Mrp2 
in the apical membrane (chapter 4 and 7) and by the prevention of toxicity (chapter 
4), suggesting a role for MRP2/Mrp2 in this nephroprotective process. However, it 
should be noted that ET signaling and gentamicin preconditioning may have 
affected more than MRP2/Mrp2 expression and function alone. It is important to 
determine whether changes in other genes or enzyme/transporter functions may 
also contribute to cellular protection.  
Patients may be exposed to nephrotoxic drugs like gentamicin for several 
consecutive days. However, can the triggered ET pathway shift from promoting 
cell damage in an early phase to cell protection at a later stage in humans as well? 
The initial transport inhibition, preceding the up-regulatory phase as in a 
preconditioning process, only covers a short period. In this period, inhibition of 
transport, possibly in combination with oxidative stress, may lead to severe cell 
damage or even cell death, which might prevent the cell from triggering the 
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 protective pathway. One might argue that an excessive presence of damaged or 
death cells is compensated by the continuous regenerative capacity of the kidney, 
elicited when (patho)physiological cell death occurs. Renal regeneration may result 
from dedifferentiation, cell division or cell spreading of neighbouring viable 
tubular epithelial cells, or from stem/progenitor cells resident in the kidney or from 
circulating bone marrow cells (1; 6; 10; 23). Recent results even suggest a role for 
transporters in repair mechanisms, further supporting the role of transporters and 
possibly ET in a protective mechanism. There are indications that the 
differentiation of stem cells/progenitor cells may be regulated by members of the 
ATP-binding cassette (ABC) superfamily of transmembrane transporters (chapter 
5).  
To explore possible clinical consequences of this pathway, it is important to 
come back to the second question: can ET receptor antagonists be employed 
therapeutically to prevent nephrotoxicity? ET receptor antagonists are a class of 
therapeutics already extensively proposed or used to improve a variety of 
pathological situations like certain types of cancer (2), pain perception (22), and 
vascular diseases varying form atherosclerosis, heart failure to pulmonary arterial 
hypertension (17). In the past, ETA receptor antagonists were successfully used in 
the (partial) protection against nephrotoxicity caused by immunosuppressants (5; 
14). However, ET receptor antagonists did not appear effective in the prevention of 
diabetic nephropathy (13) or nephrotoxicity caused by other toxicants, like 
radiocontrast fluids, heavy metals and aminoglycoside antibiotics (12; 21). The 
inability of the ET receptor antagonists to prevent toxicity can be caused by ET-
unrelated damage (4; 15; 33; 35), but also by inhibition of the long-term protective 
effects of ET.  
In conclusion, the overall role of ET in drug transport seems to promote cell 
protection through its up-regulating effect on MRP2-mediated transport. This up-
regulation following an initial inhibition of transport appears to be part of a 
preconditioning process. The use of ETB receptor antagonists to prevent kidney 
damage during the initial inhibition seems not advisable, since blocking of ET 
signaling will also prevent the activation of subsequent protective mechanisms. 
Taking into account that ET signaling and gentamicin preconditioning might affect 
more than MRP2 expression and function, it is important to determine what confers 
increased resistance to nephrotoxicity and whether ET and/or MRP2 are key 
players in this process. In addition, it will be interesting to define whether ABC 
transporters, and possibly ET, are involved in the regulation of cell regeneration. 
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The kidney proximal tubule is particularly vulnerable to toxic effects of 
xenobiotics. This is a result of its high renal blood flow and concentrative function. 
Proximal tubular cells are equipped with uptake and efflux systems for anionic and 
cationic xenobiotics. In general, tubular uptake processes proceed rapidly and 
efficiently, and by regulating the activity of efflux transporters the cell can control 
and prevent accumulation of potentially toxic substances. The vasoactive hormone 
endothelin (ET) has recently been discovered to be involved in the regulation of 
two important efflux transporters belonging to the ATP-binding cassette (ABC) 
superfamily, i.e. the multidrug resistance protein 2 (MRP2; anionic substrates) and 
multidrug resistance 1 P-glycoprotein (MDR1 P-gp; uncharged and cationic 
substrates). In intact killifish renal proximal tubules, it was shown that ET triggers 
a pathway following calcium influx, which occurs after exposure to 
nephrotoxicants. ET in turn binds to the ET B-type (ETB) receptor, causing 
stimulation of protein kinase C (PKC) and subsequent inhibition of Mrp2 and Mdr1 
P-gp transport activity (3; 9). As reviewed in chapter 1, ET and the decreased 
activity of MDR1 P-gp and MRP2 have been implicated in several disease 
processes and renal damage due to toxicity. ET has several actions promoting 
kidney damage, including vasoconstriction, the production of reactive oxygen 
species, the release of growth and inflammatory factors and the inhibition of drug 
transporters. However, dependent on exposure time, several nephrotoxicants can 
also induce the activity of drug efflux pumps by a mechanism in which ET is 
involved, suggesting also a renoprotective function of this hormone. 
The studies described in this thesis were focused on the physiological and 
pathological roles of ET in relation to renal drug transport, in order to explore the 
potential therapeutic value of ET receptor antagonists to protect the kidney against 
drug-induced toxicity. For this purpose the ET pathway triggered by 
nephrotoxicants was studied after short-term and long-term exposure.  
 
First, the ET-fired pathway triggered after short-term exposure, as already 
described previously, was studied in more detail in a killifish model (2-4). Using 
confocal microscopy and quantative image analysis, Mrp2-mediated efflux of the 
fluorescent substrate, fluorescein methotrexate (FL-MTX), was measured as an 
indicator of the status of this ET-fired, intracellular signaling pathway. In chapter 
2, tubules exposed to the nitric oxide (NO) donor, sodium nitroprusside (SNP), 
signaled a 50 % reduction in Mrp2-mediated FL-MTX efflux. This reduction was 
already observed within 10 min of exposure to SNP. To determine whether NO 
release was a consequence of ET-1 exposure, tubules were exposed to ET-1 in the 
absence or presence of a nitric oxide synthase (NOS) inhibitor, which blocked the 
action of ET-1 on transport. Moreover, NO generation was implicated in the 
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actions of several unrelated nephrotoxicants, i.e., diatrizoate, gentamicin, amikacin, 
mercury and cadmium, each of which decreased Mrp2-mediated transport by 
activating ET signaling. ET-1 and each of the nephrotoxicants stimulated NO 
production by the tubules, as determined by a fluorescence-based assay using an 
NO indicator. Since SNP effects on FL-MTX efflux were blocked by a PKC 
selective inhibitor but not by an ETB receptor antagonist, generation of NO 
occurred after ETB receptor signaling but before PKC activation.  
NO is also one of the signals known to trigger the production of cGMP. This 
second messenger is generated by the activation of guanylyl cyclase and is 
involved in the regulation of various transporters (6; 10). In addition, cGMP may 
be involved in nephrotoxicity (7). Therefore, the role of guanylyl cyclase and 
cGMP in the short-term regulation of Mrp2-mediated efflux in renal proximal 
tubule was studied, as described in chapter 3. It was found that oxadiazole 
quinoxalin (ODQ), an inhibitor of guanylyl cyclase, was effective in preventing the 
reduction of Mrp2 efflux by ET-1, irrespective of the source of the initial signal. 
ODQ also blocked the effects of the NO generation by SNP, but not the effects of 
PKC activation. Exposing tubules to a cell permeable cGMP analog decreased 
luminal FL-MTX accumulation. This effect was abolished by a PKC inhibitor, but 
not by an NOS inhibitor. Together, these data indicate that ET regulation of Mrp2 
involves activation of guanylyl cyclase and generation of cGMP. Signaling by 
cGMP follows NO release and precedes PKC activation. PKC in turn inhibits 
Mrp2-mediated transport in the renal proximal tubule.  
In contrast to this short-term regulation, previous results in killifish tubules 
showed that after 6 h exposure to a relatively low concentration of cadmium 
transport activity and protein expression of Mrp2 at the luminal membrane were 
increased (8). This long-term induction of Mrp2 may function as a compensatory 
mechanism for the initially reduced efflux of potentially toxic Mrp2 substrates, 
serving a protective route. To study the long-term effects in more detail, killifish 
tubules were exposed to either ET-1 or gentamicin for 30 min and placed in 
recovery medium for different time periods (chapter 4). Proximal tubules 
recovered fully within 3 h from the initial decrease in Mrp2-mediated transport, 
which was sustained at least 12 h after the initial insult. However, 24 h after 
exposure, luminal accumulation of an Mrp2 substrate had increased by 50%. An 
increased transporter protein content at the luminal plasma membrane, as measured 
by immunostaining, accompanied this increased transport at 24 h. Blocking of ET-1 
signaling at the ETB receptor or downstream at NOS or guanylyl cyclase abolished 
both stimulation of transport and increased transporter expression. Thus, regardless 
of whether signaling was initiated by a short exposure to ET-1 or to a 
nephrotoxicant, the time course of the Mrp2 response to ETB signaling was similar 
and multiphasic. The produced cGMP might cause de novo synthesis of Mrp2, 
stimulation of Mrp2 insertion in the luminal membrane of the renal proximal tubule 
and/or inhibition of Mrp2 retrieval from the luminal membrane, eventually leading 
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 to increased Mrp2-mediated transport. Finally, when tubules were exposed to non-
toxic concentrations of gentamicin for 30 min and removed to gentamicin-free 
medium for 24 h, they were less sensitive to acute gentamicin toxicity than paired 
controls not initially exposed to the drug. Thus, short-term exposure to ET-1 or 
gentamicin resulted in long-term protection against a second insult. 
ATP-binding cassette (ABC) transporters, like MRP2 and MDR1 P-gp, have 
also been implicated in the regulation of stem cell differentiation (1; 11) and might 
play a role in repair mechanisms, further supporting their role in protective 
mechanisms. The pilot study described in chapter 5 is a first attempt to gain insight 
in how renal stem cells are established in the adult kidney and are mobilized after 
injury in relation to these transporters. The localization of Mdr1 P-gp, Mrp2 and 
two other ABC transporters, the multidrug resistance protein 4 (Mrp4) and the 
breast cancer resistance protein (Bcrp), were determined in interstitial tissue, the 
inducible nephrogenic zone and tubular tissue. Renal tissues from little skate 
(Leucoraja erinacea), spiny dogfish (Squalus acanthias) and zebrafish (Danio 
Rerio) were evaluated using light microscopy and immunohistochemistry. Mdr1 P-
gp, Mrp2 and Mrp4 were present in the luminal membrane of kidney tubules in 
these species, which is in agreement with the mammalian and killifish kidney 
(chapter 4 and Refs. 3 and 5). In addition, a Bcrp-like protein appears to be 
conserved in a small number of single cells in the hematopoietic tissue of zebrafish. 
Furthermore, a few single positive cells for Mrp2 were found in the contralateral 
non-operated kidney of the little skate. These cells are possible candidates for 
progenitor cells, however, further research is needed to identify these cells in the 
vicinity of nephrogenic tissue.  
The results described above were all obtained in non-mammalian tissues. 
Although the transport proteins are highly conserved in evolution, their regulation 
in mammalian kidneys is still largely unknown. Madin Darby Canine Kidney type 
II (MDCKII) cells and isolated perfused rat kidneys were used to investigate the 
regulation of Mrp2. Chapter 6 describes the transport of three fluorescent Mrp2 
substrates, calcein, fluo-3 and lucifer yellow, in the kidney of both Wistar-
Hannover (WH) rats and Mrp2 deficient, TR-, rats. Isolated rat kidneys were 
perfused with the non-fluorescent calcein-AM or fluo3-AM, which enter the 
tubular cells by diffusion and are hydrolyzed intracellularly into the fluorescent 
anions, calcein and fluo-3. The urinary excretion rates of calcein and fluo-3 were 3-
4 times higher in perfused kidneys from WH rats as compared to TR- rats. Renal 
excretion of lucifer yellow was somewhat delayed, but appeared unimpaired in TR- 
rats. Experiments using membrane vesicles isolated from Sf9 cells expressing 
human MRP2 or human MRP4 confirmed these results, and indicated that MRP2 
exhibits a preferential affinity for calcein and fluo-3, whereas lucifer yellow is a 
better substrate for MRP4.  
Chapter 7 describes the influence of gentamicin on the functional expression of 
Mrp2/MRP2 in mammalian tissue. MDCKII cells, transfected with MRP2, were 
148     Chapter 9 
exposed to different concentrations of gentamicin for either 1 h, 24 h or for 1 h 
followed by 24 h recovery. In contrast to the results in killifish, no effect was 
observed with gentamicin on the initial transport rate of glutathione-methyl 
fluorescein (GS-MF), an MRP2 substrate, or on the expression of MRP2 after 1 h 
exposure. After 24 h of exposure to gentamicin or after a 24 h recovery period 
following 1 h exposure, however, a significant increase in GS-MF transport was 
seen in cells exposed to gentamicin. This up-regulation was confirmed by a 2-fold 
increased expression of MRP2 in the apical membrane, whilst the absolute 
expression of MRP2 in total cell lysates stayed the same. In isolated perfused rat 
kidneys no effect on the excretion of calcein was observed after a short-term 
exposure period to gentamicin. Again, long-term exposure to gentamicin, i.e. for 7 
consecutive days, resulted in an increase in the urinary excretion rate of calcein and 
luminal Mrp2 expression. This long-term effect was prevented by the addition of 
the dual ET receptor antagonist, bosentan. No effect of gentamicin on Mrp2 mRNA 
expression was found. From mammalian data it can, therefore, be concluded that 
increased shuttling to or decreased retrieval of the transporter from the apical 
membrane takes place in response to gentamicin exposure, which is triggered by 
ET. 
Chapter 8 discusses all results described in this thesis with special reference to 
the role of ET in either nephroprotective or nephrotoxic pathways, as well as the 
value of the different renal models used and the possible therapeutic use of ET 
receptor antagonists in nephroprotection. Based on the results described in this 
thesis, it is concluded that there is no therapeutic rationale for the use of ETB 
receptor antagonists to prevent kidney damage during the initial inhibition of 
MRP2/Mrp2, since blocking of ET signaling will also prevent the activation of 
tubular protective mechanisms due to long-term signaling events. 
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 Samenvatting 
 
De proximale tubulus van de nier is in het bijzonder kwetsbaar voor toxische 
effecten van lichaamsvreemde stoffen (xenobiotica). Een belangrijke reden 
hiervoor is de goede bloedvoorziening en concentrerende functie van dit deel van 
de niertubulus. Proximale tubuluscellen beschikken over transportsystemen voor de 
opname en uitscheiding (efflux) van anionische en kationische xenobiotica. Over 
het algemeen verloopt het proces van tubulaire opname snel en efficiënt in 
vergelijking met de efflux. Door regulatie van de activiteit van de 
effluxtransporters kan de cel de hoeveelheid potentieel toxische stoffen controleren 
en ophoping ervan voorkomen. Uit eerder onderzoek is gebleken dat het 
vasoactieve hormoon endotheline (ET) betrokken is bij de regulatie van twee 
belangrijke effluxtransporters in de proximale niertubulus, namelijk 
mulitdrugresistentie-proteïne 2 (MRP2) en multidrugresistentie 1 P-glycoproteïne 
(MDR1 P-gp). MRP2 transporteert voornamelijk organische anionen, terwijl 
MDR1 P-gp organische kationen en neutrale stoffen de cel uit pompt. In de 
proximale tubulus van de nier van de tandkarper (killifish) is aangetoond dat ET 
een cellulaire signaaltransductieroute in gang zet. Wanneer tubuli worden 
blootgesteld aan niertoxische stoffen, vindt er een calciuminstroom plaats waarna 
ET wordt uitgescheiden door de tubuluscel. Het vrijgemaakte ET bindt vervolgens 
aan endothelinereceptoren van het B-type (ETB) op de plasmamembraan, waardoor 
proteïnekinase-C (PKC) in de cel wordt geactiveerd. Dit resulteert uiteindelijk in 
een remming van Mrp2- en Mdr1 P-gp-gemedieerd transport (3; 9). Zoals 
beschreven in hoofdstuk 1, zijn zowel ET als het verminderd functioneren van 
MDR1 P-gp en MRP2 betrokken bij nierziekten en nierschade door toxiciteit. 
Verschillende processen kunnen leiden tot ET-gemedieerde nierschade, zoals 
vasoconstrictie, de productie van reactieve zuurstofradicalen, stimulatie van de 
afgifte van groei- en ontstekingsfactoren en remming van transporteiwitten. Een 
langere blootstelling aan sommige nefrotoxische stoffen kan daarentegen ook 
resulteren in een stimulerend effect op de activiteit en expressie van de 
transporteiwitten. In enkele gevallen zijn er aanwijzingen dat ET hierbij ook is 
betrokken. Dit suggereert dat ET mogelijk ook nierbeschermende effecten heeft.  
De studies beschreven in dit proefschrift zijn voornamelijk gericht op de 
fysiologische en pathologische rol van ET in de regulatie van niertransport, en om 
de mogelijke therapeutische toepasbaarheid van ET-receptorantagonisten in de 
preventie van nierschade door xenobiotica te verkennen. Hiertoe is de door 
nefrotoxische stoffen geactiveerde ET-signaaltransductieroute verder bestudeerd 
onder verschillende omstandigheden, namelijk na korte termijnblootstelling, al dan 
niet gevolgd door een herstelperiode en blootstelling over lange termijn. 
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Gebruikmakend van het killifish-model (2-4) is met confocale microscopie en 
kwantitatieve beeldanalyse het Mrp2-gemedieerd transport bepaald van het 
fluorescerende substraat, fluoresceïne-methotrexaat (FL-MTX). In hoofdstuk 2 
wordt beschreven hoe met deze methode een vermindering in uitscheiding van FL-
MTX werd gevonden in tubuli blootgesteld aan nitroprusside-natrium (SNP), een 
donor van stikstofoxide (NO). Deze afname in transport was binnen 10 min. na 
blootstelling aan SNP waarneembaar. Door gebruik te maken van een NO-synthase 
(NOS)-remmer kon worden vastgesteld dat de afgifte van NO plaatsvindt na 
blootstelling aan ET-1, alsmede aan verscheidene niertoxische verbindingen 
(diatrizoate, gentamicine, amikacine, kwik en cadmium). ET-1 en alle genoemde 
nefrotoxische stoffen stimuleren de productie van NO in tubuli, zoals gemeten met 
een fluorescerende NO-indicator. De afname in FL-MTX-uitscheiding door SNP 
kon worden geblokkeerd met een selectieve remmer van PKC, maar niet met een 
ETB-receptorantagonist. Hieruit kan worden geconcludeerd dat NO-productie 
plaatsvindt ná binding van ET aan de basolaterale ETB-receptor, maar vóór de 
activatie van PKC.  
Het is bekend dat NO ook een van de signaaltransductiemoleculen is die 
verantwoordelijk zijn voor de stimulatie van de productie van cyclisch-GMP 
(cGMP). cGMP wordt vrijgemaakt na activatie van het enzym guanylylcyclase, en 
is betrokken bij de regulatie van verschillende transporteiwitten (6; 10). Daarnaast 
is cGMP ook geassocieerd met nefrotoxiciteit (7). In hoofdstuk 3 wordt de rol van 
guanylylcyclase en cGMP in de regulatie van Mrp2-gemedieerd transport in 
killifish-tubuli beschreven. Deze studie toont aan dat een remmer van 
guanylylcyclase in staat was om de afname in Mrp2-gemedieerde uitscheiding, 
veroorzaakt door ET of door nefrotoxische stoffen, te voorkomen. De 
guanylylcylcaseremmer blokkeerde ook de effecten van NO op Mrp2-gemedieerd 
transport, maar was niet in staat om de afname in transport na PKC-activatie te 
voorkomen. Verder resulteerde blootstelling van de tubuli aan een celpermeabele 
cGMP-analoog in een verlaging van de luminale FL-MTX-accumulatie. Dit effect 
werd opgeheven door remming van PKC, maar niet door NOS-remming. 
Samengevat tonen deze resultaten aan dat activatie van guanylylcyclase en cGMP-
productie betrokken zijn bij de regulatie van Mrp2. NO activeert PKC via 
stimulering van de productie van cGMP, hetgeen uiteindelijk leidt tot remming van 
Mrp2-gemedieerd transport in niertubuli.  
In tegenstelling tot deze regulatie op korte termijn resulteerde langdurige (6 uur) 
blootstelling aan een relatief lage concentratie cadmium in een verhoogde Mrp2-
transportactiviteit en -eiwitexpressie in de luminale membraan van killifish-tubuli 
(8). Deze inductie van Mrp2 kan gezien worden als een mogelijk 
compensatiemechanisme voor de aanvankelijke afname in uitscheiding van 
potentieel toxische Mrp2-substraten. Om de effecten op Mrp2-gemedieerd transport 
op lange termijn nader te bekijken werden niertubuli 30 min. lang blootgesteld aan 
ET-1 of gentamicine, waarna ze in staat werden gesteld zich te herstellen 
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 (hoofdstuk 4). Na een herstelperiode van 3 uur was de waargenomen initiële 
afname in Mrp2-gemedieerd transport verdwenen, en dit bleef vervolgens 
onveranderd in de daaropvolgende 6 uur. Daarentegen was na een herstelperiode 
van 24 uur het transport van FL-MTX door Mrp2 met 50% toegenomen. Door 
middel van immunokleuring met antilichamen tegen Mrp2 kon worden aangetoond 
dat de stijging in transport gepaard ging met een verhoging van het aantal 
transporters in de luminale membraan. Deze effecten op zowel het Mrp2-
gemedieerde transport als op de expressie van het transporteiwit werden 
voorkomen door remming van NOS en guanylylcyclase, hetgeen betekent dat 
zowel NO als cGMP betrokken zijn. De aanwezigheid van vergelijkbare stappen in 
deze ET-signaaltransductieroute bij zowel de korte- als langetermijnregulatie van 
Mrp2, wijzen op de aanwezigheid van een meervoudig effect veroorzaakt door één 
initiële stimulus. De productie van cGMP zou de prikkel kunnen zijn voor de novo-
synthese van Mrp2, een verhoogde insluiting van het transporteiwit in en/of 
remming van de terugtrekking van Mrp2 uit de luminale membraan. Al deze 
processen resulteren uiteindelijk in een verhoogde transportactiviteit van Mrp2. 
Tenslotte werd gevonden dat tubuli die gedurende 30 min. zijn blootgesteld aan 
gentamicine, gevolgd door een herstelperiode van 24 uur in gentamicine-vrij 
medium, minder gevoelig zijn voor acute gentamicinetoxiciteit dan tubuli die 
tevoren niet waren blootgesteld. Met andere woorden, door een korte 
blootstellingsperiode aan ET-1 of gentamicine wordt een beschermingsmechanisme 
geactiveerd, waardoor de cel op lange termijn tegen een tweede toxische aanval is 
beschermd. 
Er zijn aanwijzingen dat transporteiwitten die tot de ATP-binding cassette 
(ABC) superfamilie behoren, zoals MRP2 en MDR1 P-gp, betrokken zijn bij de 
regulatie van stamceldifferentiatie (1; 11). De transporteiwitten zouden hierdoor 
een rol kunnen spelen in het herstel van beschadigd weefsel en zo ook kunnen 
bijdragen aan een beschermend mechanisme. De pilotstudie beschreven in 
hoofdstuk 5 is een eerste poging om inzicht te krijgen in de mogelijke rol van deze 
transporteiwitten bij de mobilisatie van renale stamcellen na nierschade. Met 
lichtmicroscopie en immunohistochemie werd de lokalisatie van de ABC-
transporters Mdr1 P-gp, Mrp2, multidrugresistentie-proteïne 4 (Mrp4) en 
borstkankerresistentie-proteïne (Bcrp) bepaald in het interstitium, de nefrogene 
zone en het tubulaire weefsel van de rog (Leucoraja erinacea), hondshaai (Squalus 
acanthias) en zebravis (Danio Rerio). De expressie van Mdr1 P-gp, Mrp2 en Mrp4 
in de luminale membraan van de niertubuli van deze drie vissoorten komt 
grotendeels overeen met lokalisaties gevonden in de nieren van zoogdieren en de 
killifish (hoofdstuk 4 en Refs. 3 en 5). Bcrp expressie werd gevonden in enkele 
cellen aanwezig in het hematopoietisch weefsel van de zebravis. Daarnaast werden 
ook enkele Mrp2-positieve cellen gevonden in de niet-geopereerde, contralaterale, 
roggennier. Alhoewel het stamcellen kunnen zijn, is verder onderzoek nodig om ze 
beter te kunnen identificeren in de buurt van nefrogeen weefsel. 
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Alle hierboven beschreven resultaten werden verkregen met nierweefsel 
afkomstig van de vis. Alhoewel transporteiwitten voor xenobiotica goed 
geconserveerd zijn gedurende de evolutie, is de regulatie van MRP2/Mrp2 door ET 
nog niet onderzocht in zoogdiernieren. Madin Darby Canine Kidney type II 
(MDCKII)- cellen en de geïsoleerde geperfundeerde rattennier zijn gebruikt als 
zoogdiermodellen. Hoofdstuk 6 beschrijft het transport van de fluorescerende 
Mrp2-substraten calceïne, fluo-3 en lucifer yellow in geperfundeerde nieren van de 
gewone, Wistar-Hannover-rat (WH-rat), en de Mrp2-deficiënte TR--rat. 
Geïsoleerde rattennieren werden geperfundeerd met calceïne-AM of fluo3-AM. 
Deze stoffen diffunderen de cel in, waarna ze worden omgezet in de fluorescerende 
anionen, calceïne en fluo-3. De uitscheiding van calceïne en fluo-3 in urine was 3-4 
keer hoger bij de WH-rat dan de TR--rat. De renale excretie van lucifer yellow was 
iets vertraagd, maar uiteindelijk onveranderd in de TR--rat ten opzichte van de WH-
rat. Deze resultaten werden bevestigd door studies met geïsoleerde 
membraanblaasjes van Sf9-cellen, die humaan-MRP2 of -MRP4 tot expressie 
brengen. Calceïne en fluo-3 werden hoofdzakelijk door MRP2 getransporteerd, 
terwijl lucifer yellow een beter substraat voor MRP4 bleek te zijn. 
In hoofdstuk 7 wordt ingegaan op het effect van gentamicine op de functionele 
expressie van MRP2/Mrp2 in zoogdiernieren. MDCKII-cellen, getransfecteerd met 
humaan-MRP2, werden blootgesteld aan verschillende concentraties gentamicine 
voor een periode van 1 uur, 24 uur, of 1 uur gevolgd door een herstelperiode van 24 
uur. In tegenstelling tot eerder gevonden resultaten in de killifish werd na 
kortdurende (1 uur) blootstelling géén effect waargenomen op het transport van het 
Mrp2-substraat, glutathion-methylfluoresceïne (GS-MF) of op de expressie van 
MRP2. Een verhoging in GS-MF-transport werd wel gevonden na blootstelling 
gedurende 24 uur en na een herstelperiode volgend op de kortdurende blootstelling. 
Tegelijkertijd werd ook een tweemaal verhoogde expressie van MRP2 in de apicale 
membraan gevonden, terwijl de totale expressie van MRP2 in de cel gelijk bleef. In 
de geperfundeerde rattennier werd eveneens geen effect gevonden op de calceïne-
uitscheiding na kortdurende blootstellling. Echter na langdurige (7 dagen) 
blootstelling aan gentamicine werd wel een verhoging van de calceïne-excretie 
gevonden, die gepaard ging met een toename in Mrp2-expressie in de apicale 
membraan. De toename in Mrp2-expressie werd verhinderd door gelijktijdige 
toediening van de ET-receptorantagonist, bosentan, terwijl er geen verandering in 
Mrp2-mRNA werd gevonden. Hieruit kan de conclusie worden getrokken dat de 
door gentamicine veroorzaakte ET-signaalcascade een stimulatie van de insluiting 
van MRP2/Mrp2 in de apicale membraan en/of een remming van de terugtrekking 
uit deze membraan teweegbrengt. 
In hoofdstuk 8 worden de resultaten die in dit proefschrift staan bediscussieerd. 
Er wordt met name ingegaan op de rol van ET in zowel nierbeschermende als 
niertoxische mechanismen, op het gebruik van de verschillende niermodellen en de 
mogelijke therapeutische toepassing van ET-receptorantagonisten ten behoeve van 
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 nierbescherming. Afgaande op de resultaten kan geconcludeerd worden dat het 
gebruik van ETB-receptorantagonisten om nierschade te voorkomen is af te raden. 
Blokkade van de ET-signaalcascade om de eventuele schadelijke gevolgen van 
MRP2/Mrp2-remming op korte termijn te voorkomen, belet ook de activatie van 
waarschijnlijk belangrijkere beschermende mechanismen voor de nier op de 
langere termijn.   
 
 
References 
 
 1.  Bunting KD. ABC transporters as phenotypic markers and functional regulators of stem cells. 
Stem Cells 20: 11-20, 2002. 
 2.  Masereeuw R, Russel FGM and Miller DS. Multiple pathways of organic anion secretion in 
renal proximal tubule revealed by confocal microscopy. Am J Physiol Renal Physiol 271: 
F1173-F1182, 1996. 
 3.  Masereeuw R, Terlouw SA, Van Aubel RA, Russel FG and Miller DS. Endothelin B receptor-
mediated regulation of ATP-driven drug secretion in renal proximal tubule. Mol Pharmacol 
57: 59-67, 2000. 
 4.  Miller DS, Letcher S and Barnes DM. Fluorescence imaging study of organic anion transport 
from renal proximal tubule cell to lumen. Am J Physiol Renal Physiol 271: F508-F520, 1996. 
 5.  Miller DS, Masereeuw R, Henson J and Karnaky KJ, Jr. Excretory transport of xenobiotics by 
dogfish shark rectal gland tubules. Am J Physiol Regul Integr Comp Physiol 275: R697-R705, 
1998. 
 6.  Roczniak A and Burns KD. Nitric oxide stimulates guanylate cyclase and regulates sodium 
transport in rabbit proximal tubule. Am J Physiol Renal Physiol 270: F106-F115, 1996. 
 7.  Tack I, Marin-Castano E, Bascands JL, Pecher C, Ader JL and Girolami JP. Cyclosporine A-
induced increase in glomerular cyclic GMP in rats and the involvement of the endothelinB 
receptor. Br J Pharmacol 121: 433-440, 1997. 
 8.  Terlouw SA, Graeff C, Smeets PHE, Fricker G, Russel FGM, Masereeuw R and Miller DS. 
Short- and long-term influences of heavy metals on anionic drug efflux from renal proximal 
tubule. J Pharmacol Exp Ther 301: 578-585, 2002. 
 9.  Terlouw SA, Masereeuw R, Russel FGM and Miller DS. Nephrotoxicants induce endothelin 
release and signaling in renal proximal tubules: effect on drug efflux. Mol Pharmacol 59: 
1433-1440, 2001. 
 10.  Zhang C and Mayeux PR. NO/cGMP signaling modulates regulation of Na(+)-K(+)-ATPase 
activity by angiotensin II in rat proximal tubules. Am J Physiol Renal Physiol 280: F474-F479, 
2001. 
 11.  Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ, Lagutina I, Grosveld 
GC, Osawa M, Nakauchi H and Sorrentino BP. The ABC transporter Bcrp1/ABCG2 is 
expressed in a wide variety of stem cells and is a molecular determinant of the side-population 
phenotype. Nat Med 7: 1028-1034, 2001. 
 
154     Chapter 9 
 List of publications 
 
Terlouw SA, Masereeuw R, van den Broek PH, Notenboom S, Russel FGM. Role 
of multidrug resistance protein 2 (MRP2) in glutathione-bimane efflux from Caco-
2 and rat renal proximal tubule cells. Br J Pharmacol 134: 931-938, 2001. 
 
Notenboom S, Masereeuw R, Miller DS. Nephrotoxicants activate nitric oxide 
synthase and induce nitric oxide production in killifish renal proximal tubule. 
Mount Desert Island Biol Lab Bull 40:12-13, 2001. 
 
Notenboom S, Miller DS; Smits P, Russel FGM, Masereeuw R. Role of NO in 
endothelin-regulated drug transport in the renal proximal tubule. Am J Physiol 
Renal Physiol 282:F458-F464, 2002. 
 
Notenboom S, Masereeuw R, Russel FGM, Miller DS. Measurement of xenobiotic 
induced nitric oxide production in killifish proximal tubules. Mount Desert Island 
Biol Lab Bull 41:35, 2002. 
 
Masereeuw R, Notenboom S, Smeets PHE, Wouterse AC, Russel FGM. Impaired 
renal secretion of substrates for the multidrug resistance protein 2 in mutant 
transport-deficient (TR-) rats. J Am Soc Nephrol 14: 2741-2749, 2003. 
 
Notenboom S, Masereeuw R, Russel FGM, Miller DS. Involvement of cGMP in 
endothelin-regulated drug transport in killifish (Fundulus heteroclitus) renal 
proximal tubules. Mount Desert Island Biol Lab Bull 42:123, 2003. 
 
Notenboom S, Kuik LH, Russel FGM, Masereeuw R, Miller DS. Long-term and 
short-term effects of gentamicin exposure in killifish (Fundulus heteroclitus) renal 
proximal tubules. Mount Desert Island Biol Lab Bull 42:121-122, 2003. 
 
Notenboom S, Miller DS, Smeets PHE, Russel FGM, Masereeuw R. Involvement 
of guanylyl cyclase and cGMP in the regulation of Mrp2-mediated transport in the 
proximal tubule. Am J Physiol Renal Physiol 287:F33-F38, 2004. 
 
Notenboom S, Miller DS, Kuik  LH, Smits P., Russel FGM, Masereeuw R. Short-
term exposure of renal proximal tubules to gentamicin increases long-term Mrp2 
(Abcc2) transport function and reduces nephrotoxicant sensitivity. J Pharmacol 
Exp Ther 215, in press, 2005 
 
Notenboom S, Wouterse AC, Peters B, Kuik LH, Heemskerk S, Russel FGM, 
Masereeuw R. Increased apical insertion of the multidrug resistance protein 2 
(Mrp2/Abcc2) in renal proximal tubules by gentamicin. Submitted in adapted 
version 
List of publications     155 
  
 
 
 
156 
Dankwoord 
 
Na mijn afstuderen had ik er eigenlijk nooit echt serieus over nagedacht om te 
promoveren. Gelukkig heeft de overredingskracht van Frans en Roos ertoe geleid 
dat ik eraan begon. Ik heb er nooit spijt van gehad, alhoewel ik soms wel heb 
gedacht waar ik in hemelsnaam aan begonnen was en mijzelf wel eens af vroeg of 
Frans en Roos soms niet dachten: 'Mmm, waarom hadden we haar ook alweer 
aangenomen......?'.  Gelukkig waren er op zulke momenten altijd mensen die mij 
geholpen hebben, zodat ik nu dit boekje waar ik heel trots op ben, kan vasthouden.  
In de eerste plaats natuurlijk Frans Russel en Roos Masereeuw, die mij naast de 
aanvang ook tussendoor altijd weer enthousiast kregen voor het project, altijd tijd 
namen zaken kritisch te bekijken en geduldig al mijn veel te lange en ingewikkelde 
zinnen verbeterden. Daarnaast natuurlijk Fons Wouterse, die voor mij alle 
nierperfusiestudies heeft uitgevoerd. Heel erg bedankt hiervoor! Ook Leon Kuik en 
Bram Peters die, ondanks respectievelijk een gebroken pink en het soms ietwat 
'brak' zijn, veel data voor mij hebben verzameld en door hun vragen mij ook 
regelmatig aan het denken hebben gezet.  
Daarnaast wil ik natuurlijk ook iedereen van de afdeling Farmacologie en 
Toxicologie bedanken voor de gezellige sfeer en iedereen van de afdeling 
Membraanbiochemie van de zevende verdieping. Het was erg prettig en gezellig 
werken, al leek het volgens sommigen soms wel een kippenhok. In het bijzonder 
wil ik Femke van de Water bedanken, die misschien wel een beetje aan mij vast 
zat, aangezien ik naast haar in het u-tje zat. Ik vond dat in ieder geval geweldig en 
kon het erg goed met haar vinden tijdens het werk en daarbuiten. Ik ben dan ook 
zeer vereerd dat zij mijn paranimf wil zijn. Nog steeds vraag ik me af wat iedereen 
van ons dacht toen we begonnen met het houden van een 'labvis'. Amateurs..., kijk 
daar drijft weer een vis levenloos in zijn kom. Gelukkig bracht Kim Wever, 
studente medische biologie, die ook naar vissennieren keek uitkomst door guppies 
te doneren die door verhuizing van de afdeling Organismale Dierfysiologie toch 
een nieuw aquariumpje zochten. Femke, ik wens je hoe dan ook nog heel veel 
sterkte toe in je verdere loopbaan en leven. En ik hoop dat je op een plaats 
terechtkomt waar je je in je werk thuis zult voelen. Verder wil ik natuurlijk ook 
Aloys Sesink bedanken voor zijn actieve bijdrage aan de cursus 'farmacokinetiek' 
in café Jos en zijn hartelijke interesse in alles. Daarnaast ook Sylvie Terlouw, 
Pascal Smeets en Bas van Balkom die mij de benodigde technieken hebben 
aangeleerd, maar vooral Janny Peters die naast praktische tips, altijd een luisterend 
oor had en altijd geïnteresseerd informeerde naar hoe het nou ging met persoonlijke 
zaken buiten het werk. Dat heb ik vooral in sommige periodes echt op prijs gesteld.  
Natuurlijk had ik ook het geluk om tijdens mijn project erg leerzame uitstapjes te 
maken naar het buitenland. Dear David Miller, I want to thank you sincerely for 
giving me the opportunity to work with you during several summers at the Mount 
Dankwoord     157 
 Desert Island Biological Laboratory in Maine. These inspiring months really 
contributed to my growing interest in transport research and resulted in the 
collection of a large number of data for this thesis. I would also like to thank you 
for your important contribution to the published articles and in helping me to find a 
suitable post-doc position. 
Gerne möchte ich auch Dr. Marlies Elger, Prof. dr. Hartmut Hentschel und Prof. 
dr. Haller herzlich danken. Dank ihrer Kooperation konnte ich Erfahrung mit 
histochemischen Techniken gewinnen. Marlies und Hartmut danke ich für 
geduldige Erklärungen über die Anatomie der Fisch-Niere. Es war mir eine grosse 
Hilfe das sie nie ermüdeten durchs Mikroskop zu schauen und meine Fragen zu 
beantworten. Auch ihr Interesse an Niederländisch hat mich stets erfreut und gerne 
haben ich mit ihnen über den 'Stichling' diskutiert. 
Ook wil ik mijn vrienden bedanken, die naast mijn familie ervoor hebben 
gezorgd dat ik nog een leven buiten mijn werk had. Zonder dat had ik niet kunnen 
functioneren. Dank je wel voor het gezellig samen eten en kletsen na soms veel 
heen en weer ge-email om een dag te vinden waarop iedereen kon, of als dat niet 
lukte, de meeste konden. Ik hoop echt dat dit niet verloren zal gaan. 
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